WO2006066978A1 - Novel ligands that modulate rar receptors, and use thereof in human medicine and in cosmetics - Google Patents

Novel ligands that modulate rar receptors, and use thereof in human medicine and in cosmetics Download PDF

Info

Publication number
WO2006066978A1
WO2006066978A1 PCT/EP2005/014217 EP2005014217W WO2006066978A1 WO 2006066978 A1 WO2006066978 A1 WO 2006066978A1 EP 2005014217 W EP2005014217 W EP 2005014217W WO 2006066978 A1 WO2006066978 A1 WO 2006066978A1
Authority
WO
WIPO (PCT)
Prior art keywords
butyl
terphenyl
ethyl
carboxylic acid
diethylamino
Prior art date
Application number
PCT/EP2005/014217
Other languages
French (fr)
Inventor
Thibaud Biadatti
Laurence Dumais
Catherine Soulet
Sandrine Talano
Sébastien DAVER
Original Assignee
Galderma Research & Development
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0413848A external-priority patent/FR2880020B1/en
Priority to DK05824484.9T priority Critical patent/DK1831149T3/en
Priority to SI200531509T priority patent/SI1831149T1/en
Priority to ES05824484T priority patent/ES2380777T3/en
Priority to JP2007547399A priority patent/JP5258299B2/en
Priority to KR1020077014372A priority patent/KR101316992B1/en
Priority to AT05824484T priority patent/ATE542791T1/en
Priority to AU2005318292A priority patent/AU2005318292B2/en
Application filed by Galderma Research & Development filed Critical Galderma Research & Development
Priority to CA2590246A priority patent/CA2590246C/en
Priority to EP05824484A priority patent/EP1831149B1/en
Priority to CN2005800447781A priority patent/CN101087752B/en
Priority to PL05824484T priority patent/PL1831149T3/en
Priority to MX2007007696A priority patent/MX2007007696A/en
Priority to BRPI0517500A priority patent/BRPI0517500B8/en
Publication of WO2006066978A1 publication Critical patent/WO2006066978A1/en
Priority to US11/819,068 priority patent/US7807708B2/en
Priority to US12/842,347 priority patent/US8227507B2/en
Priority to US13/527,299 priority patent/US8470871B2/en
Priority to NL301042C priority patent/NL301042I2/en
Priority to LTPA2022002C priority patent/LTC1831149I2/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/54—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Definitions

  • Novel ligands that modulate RAR receptors and use thereof in human medicine and in cosmetics
  • the invention relates to novel compounds as novel and useful industrial products, which are ligands that modulate RAR receptors.
  • the invention also relates to compositions containing them, to processes for preparing them and to their use in pharmaceutical compositions for use in human or veterinary medicine, or alternatively in cosmetic compositions, and to the non-therapeutic use of these compositions.
  • vitamin A and its derivatives Compounds with activity of retinoid type (vitamin A and its derivatives) are widely described in the literature as having activity in cell proliferation and differentiation processes. These properties give this class of compounds high potential in the treatment or prevention of numerous pathologies, and more particularly in dermatology and cancer. Many biological effects of retinoids are mediated by modulating the nuclear retinoic acid receptors (RAR).
  • RAR nuclear retinoic acid receptors
  • RAR receptors activate transcription by binding to DNA sequence elements, known as RAR response elements (RARE), in the form of a heterodimer with the retinoid X receptors (known as RXRs).
  • RARE RAR response elements
  • RAR ⁇ Three subtypes of human RARs have been identified and described: RAR ⁇ , RAR ⁇ and RAR ⁇ .
  • patent US 6 150 413 which describes triaromatic compounds
  • patent US 6 214 878 which describes stilbene compounds
  • patent US 6 218 128, which describes a family of bicyclic or tricyclic molecules.
  • the Applicant has invented novel compounds that modulate retinoic acid receptors.
  • R 1 is a hydrogen atom, an alkyl radical of 1 to 4 carbon atoms or a -CF 3 radical;
  • R 2 is a hydrogen atom, an alkyl or alkoxy radical of 1 to 4 carbon atoms or a chlorine atom;
  • R 3 is a hydrogen atom, a linear or branched alkyl or alkoxy radical of 1 to 10 carbon atoms and preferably 1 to 6 carbon atoms optionally substituted with a methoxy group, or alternatively a linear or branched alkyl radical of 1 to 10 carbon atoms and preferably 1 to 6 carbon atoms containing an ether function;
  • R 4 is a hydrogen atom or an alkyl radical of 1 to 3 carbon atoms
  • R 5 is a hydrogen atom or an alkyl radical of 1 to 3 carbon atoms
  • - Y represents two hydrogen atoms or a hetero atom, for instance oxygen or sulfur;
  • - Ar represents a 1 ,4-phenyl, 2,5-pyridyl, 5,2-pyridyl or 2,5-thiophenyl ring;
  • - X represents an oxygen atom optionally substituted with an alkyl or alkylamine chain or a C-C single bond
  • o Q is an oxygen atom or an -NH- bond
  • o Re represents a hydrogen atom, an alkyl radical of 1 to 6 carbon atoms, a cycioalkyl radical of 3 to 6 carbon atoms or a -C(O)CH 3 or -C(O)CH 2 CH 3 radical;
  • R 7 and R 7 ' represent, independently of each other, a hydrogen atom or a hydroxyl group, on condition that R 7 and R 7 ' are not simultaneously a hydroxyl group;
  • o n 0, 1, 2, 3, 4 or 5;
  • the compounds according to the invention are in the form of a salt, it is preferably an alkali metal or alkaline-earth metal salt, or alternatively a zinc salt or a salt of an organic amine or of an acidic partner when the compound is itself basic.
  • the alkyl radicals of 1 to 3 carbon atoms are preferably chosen from methyl, ethyl, i-propyl and n-propyl radicals.
  • the alkyl radicals of 1 to 4 carbon atoms are preferably chosen from methyl, ethyl, i-propyl, i-butyl and t-butyl radicals.
  • the alkyl radicals of 1 to 6 carbon atoms are preferably chosen from methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl and hexyl.
  • the alkyl radicals of 1 to 10 carbon atoms are linear or branched chains preferably chosen from methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t- butyl, pentyl, hexyl, heptyl, octyl, nonyl and dodecyl.
  • alkoxy radical containing from 1 to 10 carbon atoms means an alkyl radical containing from 1 to 10 carbon atoms linked to the rest of the molecule via an oxygen atom.
  • the alkoxy radical is chosen from methoxy, ethoxy, isopropyloxy, tert- butoxy and hexyloxy radicals.
  • alkoxy radical containing from 1 to 6 carbon atoms means an alkyl radical containing from 1 to 6 carbon atoms linked to the rest of the molecule via an oxygen atom.
  • the alkoxy radical is chosen from methoxy, ethoxy, isopropyloxy, te/ ⁇ -butoxy and hexyloxy radicals.
  • alkoxy radical containing from 1 to 4 carbon atoms means an alkyl radical containing from 1 to 4 carbon atoms linked to the rest of the molecule via an oxygen atom.
  • the alkoxy radical is chosen from methoxy, ethoxy, isopropyloxy and terf-butoxy radicals.
  • the cycloalkyl radicals of 3 to 6 carbon atoms are preferably chosen from cyclopropyl, cyclopentyl and cyclohexyl.
  • the compounds of formula (I) that are more particularly preferred are those for which at least one, and preferably all, of the conditions below are satisfied: - R1 is a hydrogen atom or a t-butyl or i-propyl radical;
  • R2 is a hydrogen atom or a t-butyl or i-propyl radical
  • R3 is a hydrogen atom or an ethyl radical
  • R4 and R5 are, independently of each other, a methyl or ethyl radical or together form a pyrrolidine ring;
  • - A is as defined above in which R 6 represents a hydrogen atom, an i-propyl or t-butyl radical, a cycloalkyl radical of 3 to 6 carbon atoms or a -C(O)CH 3 or -C(O)CH 2 CH 3 radical.
  • a subject of the present invention is also the processes for preparing the compounds of formula (I), in particular according to the reaction schemes given in Figures 1, 2 and 3.
  • the intermediates of general formula 1 or 2 are prepared from the commercial starting material 1.
  • Compound 1 is subjected to a first step of esterification of the carboxylic acid function (a), performed under standard esterification conditions including, for example, the methods described in "Protective Groups in Organic Synthesis” by T. W. Greene & P. G. M. Wuts, 3rd edition (J. Wiley & sons), pages 373-377 or in "Comprehensive Organic Transformations” by R.C. Larock, 2 nd edition (J. Wiley & sons), pages 1932-1941.
  • a halide bromide or iodide
  • a halide bromide or iodide
  • standard bromination conditions for example by adding dibromine or an equivalent reagent such as a tetraalkylammonium tribromide
  • standard iodination conditions for example sodium iodide and sodium hypochlorite
  • the compounds of general formula 3 are then obtained via standard methods of etherification of phenols (c), for instance an etherification similar to a Williamson reaction starting with corresponding alkyl halides in the presence of a base, or alternatively a reaction of Mitsunobu type with the corresponding hydroxyl derivatives (see “Comprehensive Organic Transformations” by R.C. Larock, 2 nd edition (J. Wiley & sons), pages 889-910 or, respectively: a. Dermer, O.C., Chem. Rev. 1934, 14, 409 or Nakatsugi, T. Synthesis, 1987, 280: b. Mitsunobu, O. Synthesis 1981, 1).
  • a deprotection step (d) suited to the nature of PG, the description of which will be found in "Protective Groups in Organic Synthesis" by T. W. Greene & P. G. M. Wuts, 3rd edition (J. Wiley & sons) to obtain
  • the intermediates of general formula 7 may be obtained from the compounds 6 after a first step of bromination (f) in the para position (see above) followed by alkylation or amidation of the aniline function (g) in the presence, respectively, of a dialkyl sulfate or of an alkyl halide and a base (see, for example, Dehmlow, E.V., Tet. Lett. 1985, 25, 97 or the reference below) or in the presence of an acyl chloride or a corresponding anhydride and a base (for example Et 3 N) in accordance with the methods described, for example, in "Chemistry of the Amino Group" by S. Patai (Wiley-lnterscience, NY 1968) pages 669- 682.
  • the compounds 7 may be obtained after bromination of 6 and then formation of the ring (g), for example in the presence of a 1 ,4- dihalobutane or a 1 ,5-dihalopentane or the carbonyl analogues thereof, and of a base, or via a method described in "Chemistry of the Amino Group” by S. Patai (Wiley- lnterscience, NY 1968) pages 669-682.
  • the compounds of general formula 7 may also be generated after para- bromination (f, see above) and then formation (h) and reduction (i) of a pyrrolidinone, piperidinone, succinimide or piperidine-2,6-dione group (see, for example, Ohta, S. Heterocycles 1993, 36 (4), 743; Hubbard, J. L.; J. Heterocycl. Chem. 1992, 29 (4), 719; Akula, M. R.; Synth. Commun. 1998, 28 (11), 2063; Collins, C. J. Tetrahedron Lett. 1999, 40 (19), 3673).
  • the second reaction is the generation of a boronic acid or boronate function from the bromide group (i), for example by generating an organolithium or organomagnesium reagent trapped with a trialkyl borate (see, for example, Cladingboel, D. E. Org. Process Res. Dev. 2000, 4 (3), 153 or Li, W. J. Org. Chem. 2002, 67 (15), 5394) or alternatively by performing a coupling reaction with bis-dialkoxydiborane or dialkoxyborane in the presence of a catalyst of transition metal type (see, for example, Ishiyama, T. J. Org. Chem. 1995, 60 (23), 7508 or Murata, M., J. Org. Chem. 1997, 62 (19), 6458).
  • - Synthesis of the compounds in which X O ( Figure 2)
  • the synthesis of the final compounds of general formulae 11 and 12 may be performed according to two parallel routes for which only the order of the reactions changes.
  • a first route requires the synthesis of the intermediate 9, via a coupling reaction of Suzuki type 0) between the intermediate 2 and the boronate/boronic acid partner of formula 8, under standard Suzuki coupling conditions (see A. Suzuki et a/., Synth. Commun. 1981, 11, 513 or Sharp, MJ. Tet. Lett. 1985, 26, 5997) or alternatively, where appropriate, optimized conditions (see, for example, Littke, A. F. et a/., J. Am. Chem. Soc. 2000, 122 (17), 4020-4028).
  • the compounds 9 are obtained directly when R 3 is other than H, or after a reaction to reveal the carboxylic acid function, for example by using conditions among those described in "Comprehensive Organic Transformations" by R. C. Larock, 2 nd edition (J. Wiley & sons), pages 1959-1968.
  • the intermediate 9 may also be subjected to the conditions (c) described above in order to obtain the compounds of general formula 10.
  • these same final compounds 11 and 12 may be obtained by subjecting, respectively, the intermediates 4 and 5 to the coupling conditions (j) described above.
  • the advanced intermediates 11 and 12 may be subjected to reactions to reveal the carboxylic acid function, for example using conditions among those described in "Comprehensive Organic Transformations” by R.C. Larock, 2 nd edition (J. Wiley & sons), pages 1959-1968.
  • the compounds of general formula 13 may be obtained after a sequence of conversion of the primary alcohol function of 11 into an amine, for example via oxidation (k) followed by reductive amination (I) (see, for example, "Comprehensive Organic Transformations” by R.C. Larock, 2 nd edition (J. Wiley & sons)) or alternatively conversion of the alcohol into a halide and substitution of the halogen atom with an amine.
  • the intermediates of general formula 9 are first converted into suitable sulfonyl esters under standard conditions, for example into triflates (see, for example, Robl, J. A. Tetrahedron Lett. 1990, 31 (24), 3421) (m), and this group is then subjected to an allylation reaction (n), for example in the presence of tributylallyltin and of a transition metal catalyst, for example tetrakis(triphenylphosphine)palladium (for an example, see Martorell, G.; Garcia-Raso, A.; Saa, J. M.; Tetrahedron Lett. 1990, 31 (16), 2357), to obtain the intermediates of type 14.
  • a transition metal catalyst for example tetrakis(triphenylphosphine)palladium
  • the final compounds of general formula 15 may then be obtained via an oxidation reaction (o) of the olefin function, for instance an oxidative hydroboration reaction (see, for example, Luo, F. T.; Negishi, E.; J. Org. Chem. 1983, 48, 5144 or "Comprehensive
  • the compounds according to the invention have modulatory properties on retinoic acid receptors (RAR). This activity on the RAR ⁇ , ⁇ and v receptors is measured in a transactivation test and quantified by means of the dissociation constant Kdapp (apparent), as described in Example 55.
  • the preferred compounds of the present invention have a dissociation constant of less than or equal to 5000 nM, advantageously less than or equal to 1000 nM and preferentially less than or equal to 1 nM.
  • the compounds are at least modulators of receptors of RARy type, selectively relative to the subtypes ⁇ and ⁇ , i.e. they have a ratio between the Kdapp for the RAR ⁇ or RAR ⁇ receptors, and the Kdapp for the RARy receptors, of greater than or equal to 5.
  • this ratio RAR ⁇ /RAR ⁇ or RARy/RAR ⁇ is greater than or equal to 10, advantageously greater than or equal to 50 and more advantageously greater than or equal to 100.
  • a subject of the present invention is also the compounds of formula (I) as described above, as medicaments.
  • pigmentation disorders such as hyperpigmentation, melasma, hypopigmentation or vitiligo
  • lipid metabolism complaints such as obesity, hyperlipidaemia, or non-insulin-dependent diabetes
  • a subject of the present invention is also a pharmaceutical composition
  • a pharmaceutical composition comprising, in a physiologically acceptable medium, at least one compound of formula (I) as defined above.
  • a subject of the present invention is also a novel medicinal composition intended especially for treating the abovementioned complaints, which is characterized in that it comprises, in a pharmaceutically acceptable support that is compatible with the mode of administration selected for this composition, at least one compound of formula (I), an optical isomer thereof or a salt thereof.
  • composition according to the invention may be administered orally, enterally, parenterally, topically or ocularly.
  • the pharmaceutical composition is preferably packaged in a form that is suitable for topical application.
  • the composition may be in the form of tablets, gel capsules, dragees, syrups, suspensions, solutions, powders, granules, emulsions, suspensions of microspheres or nanospheres or lipid or polymer vesicles allowing a controlled release.
  • the composition may be in the form of solutions or suspensions for infusion or for injection.
  • the compounds according to the invention are generally administered at a daily dose of about 0.01 mg/kg to 100 mg/kg of body weight, in one or more dosage intakes.
  • the compounds are used systemically, at a concentration generally of between 0.001% and 10% by weight and preferably between 0.01% and 1% by weight, relative to the weight of the composition.
  • the pharmaceutical composition according to the invention is more particularly intended for treating the skin and mucous membranes and may be in liquid, pasty or solid form, and more particularly in the form of ointments, creams, milks, pomades, powders, impregnated pads, syndets, solutions, gels, sprays, mousses, suspensions, sticks, shampoos or washing bases. It may also be in the form of suspensions of microspheres or nanospheres or of lipid or polymer vesicles or gelled or polymer patches allowing a controlled release.
  • the compounds are used topically at a concentration generally of between 0.001% and 10% by weight and preferably between 0.01% and 1% by weight, relative to the total weight of the composition.
  • the compounds of formula (I) according to the invention also find an application in cosmetics, in particular in body and hair hygiene and especially for treating acne-prone skin, for promoting regrowth of the hair or for limiting hair loss, for combating the greasy appearance of the skin or the hair, in protection against the harmful aspects of sunlight or in the treatment of physiologically dry skin, and for preventing and/or combating photoinduced or chronological ageing.
  • a subject of the invention is thus also a cosmetic composition
  • a cosmetic composition comprising, in a physiologically acceptable support, at least one of the compounds of formula (I).
  • a subject of the invention is also the non-therapeutic use of a cosmetic composition comprising at least one compound of formula (I) for preventing and/or treating the signs of ageing and/or dry skin.
  • a subject of the invention is also the non-therapeutic use of a cosmetic composition comprising at least one compound of formula (I) for body or hair hygiene.
  • the cosmetic composition according to the invention containing, in a physiologically acceptable medium, at least one compound of formula (I) or an optical or geometrical isomer thereof or a salt thereof may be especially in the form of a cream, a milk, a gel, suspensions of microspheres or nanospheres or lipid or polymer vesicles, impregnated pads, solutions, sprays, mousses, sticks, soaps, washing bases or shampoos.
  • the concentration of compound of formula (I) in the cosmetic composition is preferably between 0.001 % and 3% by weight, relative to the total weight of the composition.
  • physiologically acceptable medium means a medium that is compatible with the skin and optionally with its integuments (eyelashes, nails or hair) and/or mucous membranes.
  • compositions as described above may also contain inert additives, or even pharmacodynamically active additives as regards the pharmaceutical compositions, or combinations of these additives, and especially:
  • - preserving agents such as para-hydroxybenzoic acid esters; - stabilizers; - moisture regulators;
  • antioxidants such as ⁇ -tocopherol, butylhydroxyanisole, butylhydroxytoluene, superoxide dismutase, ubiquinol or certain metal-chelating agents;
  • - depigmenting agents such as hydroquinone, azelaic acid, caffeic acid or kojic acid
  • emollients for instance glycerol, PEG 400, thiamorpholinone and its derivatives or urea
  • antiseborrhoeic or anti-acne agents such as S-carboxymethylcysteine, S- benzylcysteamine, salts thereof or derivatives thereof, or benzoyl peroxide
  • antibiotics for instance erythromycin and its esters, neomycin, clindamycin and its esters, and tetracyclines;
  • antifungal agents such as ketoconazole or poly-4,5-methylene-3-isothiazolidones
  • agents for promoting regrowth of the hair for instance Minoxidil (2,4-diamino-6- piperidinopyrimidine 3-oxide) and its derivatives, Diazoxide (7-chloro-3-methyl-1 ,2,4- benzothiadiazine 1,1-dioxide) and Phenytoin (5,4-diphenylimidazolidine-2,4-dione); - non-steroidal anti-inflammatory agents;
  • ⁇ - ⁇ -hydroxy acids and ⁇ -keto acids or derivatives thereof such as lactic acid, malic acid, citric acid, glycolic acid, mandelic acid, tartaric acid, glyceric acid or ascorbic acid, and also salts, amides or esters thereof, or ⁇ -hydroxy acids or derivatives thereof, such as salicylic acid and its salts, amides or esters;
  • - ion-channel blockers such as potassium-channel blockers
  • compositions in combination with medicaments known to interfere with the immune system (for example cyclosporin, FK 506, glucocorticoids, monoclonal antibodies, cytokines or growth factors, etc.).
  • medicaments known to interfere with the immune system for example cyclosporin, FK 506, glucocorticoids, monoclonal antibodies, cytokines or growth factors, etc.
  • a person skilled in the art will take care to select the optional compound(s) to be added to these compositions such that the advantageous properties intrinsically attached to the present invention are not, or are not substantially, adversely affected by the envisaged addition.
  • Another subject of the invention relates to a cosmetic process for enhancing the appearance of the skin, characterized in that a composition comprising at least one compound of formula (I) as defined above is applied to the skin.
  • Activation of the retinoic acid receptors with the compounds of formula (I) according to the invention makes it possible to obtain skin of enhanced surface appearance.
  • the temperature is raised to room temperature and the reaction medium is stirred for 3 hours.
  • the reaction medium is cooled again to -7O 0 C and 69 mL of 1M hydrochloric acid solution (69 mmol) are added.
  • the temperature is raised to O 0 C and the reaction medium is stirred for 30 minutes.
  • the reaction is extracted after addition of 250 mL of water and 250 mL of ethyl acetate.
  • aqueous 1 N sodium hydroxide solution 0.9 mL of aqueous 1 N sodium hydroxide solution is added to a solution of 300 mg of ethyl 3"-fert-butyl-4"-diethylamino-4'-(4-hydroxybutoxy)-[1 , 1 ';3', 1 "]terphenyl-4-carboxylate (Example 2b) in a mixture of 10 mL of tetrahydrofuran and 3 mL of water.
  • the reaction medium is stirred at room temperature for 12 hours.
  • 0.5 mL of aqueous 1N sodium hydroxide solution is then added. After 12 hours at room temperature, the reaction medium is heated to 50 0 C and then left at room temperature for 3 days. The reaction is stopped by adding 5 mL of water.
  • Example 1d In a manner similar to that of Example 2a, by reacting 1 g of ethyl 3"-te/f-butyl-4"- diethylamino-4'-hydroxy[1 ,1';3',1"]terphenyl-4-carboxylate (obtained in Example 1d) (2.2 mmol) in 20 mL of dimethylformamide with 880 mg (2.7 mmol) of caesium carbonate and 0.6 mL of 1-bromo-3-(terf-butyldimethylsilanyloxy)propane (2.4 mmol).
  • Example 2b In a manner similar to that of Example 2b, by reacting 1 g of ethyl 3"-fert-butyl-4'-[4-(fert- butyldimethylsilanyloxy)propoxy]-4"-diethylamino[1 ,1';3',1"]terphenyl-4-carboxylate (1.62 mmol) in 25 mL of tetrahydrofuran with 2 mL of 1 M tetrabutylammonium fluoride.
  • Example 1d In a manner similar to that of Example 1d, by reacting 1 g of ethyl 3'-bromo-4'-[3-(fe/f- butyldimethylsilanyloxy)propoxy]biphenyl-4-carboxylate (2 mmol) with 580 mg of 4- diethylaminophenylboronic acid (3 mmol) in the presence of tetrakis(triphenylphosphine)- palladium.
  • the reaction medium is heated at the reflux temperature of the tetrahydrofuran for 5 hours.
  • the reaction medium is concentrated under vacuum.
  • Example 2b In a manner similar to that of Example 2b, by reacting 400 mg of ethyl 4'-[4-(tert- butyldimethylsilanyloxy)butoxy]-4"-pyrrolidin-1-yl-3"-trifluoromethyl[1 ,1';3',1"]terphenyl-4- carboxylate (0.6 mmol) with 0.75 ml.
  • Example 9b ethyl 3'-bromo-4'-[3-(feAt- butyldimethylsilanyloxy)propoxy]biphenyl-4-carboxylate obtained in Example 9b (1.2 mmol) with 380 mg of 3-tert-butyl-4-pyrrolidinophenylboronic acid (1.5 mmol) obtained in Example 17b in the presence of 1.3 ml.
  • Example 13a In a manner similar to that of Example 1d, by reacting 800 mg of ethyl 3'-bromo-4'-(2- acetoxyethoxy)biphenyl-4-carboxylate obtained in Example 13a (2 mmol) with 730 mg of
  • Example 14a In a manner similar to that of Example 14a, by reacting 110 mg of ethyl 4'-(2- acetoxyethoxy)-3"-terf-butyl-4"-pyrrolidin-1 -yl[1 , 1 ';3', 1 "]terphenyl-4-carboxylate (0.2 mmol) with 2 ml.
  • Example 1d 1.1 g of ethyl 3"-fe/f-butyl-4"-diethyiamino-4'-hydroxy[1,1';3',1"]terphenyl-4-carboxylate obtained in Example 1d (2.5 mmol) are dissolved at room temperature in 22.4 mL of dichloromethane and the temperature of the reaction medium is then lowered to O 0 C; 112 mg of dimethylaminopyridine are added, followed by addition of 0.88 mL of triethylamine (6 mmol) and dropwise addition of 0.5 mL of trifiic anhydride (3 mmol). The temperature is raised to room temperature and the reaction medium is stirred for 20 minutes.
  • reaction medium is again reduced to 0 0 C, 52.8 mL of NaOH (53 mmol) are added portionwise, and the medium is stirred for 10 minutes at O 0 C; 37.3 mL of H 2 O 2 (426 mmol) are then added dropwise and the reaction medium is warmed to room temperature and then stirred for 2 hours 30 minutes.
  • the reaction is stopped by adding 500 mL of ice- water and then extracted with 500 mL of ethyl acetate.
  • the organic phases are washed with 1 L of water and then dried over magnesium sulfate.
  • the solvents are evaporated off and the residue is then purified by chromatography on silica gel (eluent: 7/3 heptane/ethyl acetate).
  • Example 32b 150 mg of ethyl 3"-feAf-butyl-4"-diethylamino-4 l -vinyl[1,1';3',1"]te ⁇ henyl-4-carboxylate obtained in Example 32b are dissolved in 10 mL of dichloromethane under a nitrogen atmosphere. 45 mg of N-methylmorpholine are added to the reaction medium, and
  • the dissolution is performed under cold conditions (0 0 C), and 11.4 mL of trioctylphosphine are then added (26 mmol) followed by addition of a solution of 8.5 g of carbon tetrabromide (26 mmol) dissolved in 10 volumes of Et 2 O added dropwise.
  • the reaction medium is stirred at 0°C for 30 minutes and then for 1 hour 30 minutes at room temperature.
  • the reaction is stopped by adding 100 mL of water and then extracted with 100 mL of ethyl acetate.
  • the organic phases are washed with 400 mL of water and then dried over magnesium sulfate.
  • the reaction medium is heated at 100 0 C for 3 hours and is then poured into water beforehand and acidified slightly with a 1 mol/L solution of hydrochloric acid, and extracted twice with ethyl acetate. The organic phases obtained are combined and washed with water, dried over anhydrous magnesium sulfate, filtered and evaporated to give a brownish oil.
  • N-(2-tert-Butyl-4-bromophenyl)-4-chlorobutanamide 20 g (0.0877 mol; 1 eq.) of 2-tert-butyl-4-bromoaniline (prepared according to Example 1 a)) are dissolved in 100 ml of dichloromethane at about O 0 C.
  • reaction medium is returned to room temperature and stirred for 1 hour 30 minutes. 70 ml of H 2 O are added and the reaction medium is then allowed to settle. The aqueous phase is re-extracted with dichloromethane, and the organic phases are collected and washed successively with aqueous 1M NaHC ⁇ 3 and then with H 2 O.
  • reaction medium cooled to room temperature and filtered through a sinter funnel packed with Celite; the filter cake is rinsed thoroughly with ethyl acetate, and H 2 O is added to the filtrate, which is then allowed to settle.
  • the organic phase obtained is then concentrated on a rotavapor to give a residue, which is purified by chromatography on silica.
  • step d (obtained in step d)) are dissolved in 300 ml of tetrahydrofuran. 10.9 g (0.259 mol; 1.5 eq.) of lithium hydroxide monohydrate as a solution in 70 ml of H 2 O are added at room temperature.
  • the reaction medium is refluxed for about 1 hour 30 minutes.
  • reaction medium is then cooled to room temperature and dilute hydrochloric acid solution is added (330 ml; ⁇ 1M). 100 ml of H 2 O are added and this suspension is cooled to about 0 0 C; it is maintained at this temperature for about 15 minutes then filtered. After drying, 59 g of a white powder are obtained.
  • reaction medium is cooled to room temperature and filtered through a sinter funnel packed with Celite; the filter cake is rinsed thoroughly with ethyl acetate, and H 2 O is added to the filtrate and the phases are allowed to separate by settling.
  • [1 ,1 ',3',1"]terphenyl-4-benzoate are dissolved in 10 ml of absolute ethanol.
  • 312 mg (7.8 mmol; 4.5 eq.) of sodium hydroxide and 4 ml of H 2 O are added at room temperature and the mixture is then heated to reflux. These conditions are maintained for about 1 hour 30 minutes.
  • the reaction medium is concentrated to a small volume; H 2 O is added to the precipitate formed, and the mixture is then acidified with acetic acid to pH ⁇ 4-5.
  • This suspension is fluidized by adding H 2 O and stirred at room temperature for 1 hour.
  • the resulting mixture is filtered through a sinter funnel, rinsed with H 2 O until the filtrate is neutral, and oven-dried.
  • the activation of receptors with an agonist (activator) in HeLa cells leads to the expression of a reporter gene, luciferase, which, in the presence of a substrate, generates light.
  • the activation of the receptors may thus be measured by quantifying the luminescence produced after incubating the cells in the presence of a reference agonist.
  • the inhibitory products displace the agonist from its site, thus preventing activation of the receptor.
  • the activity is measured by quantifying the reduction in light produced. This measurement makes it possible to determine the inhibitory activity of the compounds according to the invention.
  • KdApp Kd apparent
  • the HeLa cell lines used are stable transfectants containing the plasmids ERE- ⁇ Glob- Luc-SV-Neo (reporter gene) and RAR ( ⁇ , ⁇ , ⁇ ) ER-DBD-puro. These cells are inoculated into 96-well plates at a rate of 10 000 cells per well in 100 ⁇ l of DMEM medium without phenol red, and supplemented with 10% defatted calf serum. The plates are then incubated at 37°C and 7% CO 2 for 4 hours.
  • test products of the reference ligand (4-[2-(5, 5,8,8- tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)propenyl]benzoic acid), of the 100% control (100 nM 4-[2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)propenyl]benzoic acid) and of the 0% control (500 nM 4- ⁇ (E)-3-[4-(4-tert-butylphenyl)-5,5,8,8-tetramethyl-5,6,7,8- tetrahydro-2-naphthyl]-3-oxopropenyl ⁇ benzoic acid) are added at a rate of 5 ⁇ l per well. The plates are then incubated for 18 hours at 37°C and 7% CO 2 .
  • the culture medium is removed by turning over and 100 ⁇ l of a 1 :1 PBS/luciferine mixture is added to each well. After 5 minutes, the plates are read using the luminescence reader.
  • This example illustrates various concrete formulations based on the compounds according to the invention.
  • Liquid petroleum jelly oil 9.10O g
  • Silicone oil (“Abil 300 000 cSt” sold by Goldschmidt) qs 100 g
  • Glyceryl monostearate 2.500 g

Abstract

The present invention relates to novel compounds corresponding to the general formula (I) below: to compositions containing them, to processes for preparing them and to their use in pharmaceutical compositions intended for use in human or veterinary medicine, or alternatively in cosmetic compositions.

Description

Novel ligands that modulate RAR receptors, and use thereof in human medicine and in cosmetics
The invention relates to novel compounds as novel and useful industrial products, which are ligands that modulate RAR receptors. The invention also relates to compositions containing them, to processes for preparing them and to their use in pharmaceutical compositions for use in human or veterinary medicine, or alternatively in cosmetic compositions, and to the non-therapeutic use of these compositions.
Compounds with activity of retinoid type (vitamin A and its derivatives) are widely described in the literature as having activity in cell proliferation and differentiation processes. These properties give this class of compounds high potential in the treatment or prevention of numerous pathologies, and more particularly in dermatology and cancer. Many biological effects of retinoids are mediated by modulating the nuclear retinoic acid receptors (RAR).
The RAR receptors activate transcription by binding to DNA sequence elements, known as RAR response elements (RARE), in the form of a heterodimer with the retinoid X receptors (known as RXRs).
Three subtypes of human RARs have been identified and described: RARα, RARβ and RARγ.
The prior art contains a large number of chemical compounds that are RAR type receptor ligands. Among the prior art documents, examples that may be mentioned include patent US 6 150 413, which describes triaromatic compounds, patent US 6 214 878, which describes stilbene compounds, or patent US 6 218 128, which describes a family of bicyclic or tricyclic molecules.
The Applicant has invented novel compounds that modulate retinoic acid receptors.
Thus, the present invention relates to compounds corresponding to the general formula (I) below:
Figure imgf000003_0001
hich:
- R1 is a hydrogen atom, an alkyl radical of 1 to 4 carbon atoms or a -CF3 radical;
R2 is a hydrogen atom, an alkyl or alkoxy radical of 1 to 4 carbon atoms or a chlorine atom;
- R3 is a hydrogen atom, a linear or branched alkyl or alkoxy radical of 1 to 10 carbon atoms and preferably 1 to 6 carbon atoms optionally substituted with a methoxy group, or alternatively a linear or branched alkyl radical of 1 to 10 carbon atoms and preferably 1 to 6 carbon atoms containing an ether function;
- R4 is a hydrogen atom or an alkyl radical of 1 to 3 carbon atoms;
- R5 is a hydrogen atom or an alkyl radical of 1 to 3 carbon atoms;
- or alternatively R4 and R5 form, together with the bond -N-C(=Y)-, a ring of pyrrolidine, pyrrolidinone, piperidine or piperidinone type;
- Y represents two hydrogen atoms or a hetero atom, for instance oxygen or sulfur;
- Ar represents a 1 ,4-phenyl, 2,5-pyridyl, 5,2-pyridyl or 2,5-thiophenyl ring;
- X represents an oxygen atom optionally substituted with an alkyl or alkylamine chain or a C-C single bond;
- A represents a hydrogen atom or the following formula: R 6 R c- R 7
in which, o Q is an oxygen atom or an -NH- bond;
o Re represents a hydrogen atom, an alkyl radical of 1 to 6 carbon atoms, a cycioalkyl radical of 3 to 6 carbon atoms or a -C(O)CH3 or -C(O)CH2CH3 radical;
o R7 and R7' represent, independently of each other, a hydrogen atom or a hydroxyl group, on condition that R7 and R7' are not simultaneously a hydroxyl group;
o n is 0, 1, 2, 3, 4 or 5;
and the salts of the compounds of formula (I) when R3 represents a hydrogen atom, and also the geometrical isomers of the said compounds of formula (I).
When the compounds according to the invention are in the form of a salt, it is preferably an alkali metal or alkaline-earth metal salt, or alternatively a zinc salt or a salt of an organic amine or of an acidic partner when the compound is itself basic.
According to the present invention, the alkyl radicals of 1 to 3 carbon atoms are preferably chosen from methyl, ethyl, i-propyl and n-propyl radicals.
According to the present invention, the alkyl radicals of 1 to 4 carbon atoms are preferably chosen from methyl, ethyl, i-propyl, i-butyl and t-butyl radicals.
According to the present invention, the alkyl radicals of 1 to 6 carbon atoms are preferably chosen from methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl and hexyl.
According to the present invention, the alkyl radicals of 1 to 10 carbon atoms are linear or branched chains preferably chosen from methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t- butyl, pentyl, hexyl, heptyl, octyl, nonyl and dodecyl.
The term "alkoxy radical containing from 1 to 10 carbon atoms" means an alkyl radical containing from 1 to 10 carbon atoms linked to the rest of the molecule via an oxygen atom. Preferably, the alkoxy radical is chosen from methoxy, ethoxy, isopropyloxy, tert- butoxy and hexyloxy radicals.
Similarly, the term "alkoxy radical containing from 1 to 6 carbon atoms" means an alkyl radical containing from 1 to 6 carbon atoms linked to the rest of the molecule via an oxygen atom. Preferably, the alkoxy radical is chosen from methoxy, ethoxy, isopropyloxy, te/ϊ-butoxy and hexyloxy radicals.
Finally, the term "alkoxy radical containing from 1 to 4 carbon atoms" means an alkyl radical containing from 1 to 4 carbon atoms linked to the rest of the molecule via an oxygen atom. Preferably, the alkoxy radical is chosen from methoxy, ethoxy, isopropyloxy and terf-butoxy radicals.
According to the present invention, the cycloalkyl radicals of 3 to 6 carbon atoms are preferably chosen from cyclopropyl, cyclopentyl and cyclohexyl.
According to the present invention, the compounds of formula (I) that are more particularly preferred are those for which at least one, and preferably all, of the conditions below are satisfied: - R1 is a hydrogen atom or a t-butyl or i-propyl radical;
- R2 is a hydrogen atom or a t-butyl or i-propyl radical;
- R3 is a hydrogen atom or an ethyl radical;
- R4 and R5 are, independently of each other, a methyl or ethyl radical or together form a pyrrolidine ring; - A is as defined above in which R6 represents a hydrogen atom, an i-propyl or t-butyl radical, a cycloalkyl radical of 3 to 6 carbon atoms or a -C(O)CH3 or -C(O)CH2CH3 radical.
Among the compounds of formula (I) falling within the context of the present invention, mention may be made especially of the following compounds: 1. ethyl 3"-terf-butyl-4"-diethylamino-4'-hydroxy[1 ,1 ';3',1 "]terphenyl-4-carboxylate
2. ethyl 3"-fert-butyl-4"-diethylamino-4'-(4-hydroxybutoxy)-[1 , 1 ';3', 1 "]terphenyl-4- carboxylate
3. 3"-fe/t-butyl-4"-diethylamino-4'-(4-hydroxybutoxy)-[1 ,1';3',1"]terphenyl-4-carboxylic acid
4. ethyl 4"-(acetylethylamino)-3"-te/f-butyl-4'-(4-hydroxybutoxy)-[1 ,r;3',1"]terphenyl-4- carboxylate
5. 4"-(acetylethylamino)-3"-ferf-butyl-4'-(4-hydroxybutoxyH1 ,1 ';3',1"]terphenyl-4- carboxylic acid 6. 3"-te/f-butyl-4"-diethylamino-4'-(2-hydroxyethoxy)-[1 , 1 ';3', 1 "]terphenyl-4-carboxylic acid
7. ethyl 3"-te/f-butyl-4"-diethylamino-4'-(3-hydroxypropoxy)-[1 ,1 ';3',1"]terphenyl-4- carboxylate
8. 3"-fe/f-butyl-4"-diethylamino-4'-(3-hydroxypropoxy)-[1 , 1 ';3', 1 "]terphenyl-4-carboxylic acid
9. ethyl ^'-diethylamino-^-β-hydroxypropoxyHI ,1';3',1"]terphenyl-4-carboxylate
10. 4"-diethylamino-4'-(3-hydroxypropoxy)-[1 ,1';3',1"]terphenyl-4-carboxylic acid
11. ethyl 4"-diethylamino-3"-ethyl-4'-(3~hydroxypropoxy)-[1 , 1 ';3', 1 "]terphenyl-4- carboxylate 12. 4"-diethylamino-3"-ethyl-4'-(3-hydroxypropoxy)-[1 ,1 ';3',1 "]terphenyl-4-carboxylic acid
13. 4"-diethylamino-3"-ethyl-4'-(2-hydroxyethoxy)-[1 , 1 ';3', 1 "]terphenyl-4-carboxylic acid
14. ethyl 4"-diethylamino-3"-ethyl-4l-(2-hydroxyethoxy)-[1 , 1 ';3', 1 "Jterphenyl-4-carboxylate
15. 3"-fe/t-butyl-4"-diethylamino-4'-(2-hydroxyethoxy)-[1 , 1 ';3', 1 "]terphenyl-4-carboxylate
16. ethyl 4"-diethylamino-4'-(3-hydroxypropoxy)-3"-methyl[1 ,1I;3',1"]terphenyl-4- carboxylate
17. 4"-diethylamino-4'-(3-hydroxypropoxy)-3"-methyl[1 , 1 ';3', 1 "]terphenyl-4-carboxylic acid
18. ethyl 3"-fert-butyl-4'-(4-hydroxybutoxy)-4"-pyrrolidin-1-yl[1 ,1 ';3',1 "]terphenyl-4- carboxylate 19. 3"-te/if-butyl-4l-(4-hydroxybutoxy)-4"-pyrrolidin-1 -yl[1 , 1 ';3', 1 "]terphenyl-4-carboxylic acid
20. ethyl 4'-(4-hydroxybutoxy)-4"-pyrrolidin-1 -yl-3"-trifluoromethyl[1 , 1 ';3', 1 "]terphenyl-4- carboxylate
21. 4'-(4-hydroxybutoxy)-4"-pyrrolidin-1 -yl-3"-trifluoromethyl[1 , 1 ';3', 1 "]terphenyl-4- carboxylic acid 22. ethyl 3"-fe/f-butyl-4'-(3-hydroxypropoxy)-4"-pyrroliclin-1 -yl[1 , 1 ';3\ 1 "]terphenyl-4- carboxylate
23. 3"-fe/t-butyl-4l-(3-hydroxypropoxy)-4"-pyrrolidin-1-yl[1 ,1';3',1"]terphenyl-4-carboxylic acid 24. ethyl 3"-fert-butyl-4'-(2-hydroxyethoxy)-4"-pyrrolidin-1-yl[1 ,1';3',1"]terphenyl-4- carboxylate
25. 3"-tert-butyl-4'-(2-hydroxyethoxy)-4"-pyrrolidin-1 -yl[1 , 1 ';3', 1 "]terphenyl-4-carboxylic acid
26. 4'-(3-hydroxypropoxy)-4"-pyrrolidin-1-yl[1 ,1 ';3',1"]terphenyl-4-carboxylic acid 27. 3"-ferf-butyl-4"-diethylamino-4'-hydroxy[1,1';3',1"]terphenyl-4-carboxylic acid
28. ethyl 4"-diethylamino-4'-hydroxy-3"-trifluoromethyl[1,1';3',1"]terphenyl-4-carboxylate
29. 4"-diethylamino-4'-hydroxy-3"-trifluoromethyl[1,1';3',1"]terphenyl-4-carboxylic acid
30. 3"-tert-butyl-4"-diethylamino-4'-(4-isopropylaminobutoxy)-[1 ,1 ';3',1"]terphenyl-4- carboxylic acid 31. 3"-fe/f-butyl-4l-(4-isopropylaminobutoxy)-4"-pyrrolidin-1-yl[1 ,1';3',1"]terphenyl-4- carboxylic acid
32. ethyl 3"-te/t-butyl-4"-diethylamino-4'-(3-hydroxypropyl)-[1 ,1';3',1"]terphenyl-4- carboxylate
33. 3"-fe/t-butyl-4"-diethylamino-4'-(3-hydroxypropyl)-[1 ,1';3',1"]terphenyl-4-carboxylic acid
34. ethyl 3"-tert-butyl-4"-diethylamino-4l-(2,3-dihydroxypropyl)-[1 ,1 ';3',1"]terphenyl-4- carboxylate
35. 3"-fe/f-butyl-4"-diethylamino-4I-(2,3-dihydroxypropyl)-[1 ,1';3',1"]terphenyl-4-carboxylic acid 36. ethyl 4"-(acetylethylamino)-3"-fθrt-butyl-4'-(3-hydroxypropyl)-[1 ,1';3',1"]terphenyl-4- carboxylate
37. 4"-(acetylethylamino)-3"-tert-butyl-4I-(3-hydroxypropyl)-[1,1';3',1"]terphenyl-4- carboxylic acid
38. ethyl 3"-fe/t-butyl-4'-(3-cyclopropylaminopropyl)-4"-diethylamino[1 ,1';3',1"]terphenyl- 4-carboxylate
39. S'^ferf-butyl^'^S-cyclopropylaminopropyO-^'-diethylaminoti ,1 ';3',1"]terphenyl-4- carboxylic acid
40. ethyl S'^te/f-butyl-^-CS-cyclopentylaminopropyO-^'-diethylaminoII ,1 ';3',1"]terphenyl- 4-carboxylate 41. 3"-fert-butyl-4'-(3-cyclopentylaminopropyl)-4"-diethylamino[1 ,1';3',1"]terphenyl-4- carboxylic acid
42. ethyl 3"-terf-butyl-4'-(3-cyclohexylaminopropyl)-4"-diethylamino[1 , 1 ';3', 1 "]terphenyl-4- carboxylate 43. 3"-tert-butyl-4'-(3-cyclohexylaminopropyl)-4"-diethylamino[1 ,1';3',1 "]terphenyl-4- carboxylic acid
44. ethyl 3"-feAf-butyl-4'-(3-fe/t-butylaminopropyl)-4"-diethylamino[1 ,1';3',1"]terphenyl-4- carboxylate
45. 3ll-fert-butyl-4l-(3-teAf-butylaminopropyl)-4"-diethylamino[1 ,1';3',1"]terphenyl-4- carboxylic acid
46. ethyl 4"-(acetylethylamino)-3"-fe/f-butyl-4'-(3-cyclopropylaminopropyl)-[1 , 1 ';3', 1 "]ter- phenyl-4-carboxylate
47. 4"-(acetylethylamino)-3"-ferf-butyl-4'-(3-cyclopropylaminopropyl)-[1 ,1';3'I1"]terphenyl- 4-carboxylic acid 48. ethyl 3"-fert-butyl-4"-diethylamino-4l-(3-isopropylaminopropyl)-[1,1';3',1"]terphenyl-4- carboxylate
49. 3"-tert-butyl-4"-diethylamino-4'-(3-isopropylaminopropyl)-[1 ,1';3',1"]terphenyl-4- carboxylic acid
50. ethyl 4l-(3-aminopropyl)-3"-te/f-butyl-4"-diethylamino[1 ,1';3')1"]terphenyl-4- carboxylate
51. 4'-(3-aminopropyl)-3"-terf-butyl-4"-diethylamino[1 ,1 ';3',1"]terphenyl-4-carboxylic acid
52. [3"-terf-butyl-4-carboxy-4'-(3-hydroxypropyl)-[1 , 1 ';3', 1 "]terphenyl-4"-yl]diethylamine hydrochloride
53. 3"-tert-butyl-4I-(2-hydroxyethoxy)-4"-(2-oxopyrrolidin-1-yl)-[1 I1l;3l,1"]terphenyl-4- carboxylic acid
54. 3"-tert-butyl-4"-ethylamino-4'-(3-hydroxypropoxy)-[1 , 1 ';3\ 1 "]terphenyl-4-carboxylic acid
55. 4'-(3-acetoxypropoxy)-3"-ferf-butyl-4"-diethylamino[1 , 1 ';3', 1 "]terphenyl-4-carboxylic acid 56. 3"-te/τf-butyl-4"-diethylamino-4'-(3-propionyloxypropoxy)-[1 , 1 ';3', 1 "]terphenyl-4- carboxylic acid
57. methyl 3"-te/t-butyl-4"-diethylamino-4'-(3-hydroxypropoxy)-[1 , 1 ';3', 1 "]terphenyl-4- carboxylate
58. isopropyl 3"-te/f-butyl-4"-diethylamino-4'-(3-hydroxypropoxy)-[1 , 1 ';3', 1 "]terphenyl-4- carboxylate 59. isobutyl 3"-terf-butyl-4"-diethylamino-4l-(3-hydroxypropoxy)-[1 ,1';3',1"]terphenyl-4- carboxylate
60. 3"-teAt-butyl-4"-diethylamino-4'-(3-hydroxypropoxy)-5"-methyl[1 , 1 ';3', 1 "]terphenyl-4- carboxylic acid 61. 4"-diethylamino-4'-(3-hydroxypropoxy)-3"-isopropyl-5"-methyl[1 ,1';3',1"]terphenyl-4- carboxylic acid
62. 3"-tøAt-butyl-5ll-chloro-4"-diethylamino-4l-(3-hydroxypropoxy)-[1 , 1 ';3', 1 "]terphenyI-4- carboxylic acid
63. 4"-diethylamino-4l-(3-hydroxypropoxy)-3",5"-diisopropyl[1 ,1';3',1"]terphenyl-4- carboxylic acid
64. 3",5"-di-fe/f-butyl-4"-diethylamino-4'-(3-hydroxypropoxy)-[1 , 1 ';3\ 1 "]terphenyi-4- carboxylic acid
65. 4"-diethylamino-4'-(3-hydroxypropoxy)-3"-trifluoromethyl[1 ,1';3'lT']terphenyl-4- carboxylic acid 66. 3"-feff-butyl-4"-(ethylmethylamino)-4'-(2-hydroxyethoxyH1 , 1 ';3\ 1 "]terphenyl-4- carboxylic acid
67. 3"-tert-butyl-4"-dimethylamino-4'-(2-hydroxyethoxy)-[1 , 1 ';3', 1 "]terphenyl-4-carboxylic acid
68. 3"-fert-butyl-4"-(ethylisopropylamino)-4l-(2-hydroxyethoxy)-[1 ,r;3',1"]terphenyl-4- carboxylic acid
69. 3"-te/f-butyl-4"-(ethylpropylamino)-4'-(2-hydroxyethoxy)-[1 , 1 ';3', 1 "]terphenyl-4- carboxylic acid
70. 3"-tert-butyl-4"-dipropylamino-4'-(2-hydroxyethoxy)-[1 , 1 ';3', 1 "]terphenyl-4-carboxylic acid 71. 3"-te/f-butyl-4"-(ethylpropionylamino)-4'-(2-hydroxyethoxy)-[1 , 1 ';3', 1 "]terphenyl-4- carboxylic acid
72. 6-[3'-te/f-butyl-4I-diethylamino-6-(2-hydroxyethoxy)biphenyl-3-yl]nicotinic acid
73. 5-[3'-te/t-butyl-4'-diethylamino-6-(2-hydroxyethoxy)biphenyl-3-yl]pyridine-2-carboxylic acid 74. 5-[3'-te/f-butyl-4'-diethylamino-6-(2-hydroxyethoxy)biphenyl-3-yl]thiophene-2- carboxylic acid
75. 3"-fert-butyl-4l-(2-hydroxyethoxy)-5ll-methyl-4"-pyrrolidin-1-yl[1 ,1';3I,1"]terphenyl-4- carboxylic acid
76. 3"-te/τf-butyl-5"-chloro-4I-(2-hydroxyethoxy)-4"-pyrrolidin-1 -yl[1 , 1 ';3', 1 "]terphenyl-4- carboxylic acid 77. 4'-(2-hydroxyethoxy)-3"-isopropyl-4"-pyrrolidin-1-yl[1,1';3',1"]terphenyl-4-carboxylic acid
78. 3"-ethyl-4'-(2-hydroxyethoxy)-4"-pyrrolidin-1 -yl[1 , 1 ';3', 1 "]terphenyl-4-carboxylic acid
79. 4l-(2-hydroxyethoxy)-3",5"-diisopropyl-4"-pyrrolidin-1-yl[1 ,1';3',1"]terphenyl-4- carboxylic acid
80. 3",5"-diethyl-4'-(2-hydroxyethoxy)-4"-pyrrolidin-1-yl[1 ,1';3',1"]terphenyl-4-carboxylic acid
81. 3",5"-dimethyl-4'-(2-hydroxyethoxy)-4"-pyrrolidin-1-yl[1 ,1';3',1"]terphenyl-4-carboxylic acid 82. 4'-(2-acetoxyethoxy)-3"-fe/f-butyl-4"-pyrroiidin-1 -yl[1 , 1 ';3', 1 "]terphenyl-4-carboxylic acid
83. 4I-(2-propionyloxyethoxy)-3"-tert-butyl-4"-pyrrolidin-1-yl[1)r;3',1"]terphenyl-4- carboxylic acid
84. methyl 3"-teAf-butyl-4'-(2-hydroxyethoxy)-4"-pyrrolidin-1-yl[1 , 1 ';3', 1 "]terphenyl-4- carboxylate
85. isopropyl 3"-tert-butyl-4'-(2-hydroxyethoxy)-4"-pyrrolidin-1 -yl[1 , 1 ';3', 1 "]terphenyl-4- carboxylate
86. isobutyl 3"-te/f-butyl-4l-(2-hydroxyethoxy)-4"-pyrrolidin-1-yl[1 ,1';3',1"]terphenyl-4- carboxylate 87. ethyl 3"-fert-butyl-4l-(3-hydroxypropoxy)-4"-pyrrolidin-1-yl[1 ,1';3>,1"]terphenyl-4- carboxylate
88. ethyl 3"-te/f-butyl-5"-chloro-4l-(2-hydroxyethoxy)-4"-pyrrolidin-1-yl[1,1';3',1"]ter- phenyl-4-carboxylate
89. 6-[3'-te/t-butyl-6-(2-hydroxyethoxy)-4'-pyrrolidin-1 -ylbiphenyl-3-yl]nicotinic acid 90. 5-[3'-tert-butyl-6-(2-hydroxyethoxy)-4'-pyrrolidin-1 -ylbiphenyl-3-yl]pyridine-2- carboxylic acid
91. ethyl 6-[3'-te/t-butyl-6-(2-hydroxyethoxy)-4I-pyrrolidin-1-ylbiphenyl-3-yl]nicotinate
92. ethyl 3"-tert-butyl-4'-(3-hydroxypropyl)-4"-pyrrolidin-1 -yl[1 , 1 ';3', 1 "]terphenyl-4- carboxylate 93. 3"-terf-butyl-4l-(3-hydroxypropyl)-4"-pyrrolidin-1-yl[1,1';3'I1"]terphenyl-4-carboxylic acid
94. 3"-terf-butyl-4'-(2-hydroxyethoxy)-4ll-(2-oxopyrrolidin-1-yl)-[1 ,r;3M"]terphenyl-4- carboxylic acid
95. 3lI-tert-butyl-4I-(2-hydroxyethoxy)-4"-(2-oxopiperid-1 -yl)-[1 , 1 ';3\ 1 "]terphenyl-4- carboxylic acid 96. 3"-ferf-butyl-4'-(2-hydroxyethoxy)-4"-piperid-1-yl[1 ,1';3',1"]terphenyl-4-carboxylic acicl
97. 5-[3'-fert-butyl-6-(2-hydroxyethoxy)-4'-pyrrolidin-1-ylbiphenyl-3-yl]thiophene-2- carboxylic acid.
A subject of the present invention is also the processes for preparing the compounds of formula (I), in particular according to the reaction schemes given in Figures 1, 2 and 3.
- Synthesis of advanced fragments (Figure 1)
The intermediates of general formula 1 or 2 are prepared from the commercial starting material 1. Compound 1 is subjected to a first step of esterification of the carboxylic acid function (a), performed under standard esterification conditions including, for example, the methods described in "Protective Groups in Organic Synthesis" by T. W. Greene & P. G. M. Wuts, 3rd edition (J. Wiley & sons), pages 373-377 or in "Comprehensive Organic Transformations" by R.C. Larock, 2nd edition (J. Wiley & sons), pages 1932-1941. The introduction of a halide (bromide or iodide) into an ortho position of the phenol function (b) may be performed under standard bromination conditions (for example by adding dibromine or an equivalent reagent such as a tetraalkylammonium tribromide) or standard iodination conditions (for example sodium iodide and sodium hypochlorite), many examples of which may be found in the literature: see, for example "Comprehensive Organic Transformations" by R.C. Larock, 2nd edition (J. Wiley & sons), pages 619-628.
The compounds of general formula 3 are then obtained via standard methods of etherification of phenols (c), for instance an etherification similar to a Williamson reaction starting with corresponding alkyl halides in the presence of a base, or alternatively a reaction of Mitsunobu type with the corresponding hydroxyl derivatives (see "Comprehensive Organic Transformations" by R.C. Larock, 2nd edition (J. Wiley & sons), pages 889-910 or, respectively: a. Dermer, O.C., Chem. Rev. 1934, 14, 409 or Nakatsugi, T. Synthesis, 1987, 280: b. Mitsunobu, O. Synthesis 1981, 1). The compounds of formula 3 are, in the case where the protecting group PG does not coincide with the desired group R6, subjected to a deprotection step (d) suited to the nature of PG, the description of which will be found in "Protective Groups in Organic Synthesis" by T. W. Greene & P. G. M. Wuts, 3rd edition (J. Wiley & sons) to obtain compound 4 (R6 = H) and is then subjected, where appropriate, to a standard esterification step (e) (see above) with the carboxylic acid or acyl halide derivative corresponding to the structure of R4, in order to obtain the compounds of type 5 in which R6 is other than H. The intermediates of general formula 7 may be obtained from the compounds 6 after a first step of bromination (f) in the para position (see above) followed by alkylation or amidation of the aniline function (g) in the presence, respectively, of a dialkyl sulfate or of an alkyl halide and a base (see, for example, Dehmlow, E.V., Tet. Lett. 1985, 25, 97 or the reference below) or in the presence of an acyl chloride or a corresponding anhydride and a base (for example Et3N) in accordance with the methods described, for example, in "Chemistry of the Amino Group" by S. Patai (Wiley-lnterscience, NY 1968) pages 669- 682. Alternatively, when R4 and R5, taken together, form a ring from among the claimed sub-structures, for example a pyrrolidine ring, the compounds 7 may be obtained after bromination of 6 and then formation of the ring (g), for example in the presence of a 1 ,4- dihalobutane or a 1 ,5-dihalopentane or the carbonyl analogues thereof, and of a base, or via a method described in "Chemistry of the Amino Group" by S. Patai (Wiley- lnterscience, NY 1968) pages 669-682. Alternatively, when R4 and R5, taken together, form a ring from among the claimed sub-structures, the compounds of general formula 7 may also be generated after para- bromination (f, see above) and then formation (h) and reduction (i) of a pyrrolidinone, piperidinone, succinimide or piperidine-2,6-dione group (see, for example, Ohta, S. Heterocycles 1993, 36 (4), 743; Hubbard, J. L.; J. Heterocycl. Chem. 1992, 29 (4), 719; Akula, M. R.; Synth. Commun. 1998, 28 (11), 2063; Collins, C. J. Tetrahedron Lett. 1999, 40 (19), 3673).
Finally, the compounds of general formula 8 may be obtained via a sequence of two reactions: the first is an alkylation reaction (h) of a secondary aniline (when Y = H1 H, see above) or of an acylaniline (when Y = O)1 in the presence of a dialkyl sulfate or an alkyl halide and of a base (see, for example, Bisarya, S.C. Synth. Commun. 1992, 22 (22), 3305 or the above references); an inversion of steps (h) and (g) when Y = O allows the same precursor of the compounds of general formula 8 to be obtained. The second reaction is the generation of a boronic acid or boronate function from the bromide group (i), for example by generating an organolithium or organomagnesium reagent trapped with a trialkyl borate (see, for example, Cladingboel, D. E. Org. Process Res. Dev. 2000, 4 (3), 153 or Li, W. J. Org. Chem. 2002, 67 (15), 5394) or alternatively by performing a coupling reaction with bis-dialkoxydiborane or dialkoxyborane in the presence of a catalyst of transition metal type (see, for example, Ishiyama, T. J. Org. Chem. 1995, 60 (23), 7508 or Murata, M., J. Org. Chem. 1997, 62 (19), 6458). - Synthesis of the compounds in which X = O (Figure 2)
The synthesis of the final compounds of general formulae 11 and 12 may be performed according to two parallel routes for which only the order of the reactions changes.
A first route requires the synthesis of the intermediate 9, via a coupling reaction of Suzuki type 0) between the intermediate 2 and the boronate/boronic acid partner of formula 8, under standard Suzuki coupling conditions (see A. Suzuki et a/., Synth. Commun. 1981, 11, 513 or Sharp, MJ. Tet. Lett. 1985, 26, 5997) or alternatively, where appropriate, optimized conditions (see, for example, Littke, A. F. et a/., J. Am. Chem. Soc. 2000, 122 (17), 4020-4028). The compounds 9 are obtained directly when R3 is other than H, or after a reaction to reveal the carboxylic acid function, for example by using conditions among those described in "Comprehensive Organic Transformations" by R. C. Larock, 2nd edition (J. Wiley & sons), pages 1959-1968.
The intermediate 9 may also be subjected to the conditions (c) described above in order to obtain the compounds of general formula 10.
These compounds of general formula 10 may also be generated via the same methods Q) described above starting with the intermediates of general formula 3.
When PG is other than the desired group R6, 10 may be subjected to deprotection conditions (d) mentioned above to obtain the final compounds 11 in which R6 = H, and then, where appropriate, subjected to the conditions (e) to obtain the compounds 12 in which R6 is other than H.
Alternatively, these same final compounds 11 and 12 may be obtained by subjecting, respectively, the intermediates 4 and 5 to the coupling conditions (j) described above.
Finally, when R3 = H, the advanced intermediates 11 and 12 may be subjected to reactions to reveal the carboxylic acid function, for example using conditions among those described in "Comprehensive Organic Transformations" by R.C. Larock, 2nd edition (J. Wiley & sons), pages 1959-1968.
The compounds of general formula 13 may be obtained after a sequence of conversion of the primary alcohol function of 11 into an amine, for example via oxidation (k) followed by reductive amination (I) (see, for example, "Comprehensive Organic Transformations" by R.C. Larock, 2nd edition (J. Wiley & sons)) or alternatively conversion of the alcohol into a halide and substitution of the halogen atom with an amine.
- Synthesis of the claimed compounds in which X is a single bond (Figure 3)
When X is a single bond, the intermediates of general formula 9 are first converted into suitable sulfonyl esters under standard conditions, for example into triflates (see, for example, Robl, J. A. Tetrahedron Lett. 1990, 31 (24), 3421) (m), and this group is then subjected to an allylation reaction (n), for example in the presence of tributylallyltin and of a transition metal catalyst, for example tetrakis(triphenylphosphine)palladium (for an example, see Martorell, G.; Garcia-Raso, A.; Saa, J. M.; Tetrahedron Lett. 1990, 31 (16), 2357), to obtain the intermediates of type 14.
The final compounds of general formula 15 may then be obtained via an oxidation reaction (o) of the olefin function, for instance an oxidative hydroboration reaction (see, for example, Luo, F. T.; Negishi, E.; J. Org. Chem. 1983, 48, 5144 or "Comprehensive
Organic Transformations" by R.C. Larock, 2nd edition (J. Wiley & sons), pages 992-993 &
1005-1007) in the case where R7, R7' = H, H or alternatively via a racemic or enantioselective dihydroxylation reaction, as described, for example, in Van Rheenan, V.; Cha, D. Y.; Hartley, W. M.; Org. Synth. 1978, 58, 44 or in "Comprehensive Organic
Transformations" by R.C. Larock, 2nd edition (J. Wiley & sons), pages 996-1001.
When Q = NH, the reaction sequence (k, I) described above for the conversion of the compounds 11 into compounds 13 may be applied, in order to obtain the compounds of general formula 16. Alternatively, when Q = O and R6 is other than H, a simple standard alkylation or acylation reaction of the primary alcohol function of the intermediates of structure 15 allows the final compounds of general formula 16 to be obtained.
The compounds according to the invention have modulatory properties on retinoic acid receptors (RAR). This activity on the RARα, β and v receptors is measured in a transactivation test and quantified by means of the dissociation constant Kdapp (apparent), as described in Example 55. The preferred compounds of the present invention have a dissociation constant of less than or equal to 5000 nM, advantageously less than or equal to 1000 nM and preferentially less than or equal to 1 nM.
Preferably, the compounds are at least modulators of receptors of RARy type, selectively relative to the subtypes α and β, i.e. they have a ratio between the Kdapp for the RARα or RARβ receptors, and the Kdapp for the RARy receptors, of greater than or equal to 5. Preferably, this ratio RARγ/RARβ or RARy/RARα is greater than or equal to 10, advantageously greater than or equal to 50 and more advantageously greater than or equal to 100.
A subject of the present invention is also the compounds of formula (I) as described above, as medicaments.
The compounds according to the invention are particularly suitable in the following fields of treatment:
1) for treating dermatological complaints associated with a keratinization disorder relating to cell differentiation and proliferation, especially for treating common acne, comedones, polymorphonuclear leukocytes, acne rosacea, nodulocystic acne, acne conglobata, senile acne, and secondary acnes such as solar acne, medication-related acne or occupational acne;
2) for treating other types of keratinization disorders, especially ichthyosis, ichthyosiform conditions, Darier's disease, palmoplanar keratoderma, leukoplakia and leukoplakiform conditions, and cutaneous or mucous (buccal) lichen; 3) for treating other dermatological complaints with an inflammatory immunoallergic component, with or without cell proliferation disorder, and especially all forms of psoriasis, whether cutaneous, mucous or ungual psoriasis, and even psoriatic rheumatism, or cutaneous atopy, such as eczema, or respiratory atopy, or even gingival hypertrophy;
4) in the treatment of skin disorders caused by exposure to UV radiation, and also for repairing or combating ageing of the skin, whether photoinduced or chronological ageing, or for reducing actinic pigmentations and keratosis, or any pathology associated with chronological or actinic ageing, such as xerosis;
5) for treating all dermal or epidermal proliferations, whether benign or malignant, and whether of viral origin or otherwise, such as common warts, flat warts and verruciform epidermodysplasia, oral or florid papillomatoses, T lymphoma, and proliferations that may be induced by ultraviolet radiation, especially in the case of basocellular and spinocellular epithelioma, and also any precancerous skin lesion such as keratoacanthomas;
6) for treating other dermatological disorders such as immune dermatoses, such as lupus erythematosus, immune bullous diseases and collagen diseases, such as scleroderma;
7) in the treatment of dermatological or general complaints with an immunological component;
8) for treating certain ophthalmological disorders, especially corneopathies; 9) for preventing or curing the stigmata of epidermal and/or dermal atrophy induced by local or systemic corticosteroids, or any other form of cutaneous atrophy;
10) in the treatment of any cutaneous or general complaint of viral origin;
11) for combating sebaceous function disorders, such as the hyperseborrhoea of acne or simple seborrhoea; 12) for preventing or treating cicatrization disorders, or for preventing or repairing stretch marks, or alternatively for promoting cicatrization;
13) in the treatment of pigmentation disorders, such as hyperpigmentation, melasma, hypopigmentation or vitiligo;
14) in the treatment of lipid metabolism complaints, such as obesity, hyperlipidaemia, or non-insulin-dependent diabetes;
15) in the treatment of inflammatory complaints such as arthritis;
16) in the treatment or prevention of cancerous or precancerous conditions;
17) in the prevention or treatment of alopecia of various origins, especially alopecia caused by chemotherapy or radiation; 18) in the treatment of disorders of the immune system, such as asthma, type I sugar diabetes, multiple sclerosis or other selective dysfunctions of the immune system; and 19) in the treatment of complaints of the cardiovascular system, such as arteriosclerosis or hypertension.
A subject of the present invention is also a pharmaceutical composition comprising, in a physiologically acceptable medium, at least one compound of formula (I) as defined above.
A subject of the present invention is also a novel medicinal composition intended especially for treating the abovementioned complaints, which is characterized in that it comprises, in a pharmaceutically acceptable support that is compatible with the mode of administration selected for this composition, at least one compound of formula (I), an optical isomer thereof or a salt thereof.
The composition according to the invention may be administered orally, enterally, parenterally, topically or ocularly. The pharmaceutical composition is preferably packaged in a form that is suitable for topical application.
Via the oral route, the composition may be in the form of tablets, gel capsules, dragees, syrups, suspensions, solutions, powders, granules, emulsions, suspensions of microspheres or nanospheres or lipid or polymer vesicles allowing a controlled release. Via the parenteral route, the composition may be in the form of solutions or suspensions for infusion or for injection.
The compounds according to the invention are generally administered at a daily dose of about 0.01 mg/kg to 100 mg/kg of body weight, in one or more dosage intakes.
The compounds are used systemically, at a concentration generally of between 0.001% and 10% by weight and preferably between 0.01% and 1% by weight, relative to the weight of the composition.
Via the topical route, the pharmaceutical composition according to the invention is more particularly intended for treating the skin and mucous membranes and may be in liquid, pasty or solid form, and more particularly in the form of ointments, creams, milks, pomades, powders, impregnated pads, syndets, solutions, gels, sprays, mousses, suspensions, sticks, shampoos or washing bases. It may also be in the form of suspensions of microspheres or nanospheres or of lipid or polymer vesicles or gelled or polymer patches allowing a controlled release.
The compounds are used topically at a concentration generally of between 0.001% and 10% by weight and preferably between 0.01% and 1% by weight, relative to the total weight of the composition.
The compounds of formula (I) according to the invention also find an application in cosmetics, in particular in body and hair hygiene and especially for treating acne-prone skin, for promoting regrowth of the hair or for limiting hair loss, for combating the greasy appearance of the skin or the hair, in protection against the harmful aspects of sunlight or in the treatment of physiologically dry skin, and for preventing and/or combating photoinduced or chronological ageing.
A subject of the invention is thus also a cosmetic composition comprising, in a physiologically acceptable support, at least one of the compounds of formula (I).
A subject of the invention is also the non-therapeutic use of a cosmetic composition comprising at least one compound of formula (I) for preventing and/or treating the signs of ageing and/or dry skin.
A subject of the invention is also the non-therapeutic use of a cosmetic composition comprising at least one compound of formula (I) for body or hair hygiene.
The cosmetic composition according to the invention containing, in a physiologically acceptable medium, at least one compound of formula (I) or an optical or geometrical isomer thereof or a salt thereof, may be especially in the form of a cream, a milk, a gel, suspensions of microspheres or nanospheres or lipid or polymer vesicles, impregnated pads, solutions, sprays, mousses, sticks, soaps, washing bases or shampoos.
The concentration of compound of formula (I) in the cosmetic composition is preferably between 0.001 % and 3% by weight, relative to the total weight of the composition.
The term "physiologically acceptable medium" means a medium that is compatible with the skin and optionally with its integuments (eyelashes, nails or hair) and/or mucous membranes.
The pharmaceutical and cosmetic compositions as described above may also contain inert additives, or even pharmacodynamically active additives as regards the pharmaceutical compositions, or combinations of these additives, and especially:
- wetting agents;
- flavour enhancers;
- preserving agents such as para-hydroxybenzoic acid esters; - stabilizers; - moisture regulators;
- pH regulators;
- osmotic pressure modifiers;
- emulsifiers; - UV-A and UV-B screening agents;
- antioxidants such as α-tocopherol, butylhydroxyanisole, butylhydroxytoluene, superoxide dismutase, ubiquinol or certain metal-chelating agents;
- depigmenting agents such as hydroquinone, azelaic acid, caffeic acid or kojic acid;
- emollients; - moisturizers, for instance glycerol, PEG 400, thiamorpholinone and its derivatives or urea; antiseborrhoeic or anti-acne agents, such as S-carboxymethylcysteine, S- benzylcysteamine, salts thereof or derivatives thereof, or benzoyl peroxide;
- antibiotics, for instance erythromycin and its esters, neomycin, clindamycin and its esters, and tetracyclines;
- antifungal agents such as ketoconazole or poly-4,5-methylene-3-isothiazolidones;
- agents for promoting regrowth of the hair, for instance Minoxidil (2,4-diamino-6- piperidinopyrimidine 3-oxide) and its derivatives, Diazoxide (7-chloro-3-methyl-1 ,2,4- benzothiadiazine 1,1-dioxide) and Phenytoin (5,4-diphenylimidazolidine-2,4-dione); - non-steroidal anti-inflammatory agents;
- carotenoids and especially β-carotene;
- anti-psoriatic agents such as anthralin and its derivatives;
- eicosa-5,8,11 ,14-tetraynoic acid and eicosa-5,8,11-triynoic acid, and esters and amides thereof; - retinoids, i.e. natural or synthetic RXR receptor ligands;
- corticosteroids or oestrogens;
- α-hydroxy acids and α-keto acids or derivatives thereof, such as lactic acid, malic acid, citric acid, glycolic acid, mandelic acid, tartaric acid, glyceric acid or ascorbic acid, and also salts, amides or esters thereof, or β-hydroxy acids or derivatives thereof, such as salicylic acid and its salts, amides or esters;
- ion-channel blockers such as potassium-channel blockers;
- or alternatively, more particularly for pharmaceutical compositions, in combination with medicaments known to interfere with the immune system (for example cyclosporin, FK 506, glucocorticoids, monoclonal antibodies, cytokines or growth factors, etc.). Needless to say, a person skilled in the art will take care to select the optional compound(s) to be added to these compositions such that the advantageous properties intrinsically attached to the present invention are not, or are not substantially, adversely affected by the envisaged addition.
Another subject of the invention relates to a cosmetic process for enhancing the appearance of the skin, characterized in that a composition comprising at least one compound of formula (I) as defined above is applied to the skin.
Activation of the retinoic acid receptors with the compounds of formula (I) according to the invention makes it possible to obtain skin of enhanced surface appearance.
Several examples of the production of active compounds of formula (I) according to the invention, biological activity results and also various concrete formulations based on such compounds, will now be given, for illustrative purposes and with no limiting nature.
EXAMPLES
Example 1 - Ethyl 3"-tert-butyl-4"-diethylamino-4'-hvdroxyn.1':3'.1"1terphenyl-4- carboxylate
Figure imgf000020_0001
a) 4-Bromo-2-tert-butylaniline 25 g of 2 ferf-butylaniline (168 mmol) are dissolved in 250 mL of THF; the reaction mixture is stirred and cooled to O0C, and 81 g of tetrabutylammonium bromide (TBA-Br3) (168 mmol) are then added portionwise while maintaining the temperature between 00C and 5°C. The temperature is then allowed to rise to about room temperature and the mixture is stirred for 10 minutes. The reaction is stopped by adding 250 mL of water and is then extracted with 250 mL of ethyl acetate. The organic phases are washed with 1 L of saturated Na2S2O5 solution and then dried over magnesium sulfate. The solvents are evaporated off and the residue is filtered through a pad of silica (pure heptane, then a 3/7 heptane/ethyl acetate mixture). 43.6 g of 4-bromo-2-te/?-butylaniline (yield = 100%) are obtained in the form of a white solid.
b) (4-Bromo-2-tert-butylphenyl)diethylamine
6.9 g (0.17 mol) of sodium hydride are suspended in 20O mL of tetrahydrofuran. 13 g (57 mmol) of 4-bromo-2-terf-butylaniline are added, along with 200 mL of dimethyl sulfoxide, added slowly. The mixture turns blue and, after 30 minutes, 13 mL (0.17 mol) of ethyl iodide are added and the reaction medium, which has turned white, is stirred at room temperature for 13 hours. The reaction medium is then poured into saturated ammonium chloride solution and extracted with ethyl acetate, and the organic phase is then washed twice with water. It is dried and then concentrated to dryness. The residue is purified by chromatography on silica gel (eluent: 90/10 heptane/ethyl acetate). 14.8 g of (4-bromo-2- te/f-butylphenyl)diethylamine are obtained (yield = 91%) in the form of a yellow oil.
c) 3-tert-Butyl-4-diethylaminophenylboronic acid
9.8 g (35 mmol) of (4-bromo-2-fe/f-butylphenyl)diethylamine are dissolved in 118 mL of THF at room temperature, and the reaction mixture is then cooled to -78°C. 17.5 mL of a 2 M solution of n-BuLi (35 mmol) are added dropwise and the reaction medium is left stirring at -78°C for 1 hour. 12 mL of triisopropyl borate (B(OiPr)3) (52 mmol) are added slowly and the reaction medium is stirred for 15 minutes at -700C.
The temperature is raised to room temperature and the reaction medium is stirred for 3 hours. The reaction medium is cooled again to -7O0C and 69 mL of 1M hydrochloric acid solution (69 mmol) are added. The temperature is raised to O0C and the reaction medium is stirred for 30 minutes. The reaction is extracted after addition of 250 mL of water and 250 mL of ethyl acetate. The organic phases are washed with 800 mL of water and then dried over sodium sulfate. 6.5 g of 3-ferf-butyl-4-diethylaminophenylboronic acid are obtained (yield = 76%) in the form of a thick oil.
d) Ethyl 3"-tert-butyl-4"-diethylamino-4'-hydroxy[1, 1 ';3', 1 "]terphenyl-4-carboxylate
To 5.6 g of ethyl 3'-bromo-4'-hydroxy-biphenyl-4-carboxylate (17 mmol) are added 6.5 g of
3-terf-butyl-4-diethylaminophenylboronic acid (26 mmol) dissolved in 112 mL of toluene and 30.5 mL of 2M potassium carbonate (61 mmol). The reaction medium is stirred and heated to 4O0C; 2 g of tetrakis(triphenylphosphine)palladium (Pd(PPh3)4) (1.74 mmol) are added and the medium is heated to 110°C and stirred for 3 hours. The reaction is stopped by adding 200 mL of water and the medium is then extracted with 200 mL of ethyl acetate. The organic phases are washed with 400 mL of water and neutralized with 200 mL of saturated NH4CI and then dried over magnesium sulfate. The solvents are evaporated off and the residue is then purified by chromatography on silica gel (eluent: 9/1 heptane/ethyl acetate). 1.2 g of ethyl 3"-tert-butyl-4"-diethylamino-4'-hydroxy[1 ,1';3',1"]terphenyl-4- carboxylate are obtained (yield = 16%) in the form of an orange solid.
1H NMR (CDCI3, 400 MHz): 1.14 (t, J=7.4Hz, 6H); 1.44 (t, J=7.6H, 3H); 1.51 (s, 9H); 2.94 (bs, 2H); 3.00 (bs, 2H); 4.42 (q, J=7.6Hz, 2H); 5.49 (s, 1H); 7.11 (d, J=8.5Hz, 1H); 7.33- 7.41 (m, 2H); 7.53-7.57 (m, 3H); 7.68 (d, J=6.7Hz, 2H); 8.11 (d, J=6.7Hz, 2H).
Example 2 - Ethyl 3"-tert-butyl-4"-diethylamino-4'-(4-hvdroxybutoxy)-n.1':3M"1- terphenyl-4-carboxylate
Figure imgf000022_0001
a) Ethyl 3"-tert-butyl-4ψ-(tert-butyldimethylsilanyloxy)butoxy]-4"-diethylamino[1l 1!;3', 1']1 - terphenyl-4-carboxylate
1 g of ethyl 3"-tørf-butyl-4"-diethylamino-4l-hydroxy[1 ,1';3',1"]terphenyl-4-carboxylate obtained in Example 1d (2.2 mmol) are dissolved in 20 mL of dimethylformamide under a nitrogen atmosphere. 880 mg (2.7 mmol) of caesium carbonate are added. The reaction medium stirred at room temperature turns yellow. 0.64 mL of 1-bromo-4-(te/f- butyldimethylsilanyloxy)butane (2.4 mmol) is then added and the reaction medium is heated at 8O0C for 18 hours. The reaction medium is then cooled to room temperature and then filtered. The solvents are evaporated off and the residue obtained is purified by chromatography on silica gel (eluent: 70/30 heptane/ethyl acetate). 1.4 g of ethyl 3"-terf-butyl-4l-[4-(tert-butyldimethylsilanyloxy)butoxy]-4"-diethylamino- [1,1';3',1"]terphenyl-4-carboxylate are obtained (yield = 99%) in the form of an oil.
b; Ethyl 3"-tert-butyl-4"-diethylamino-4'-(4-hydroxybutoxy)-[1, 1 ';3', 1 "]terphenyl-4- carboxylate
1.6 g of ethyl 3"-terf-butyl-4'-[4-(te/f-butyldimethylsilanyloxy)butoxy]-4"-diethylamino- [1 ,1';3',1"]terphenyl-4-carboxylate (2.5 mmol) are dissolved in 2O mL of tetrahydrofuran under a nitrogen atmosphere.
3 mL of a 1M solution of tetrabutylammonium fluoride are then added dropwise. The reaction medium is stirred at room temperature for 3 hours, and the reaction is then stopped by adding 10 mL of water and then extracted with ethyl acetate. The organic phases are combined and dried over magnesium sulfate. The solvents are evaporated off and the residue is precipitated from 10 mL of heptane and filtered. 900 mg of ethyl 3"-tert- butyl-4"-diethylamino-4'-(4-hydroxybutoxy)-[1 , 1 ';3', 1 "]terphenyl-4-carboxylate are obtained (yield = 92%).
1H NMR (CDCI3 - 400 MHz): 1.12 (t, J=7.8Hz, 6H); 1.43 (t, J=7.5Hz, 3H); 1.51 (s, 9H); 1.64-1.71 (m, 2H); 1.85-2.07 (m, 2H); 2.91 (bs, 2H); 2.99 (bs, 2H); 3.62 (t, J=6.1Hz, 2H); 4.08 (t, J=6.1Hz, 2H); 4.41 (t, J=7.5Hz, 2H); 7.07 (d, J=8.0Hz, 1H); 7.30 (d, J=8.0Hz, 1H); 7.38 (d, J=8.0Hz, 1H); 7.56-7.59 (m, 1H); 7.62-7.64 (m, 2H); 7.68 (d, J=8.2Hz, 2H); 8.11 (d, J=8.2Hz, 2H).
Example 3 - 3"-tert-Butyl-4"-diethylamino-4'-(4-hvdroxybutoxy)-ri,1':3','t"1terphenyl- 4-carboxylic acid
Figure imgf000023_0001
a) y'-teii-Butyl-r-diethylamino-y-W-hydroxybutoxyMI, 1 ';3\ 1 "]terphenyl-4-carboxylic acid
0.9 mL of aqueous 1 N sodium hydroxide solution is added to a solution of 300 mg of ethyl 3"-fert-butyl-4"-diethylamino-4'-(4-hydroxybutoxy)-[1 , 1 ';3', 1 "]terphenyl-4-carboxylate (Example 2b) in a mixture of 10 mL of tetrahydrofuran and 3 mL of water. The reaction medium is stirred at room temperature for 12 hours. 0.5 mL of aqueous 1N sodium hydroxide solution is then added. After 12 hours at room temperature, the reaction medium is heated to 500C and then left at room temperature for 3 days. The reaction is stopped by adding 5 mL of water. The reaction medium is acidified to pH 5 by adding aqueous 1N hydrochloric acid solution and is then extracted with ethyl acetate. The organic phase is dried over magnesium sulfate. The solid obtained is taken up in heptane and then filtered. 235 mg of 3"-terf-butyl-4"-diethylamino-4'-(4-hydroxybutoxy)- [1 ,1';3',1"]terphenyl-4-carboxylic acid are obtained in the form of a white solid (yield = 83%, m.p. = 165°C).
1H NMR (DMSO-Dg 400 MHzV 1.06 (t, 6H); 1.45 (s, 9H); 1.52 (m, 2H); 1.73 (m, 2H); 2.9 (m, 4H); 3.39 (t, 2H); 4.05 (t, 2H); 7.2 (dd, J=8.5Hz, 1H); 7.3 (dd, J=8.15Hz, 1H); 7.39 (d, J=6.93Hz, 1H); 7.6 (s, 1H); 7.64 (s, 1H); 7.66 (d, J=8.5Hz 2H); 7.8 (d, 2H, J=8.3Hz); 7.97 (d, J=8.3Hz, 1H).
Example 4 - Ethyl 4"-(acetylethylamino)-3"-te/t-butyl-4'-(4-hvdroxybutoxy)- ri.1':3M"1terphenyl-4-carboxylate
Figure imgf000024_0001
a) (4-Bromo-2-tert-butylphenyl)ethylamine
In a 1 L three-necked flask under a nitrogen atmosphere, equipped with a magnetic stirrer, 28 g (123 mmol) of 4-bromo-2-te/f-butylphenylamine are dissolved in 28O mL of dimethylformamide. 5.4 g (135 mmol) of sodium hydride (60%) are added portionwise and the reaction medium is stirred for 10 minutes. 140 mL of dimethyl sulfoxide are then added slowly. The reaction medium is stirred at room temperature for 2 hours, 23 g (147 mmol, 11.8 ml.) of ethyl iodide are introduced dropwise and the medium is then stirred for 18 hours at room temperature. The reaction medium is poured into 1 L of water and extracted three times with ethyl acetate.
The organic phases obtained are combined and washed with water, dried over anhydrous magnesium sulfate, filtered and evaporated to give a reddish oil. This residue is purified on silica (eluent: 95/5 heptane/ethyl acetate) to give 25 g (yield = 79%) of (4-bromo-2-fe/f- butylphenyl)ethylamine in the form of a dark reddish oil.
b) N-(4-Bromo-2-tert-butylphenyl)-N-ethylacetamide
In a 250 mL three-necked flask under a nitrogen atmosphere, equipped with a magnetic stirrer, 15 g (58.5 mmol) of (4-bromo-2-terf-butylphenyl)ethylamine are dissolved in 15O mL of dichloromethane. 8.9 g (87.8 mmol, 12.2 mL) of triethylamine and 0.72 g (5.9 mmol) of 4-dimethylaminopyridine are added. 11.5 g (146 mmol, 2.5 mL) of acetyl chloride are added dropwise and the reaction medium is stirred for 1 hour at room temperature. The reaction medium is poured into 250 mL of water and extracted twice with dichloromethane. The organic phases obtained are combined and washed with water, dried over anhydrous magnesium sulfate, filtered and evaporated to give a blackish oil. This oil is purified by chromatography on silica (eluent: 80/20 heptane/ethyl acetate) to give 15 g (yield = 86%) of N-(4-bromo-2-te/f-butylphenyl)-N-ethylacetamide in the form of an orange oil.
c) N-[2-tert-Butyl-4-(4, 4, 5, 5-tetramethyl[1 , 3, 2]dioxaborolan-2-yl)phenyl]-N-ethylacetamide. In a 250 mL three-necked flask under a nitrogen atmosphere, equipped with a magnetic stirrer, 10 g (33.5 mmol) of N-(4-bromo-2-te/f-butylphenyl)-N-ethylacetamide are dissolved in 100 mL of dimethylformamide. The solution is then degassed by sparging with nitrogen for 15 minutes. 13.2 g (134 mmol) of potassium acetate, 12.8 g (50.3 mmol) of bis(pinacolato)diborane and 2.73 g (3.35 mmol) of [1,1'-bis(diphenylphosphino)- ferrocene]dichloropalladium (II) are then added; the reaction medium is heated at 8O0C and stirred at this temperature for 3 hours. The reaction medium is poured into 500 mL of water and extracted twice with ethyl acetate. The organic phases obtained are combined and washed with water, dried over anhydrous magnesium sulfate, filtered and evaporated to give a blackish oil. This oil is purified by chromatography on silica (eluent: 90/10 heptane/ethyl acetate) to give 12 g (yield = 100%) of N-[2-terf-butyl-4-(4,4,5,5- tetramethyl[1 ,3,2]dioxaborolan-2-yl)phenyl]-N-ethylacetamide in the form of a beige- coloured powder.
d) Ethyl 4"-(acetylethylamino)-3"-tert-butyl-4'-hydroxy[1! 1';3', 1 "]terphenyl-4-carboxylate. In a manner similar to that of Example 1d, by reacting 2 g of ethyl 3'-bromo-4'-hydroxy- biphenyl-4-carboxylate (6 mmol) with 2.7 g of N-[2-tert-butyl-4-(4,4,5,5-tetramethyl- [1 ,3,2]dioxaborolan-2-yl)phenyl]-N-ethylacetamide (9 mmol) in the presence of tetrakis- (triphenylphosphine)palladium. 1.9 g of ethyl 4"-(acetylethylamino)-3"-terf-butyl-4'- hydroxy[1 ,1';3',1"]terphenyl-4-carboxylate (yield = 70%) are obtained in the form of a beige-coloured powder.
e) Ethyl 4"-(acetylethylamino)-3"-teή-butyl-4'-[4-(tert-butyldimethylsilanyloxy)butoxy]- [1,1'; 3', 1 "Jterphenyl-4-carboxylate In a manner similar to that of Example 2a, by reacting 260 mg of ethyl 4"- (acetylethylamino)-3"-terf-butyl-4'-hydroxy[1,1';3',1"]terphenyl-4-carboxylate (0.56 mmol) in 12 ml_ of dimethylformamide with 225 mg of caesium carbonate and 0.16 mL of 1- bromo-4-(terf-butyldimethylsilanyloxy)butane, 310 mg of ethyl 4"-(acetylethylamino)-3"- te/f-butyl-4'-[4-(tert-butyldimethylsilanyloxy)butoxy]-[1 ,1';3',1 "]terphenyl-4-carboxylate (yield = 99%) are obtained in the form of an oil.
f) Ethyl 4"-(acetylethylamino)-3'l-tert-butyl-4'-(4-hydroxybutoxy)-[1, 1';3', 1 "]terphenyl-4- carboxylate
In a manner similar to that of Example 2b, by reacting 320 mg of ethyl 4"- (acetylethylamino)-3"-te/t-butyl-4'-[4-(ført-butyldimethylsilanyloxy)butoxyH1 ,1';3',1"]- terphenyl-4-carboxylate in 1O mL of tetrahydrofuran with 0.5 mL of 1M tetrabutylammonium fluoride, 270 mg of ethyl 4"-(acetylethylamino)-3"-fert-butyl-4'-(4- hydroxybutoxy)-[1 ,1';3',1"]terphenyl-4-carboxylate are obtained (yield = 99%).
1H NMR (CDCI3 - 400 MHz): 1.27 (t, 3H); 1.42 (s, 9H); 1.43 (t, 3H); 1.63-1.69 (m, 2H); 1.89 (S1 3H); 1.87-1.91 (m, 2H); 2.85-2.91 (m, 2H); 3.60-3.64 (m, 2H); 4.11 (t, J=6.1 Hz, 2H); 4.42 (t, J=7.5Hz, 2H); 7.06 (d, J=8.0Hz, 1H); 7.10 (d, J=8.0Hz, 1H); 7.42 (d, J=8.0Hz, 1 H); 7.61-7.63 (m, 2H); 7.68 (d, J=8.2Hz, 2H); 7.81 (s, 1H); 8.12 (d, J=8.2Hz, 2H). Example 5 - 4"-(Acetylethylamino)-3"-teft-butyl-4'-(4-hvdroxybutoxy)-ri,1':3M"1- terphenyl-4-carboxylic acid
Figure imgf000027_0001
a) 4''-(Acetylethylamino)-3''-tert-butyl-4'-(4-hydroxybutoxy)-[1, 1';3!, 1']' terphenyl-4~ carboxylic acid
In a manner similar to that of Example 3, by reacting 270 mg of ethyl 4"-(acetyl- ethylamino)-3"-ferf-butyl-4'-(4-hydroxybutoxy)-[1 ,1';3',1"]terphenyl-4-carboxylate with
0.8 mL and then 0.4 ml_ of aqueous 1N sodium hydroxide solution in a mixture of 8 mL of tetrahydrofuran and 2 mL of water. 195 mg of 4"-(acetylethylamino)-3"-fe/f-butyl-4'-(4- hydroxybutoxy)-[1 ,1';3',1"]terphenyl-4-carboxylic acid are obtained in the form of a white solid (yield = 95%, m.p. = 75°C).
1H NMR (DMSO. 400 MHz): 1.26 (m, 3H); 1.43 (s, 9H); 1.67 (m, 2H); 1.87 (s, 3H); 1.89
(m, 2H); 2.92 (m, 1H); 3.63 (m, 2H); 4.11 (m, 2H); 4.4 (m, 1H); 7.0 (m, 1H); 7.36 (m, 1H);
7.58 (m, 4H); 7.77 (m, 1H); 8.12 (m, 2H).
Example 6 - 3"-tert-Butyl-4"-diethylamino-4'-(2-hvdroxyethoxy)-n,1':3M"1- terphenyl-4-carboxylic acid
Figure imgf000028_0001
a) Ethyl 4'-(2-acetoxyethoxy)~3"-teιt-butyl-4"-diethylamino[1, 1 ';3', 1 "]teφhenyl-4- carboxylate 850 mg (1.9 mmol) of ethyl 3"-terf-butyl-4"-diethylamino-4l-hydroxy[1l1';3',1"]terphenyl-4- carboxylate (obtained in Example 1d) are dissolved in dimethylformamide under nitrogen. 92 mg (2.3 mmol) of 60% sodium hydride are added. After 20 minutes at room temperature, 0.25 mL (2.3 mmol) of 2-bromoethan-1-ol acetate are added and the mixture is stirred for 24 hours at room temperature and then poured into saturated ammonium chloride solution and extracted with ethyl acetate. The organic phase is washed with water and then dried and evaporated. The residue obtained is purified by chromatography on silica gel (eluent: 70/30 heptane/ethyl acetate). 1 g of ethyl 4'-(2- acetoxyethoxy)-3"-ferf-butyl-4"-diethylamino[1 ,1';3',1"]terphenyl-4-carboxylate is obtained (yield = 99%) in the form of a colourless oil.
b) 3"-tert-Butyl-4"-diethylamino-4'-(2-hydroxyethoxy)-[1, 1 ';3', 1 "]teφhenyl-4-carboxylic acid
1 g (1.9 mmol) of ethyl 4'-(2-acetoxyethoxy)-3"-tert-butyl-41l-diethylamino[1 l1';3')1"]- terphenyl-4-carboxylate is placed in 50 mL of tetrahydrofuran and 19 mL (19 mmol) of 1N sodium hydroxide solution are added. The mixture is stirred at reflux for 12 hours. The yellow solution obtained is poured into saturated ammonium chloride solution, the pH is adjusted to 5-6 with 1 N hydrochloric acid solution and the mixture is then extracted with ethyl acetate. The organic phase is dried over magnesium sulfate and then concentrated to dryness. 455 mg of 3"-fert-butyl-4"-diethylamino-4'-(2-hydroxyethoxy)-[1,1I;3',111]- terphenyl-4-carboxylic acid are obtained in the form of a white solid (yield = 52%, m.p. = 216°C)
1H NMR (DMSO. 400 MHz): 1.06 (t, J=7.2Hz, 6H); 1.47 (s, 9H); 2.84 (m, 2H); 2.94 (m, 2H); 4.11 (m, 2H); 7.23 (d, J=8Hz, 1H); 7.32 (d, J=8Hz, 1H); 7.48 (dd, J=1.6Hz, 8.4Hz, 1 H); 7.66 (dd, J=1.2Hz, 4Hz, 2H); 7.69 (d, J=2Hz, 1 H); 7.99 (d, J=8Hz, 2H); 7.82 (d, J=8Hz, 2H).
Example 7 - Ethyl 3"-te/t-butyl-4"-diethylamino-4'-(3-hvdroxypropoxy)-ri,1':3>,1"1- terphenyl-4-carboxylate
Figure imgf000029_0001
a) Ethyl 3"-tert-butyl-4'-[3-(tert-butyldimethylsilanyloxy)propoxy]-4"-diethylamino- [1, 1 ';3', 1 "]terphenyl-4-carboxylate
In a manner similar to that of Example 2a, by reacting 1 g of ethyl 3"-te/f-butyl-4"- diethylamino-4'-hydroxy[1 ,1';3',1"]terphenyl-4-carboxylate (obtained in Example 1d) (2.2 mmol) in 20 mL of dimethylformamide with 880 mg (2.7 mmol) of caesium carbonate and 0.6 mL of 1-bromo-3-(terf-butyldimethylsilanyloxy)propane (2.4 mmol). 1.35 g of ethyl 3"- te/t-butyl-4'-[4-(tert-butyldimethylsilanyloxy)propoxy]-4"-diethylamino[1 , 1 ';3', 1 "Jterphenyl- 4-carboxylate are obtained (yield = 99%) in the form of an oil.
b) Ethyl 3"-tert~butyl-4"-diethylamino-4'-(4-hydroxypropoxy)-[1, 1 ';3', 1 "]terphenyl-4- carboxylate
In a manner similar to that of Example 2b, by reacting 1 g of ethyl 3"-fert-butyl-4'-[4-(fert- butyldimethylsilanyloxy)propoxy]-4"-diethylamino[1 ,1';3',1"]terphenyl-4-carboxylate (1.62 mmol) in 25 mL of tetrahydrofuran with 2 mL of 1 M tetrabutylammonium fluoride. 790 mg of ethyl 3"-tøAf-butyl-4"-diethylamino-4'-(4-hydroxypropoxy)-[1,1';3',1"]terphenyl- 4-carboxylate are obtained (yield = 97%, m.p. = 114-115°C).
1H NMR (DMSO. 400 MHz): 1.10 (t, J=7.1 Hz, 6H); 1.41 (t, J=7.1Hz, 3H); 1.49 (s, 9H); 1.81 (m, 1H); 2.90 (bs, 2H); 3.0 (bm, 2H); 3.88 (m, 2H); 4.13 (t, J=4.4Hz, 2H); 4.40 (q, J=7.1 Hz, 2H); 7.08 (d, J=8.5Hz, 1H); 7.30 (m, 1H); 7.36 (m, 1H); 7.56 (m, 1H); 7.62 (m, 2H); 7.66 (d, J=8.4Hz, 2H); 8.09 (d, J=8.1 Hz, 2H).
Example 8 - 3"-fert-Butyl-4"-diethylamino-4'-(2-hvdroxyproDθxy^-H.1':3M"1- terphenyl-4-carboxylic acid
Figure imgf000030_0001
In a manner similar to that of Example 3, by reacting 870 mg of ethyl 3"-teff-butyl-4"- diethylamino-4'-(4-hydroxypropoxy)-[1 ,1';3',1"]terphenyl-4-carboxylate (Example 6b, U mmol) with 15 mL of 1N sodium hydroxide solution. 410 mg of 3"-terf-butyl-4"- diethylamino-4'-(2-hydroxypropoxy)-[1,1';3',1"]terphenyl-4-carboxylic acid are obtained in the form of a white solid (yield = 51%, m.p. = 1930C).
1H NMR (DMSO, 400 MHz): 1.05 (t, J=7Hz, 6H); 1.46 (s, 9H); 1.85 (t, J=6Hz, 2H); 2.50 (m, 2H); 2.95 (m, 2H); 3.51 (t, J=8Hz, 2H); 4.12 (t, J=4Hz, 2H); 4.50 (s, 1H); 7.22 (d, J=8Hz, 1H); 7.32 (d, J=8Hz, 1H); 7.41 (dd, J=1.6Hz, 8Hz, 1H); 7.61 (d, J=1.6Hz, 1 H); 7.65 (d, J=2.4Hz, 1H); 7.70 (dd, J=2Hz, 8Hz, 1 H); 7.83 (d, J=8.4Hz, 2H); 7.99 (d, J=8Hz, 2H); 13.1 (S, 1 H).
Example 9 - Ethyl 4"-diethylamino-4'-(3-hvdroxypropoxy)-ri,1':3M"1terphenyl-4- carboxylate
Figure imgf000031_0001
a) 4- Diethylaminophenylboronic acid
In a manner similar to that of Example 1c, by reacting 5 g of (4-bromo- phenyi)diethylamine (21.9 mmol) with 13 mL of 2.0 M n-butyllithium solution and 6 mL (26 mmol) of triisopropyl borate. 4 g of 4-diethylaminophenylboronic acid (yield = 94 %) are obtained in the form of a white solid.
b) Ethyl 3'-bromo-4'-[3-(tert-butyldimethylsilanyloxy)propoxy]biphenyl-4-carboxylate In a manner similar to that of Example 2a, by reacting 3 g of ethyl 3'-bromo-4'-hydroxy- biphenyl-4-carboxylate (9.3 mmol) in 100 mL of dimethylformamide with 448 mg (11 mmol) of sodium hydride and 2.6 mL of 1-bromo-3-(te/τf-butyldimethylsilanyloxy)- propane (11 mmol). 2.95 g of ethyl S'-bromo-^-tS-^e/t-butyldimethylsilanyloxyJpropoxy]- biphenyl-4-carboxylate are obtained (yield = 64%) in the form of an oil.
c) Ethyl 4'-[3-(tert-butyldimethylsilanyloxy)propoxy]-4"-diethylamino[1 , 1 ';3', 1 "]terphenyl~4- carboxylate
In a manner similar to that of Example 1d, by reacting 1 g of ethyl 3'-bromo-4'-[3-(fe/f- butyldimethylsilanyloxy)propoxy]biphenyl-4-carboxylate (2 mmol) with 580 mg of 4- diethylaminophenylboronic acid (3 mmol) in the presence of tetrakis(triphenylphosphine)- palladium. 1.15 g of ethyl 4'-[3-(fe/f-butyldimethylsilanyloxy)propoxy]-4"-diethylamino- [1 ,1';3',1"]terphenyl-4-carboxylate (yield = 100 %) are obtained in the form of a colourless oil.
d) Ethyl 4 "-diethylamino-4 '-(3-hydroxypropoxy)-[1 , 1 ';3', 1 "]terphenyl-4-carboxylate
In a manner similar to that of Example 2b, by reacting 730 mg of ethyl 4'-[3-(ferf- butyldimethylsilanyloxy)propoxy]-4"-diethylamino[1 , 1 ';3', 1 "]terphenyl-4-carboxylate
(1.3 mmol) in 25 mL of tetrahydrofuran with 1.6 mL of 1M tetrabutylammonium fluoride. 430 mg of ethyl 4"-diethylamino-4'-(3-hydroxypropoxy)-[1,1';3',1"]terphenyl-4-carboxylate are obtained (yield = 74%).
1H NMR (CDCU, 400 MHz): 1.22 (t, J=7.4Hz, 6H); 1.43 (t, J=7.6H, 3H); 2.05 (m, 2H); 3.42 (q, J=7.4Hz, 4H); 3.81 (m, 2H); 4.17 (t, J=5.7Hz, 2H); 4.41 (q, J=7.6Hz, 2H); 6.76 (d, J=8.9Hz, 1H); 7.08 (d, J=8.1Hz, 2H); 7.45-7.47 (m, 2H); 7.52 (dd, J1=2.3Hz, J2=8.6Hz, 1H); 7.62 (d, J=2.4Hz, 1H); 7.67 (d, J=6.7Hz, 2H); 8.10 (d, J=6.7Hz, 2H).
Example 10 - 4"-Diethvtamino-4'-(3-hvdroxypropoxy)-ri,1';3M"1terphenyl-4- carboxylic acid
Figure imgf000032_0001
In a manner similar to that of Example 3, by reacting 430 mg of ethyl 4"-diethylamino-4'- (3-hydroxypropoxy)-[1,1';3',1"]terphenyl-4-carboxylate (Example 8d, 0.9 mmol) with 1O mL of 1N sodium hydroxide solution, 100 mg of 4"-diethylamino-4'-(3- hydroxypropoxy)-[1 ,1';3',r']terphenyl-4-carboxylic acid are obtained in the form of a yellow solid (yield = 25%, m.p. = 2000C).
HPLC Thermo Aquasil C18, 3 microns, 2 x 150 mm, mobile phase: A (CH3CN / 0.1 v/v HCO2H); B (H2O / 0.1v/v HCO2H)1 Flow rate: 0.5 mL/minutes. Gradient: 0 min: 90% B, 0- 20 min: 90-5% B, 20-30 min: 5% B; retention time: 10.01 min, purity: 96%, MS (ESI) m/z 420.22 (M+H)+
Example 11 - Ethyl 4"-diethylamino-3"-ethyl-4'-(3-hvdroxypropoxy)-n.1':3M"1- terphenyl-4-carboxvlate
Figure imgf000033_0001
a) (4-Bromo-2-ethylphenyl)diethylamine
In a manner similar to that of Example 1b, by reacting 6 g (0.15 mol) of sodium hydride with 1O g (δO mmol) of 4-bromo-2-ethylaniline, 11.3 g of (4-bromo-2-ethylphenyl)- diethylamine are obtained (yield = 88 %) in the form of a yellow oil.
b) 4-Diethylamino-3-ethylphenylboronic acid
In a manner similar to that of Example 1c, by reacting 3 g of (4-bromo-2- ethylphenyOdiethylamine (11.7 mmol) with 5.2 mL of a 2.5 M solution of /7-butyllithium and 3.2 mL (14 mmol) of triisopropyl borate, 0.9 g of 4-diethylamino-3-ethylphenylboronic acid (yield = 35 %) is obtained in the form of a white solid.
c) Ethyl 4'-[3-(tert-butyldimethylsilanyloxy)propoxy]-4''-diethylamino-3"-ethyl[1, 1 ';3', 1 "]- terphenyl-4-carboxylate
In a manner similar to that of Example 1d, by reacting 1.4 g (2.9 mmol) of ethyl 3'-bromo- 4'-[3-(terf-butyldimethylsilanyloxy)propoxy]biphenyl-4-carboxylate (obtained in Example 5b) with 900 mg of 4-diethylamino-3-ethylphenylboronic acid (4 mmol) in the presence of tetrakis(triphenylphosphine)palladium, 674 mg of ethyl 4'-[3-(ferf-butyldimethylsilanyloxy)- propoxy]-4ll-diethylamino-3"-ethyl[1,1';3',1"]terphenyl-4-carboxylate (yield = 39 %) are obtained in the form of a colourless oil.
d) Ethyl 4"-diethylamino-3"-ethyl-4'-(3-hydroxypropoxy)-[1, 1 ';3', 1 "]terphenyl-4-carboxylate In a manner similar to that of Example 2b, by reacting 660 mg of ethyl 4'-[3-(terf- butyldimethylsilanyloxy)propoxy]-4"-diethylamino-3"-ethyl[1 , 1 ';3', 1 "]terphenyl-4- carboxylate (1.1 mmol) in 25 mL of tetrahydrofuran with 1.2 mL of 1M tetrabutylammonium fluoride. 280 mg of ethyl 4"-diethylarnino-3"-ethyl-4'-(3- hydroxypropoxy)-[1 ,1';3',1"]terphenyl-4-carboxylate are obtained (yield = 52%). 1H NMR (CDCI3, 400 MHz): 1.05 (t, J=7.4Hz, 6H); 1.28 (t, J=7.5Hz, 3H); 1.44 (t, J=7.6H, 3H); 2.02 (m, 2H); 2.80 (q, J=7.5Hz, 2H); 3.02 (q, J=IAHz, 4H); 3.77 (q, J=5.6Hz, 2H); 4.17 (t, J=5.7Hz, 2H); 4.42 (q, J=7.6Hz, 2H); 7.10 (d, J=8.5Hz, 1H); 7.18 (d, J=8.1 Hz, 1 H); 7.35 (dd, J1=ZIHz1 J2=8.2Hz, 1H); 7.44 (d, J=2.1 Hz, 1H); 7.57 (dd, J1=2.4Hz, J2=8.5Hz, 1H); 7.63 (d, J=2.4Hz, 1H); 7.57 (dd, J1=2.4Hz, J2=8.5Hz, 1 H); 7.64 (d, J=2.4Hz, 1H); 7.69 (d, J=6.7Hz, 2H); 8.11 (d, J=6.7Hz, 2H).
Example 12 - 4"-Diethylamino-3"-ethvi-4'-(3-hvdroxypropoxy)-ri,1':3M"Uerphenyl- 4-carboxylic acid
Figure imgf000034_0001
a) 4''-Diethylamino-3"-ethyl-4'-(3-hydroxypropoxy)-[1l 1';3', 1']' terphenyl-4-carboxylic acid Into a 25 ml_ three-necked flask under a nitrogen atmosphere, equipped with a magnetic stirrer, are placed 270 mg (0.57 mmol) of ethyl 4"-diethylamino-3"-ethyl-4'-(3- hydroxypropoxy)-[1 ,1';3',1"]terphenyl-4-carboxylate (Example 10d) and 22 mg (5.7 mmol) of solid sodium hydroxide in 5.4 mL of tetrahydrofuran. The reaction medium is heated at the reflux temperature of the tetrahydrofuran for 5 hours. The reaction medium is concentrated under vacuum. The crude reaction product obtained is taken up in water and the pH of the medium thus obtained is adjusted to pH=4 by addition of hydrochloric acid solution in a proportion of 1 mol/L. The precipitate obtained, after stirring for 30 minutes, is purified by chromatography on silica (eluent: 40/60 heptane/ethyl acetate) to give, after evaporation of the fractions, 80 mg (yield = 31%) of 4"-diethylamino-3"-ethyl-4'- (3-hydroxypropoxy)-[1 ,1';3',1"]terphenyl-4-carboxylic acid in the form of a cream-coloured powder (m.p. = 2040C).
1H NMR (DMSO, 400 MHz): 1.02 (t, J=7.2 Hz, 6H); 1.25 (t, J=7.2 Hz, 3H); 2.02 (m, 2H);
2.78 (q, J=7.6 Hz, 2H); 3.01 (q, J=6.8 Hz, 4H); 3.76 (t, J=5.6 Hz, 2H); 4.18 (t, J=5.6 Hz, 2H); 7.08 (d, J=8.4 Hz1 1H); 7.16 (d, J=8.0 Hz, 1H); 7.33 (dd, J1=ZO Hz, J2=8.4 Hz, 1H); 7.42 (d, J=1.6 Hz, 1H); 7.56 (dd, J1=ZO Hz, J2=8.4 Hz, 1H); 7.63 (d, J=2.4 Hz, 1H); 7.70 (d, J=8.4 Hz, 2H); 8.14 (d, J=8.4 Hz, 2H).
Example 13 - 4"-Diethylamino-3"-ethyl-4'-(2-hvdroxyethoxy)-π,1':3',1"1terphenyl-4- carboxylic acid
Figure imgf000035_0001
a) Ethyl 4'-(2-acetoxyethoxy)-3'-bromobiphenyl-4-carboxylate
In a manner similar to that of Example 6a, by reacting 2 g (6 mmol) of ethyl 3'-bromo-4'- hydroxybiphenyl-4-carboxylate with 320 mg (8 mmol) of 60% sodium hydride and 0.7 mL (7 mmol) 2-bromoethan-1-ol acetate, 2.2 g of ethyl 4l-(2-acetoxyethoxy)-3'-bromo- biphenyl-4-carboxylate are obtained (yield = 95%) in the form of a colourless oil.
b) Ethyl 2'-(2-acetoxyethoxy)-3-tert-butyl-4-diethylamino[1, 1 ';4', 1 "]teφhenyl-3"- carboxylate
In a manner similar to that of Example 1d, by reacting 400 mg of ethyl 4'-(2- acetoxyethoxy)-3'-bromobiphenyl-4-carboxylate (1 mmol) with 340 mg of 4-diethylamino- 3-ethylphenylboronic acid (1.5 mmol) in the presence of tetrakis(triphenyl- phosphine)pa!ladium, 500 mg of ethyl 2'-(2-acetoxyethoxy)-3-terf-butyl-4-diethylamino- [1 ,1';4',1"]terphenyl-3"-carboxylate (yield = 97 %) are obtained in the form of a white solid.
c) 4"-Diethylamino-3"-ethyl-4 '-(2-hydroxyethoxy)-[1 , 1 ';3', 1 "]terphenyl-4-carboxylic acid In a manner similar to that of Example 6b, by reacting 690 mg (1.4 mmol) of ethyl 2'-(2- acetoxyethoxy)-3-tert-butyl-4-diethylamino[1,1';4',1"]terphenyl-3"-carboxylate with 550 mg (14 mmol) of sodium hydroxide, 470 mg of 4"-diethylamino-3"-ethyl-4'-(2-hydroxyethoxy)- [1,1';3',1"]terphenyl-4-carboxylic acid are obtained (yield = 79 %) in the form of a white solid (m.p. = 2060C). 1H NMR (DMSO, 400 MHz): 1.05 (t, J=7.0 Hz, 6H); 1.27 (t, J=7.6 Hz, 3H); 2.80 (q, J=7.2 Hz, 2H); 3.03 (q, J=7.2 Hz, 4H); 3.90 (m, 2H), 4.15 (m, 2H); 7.09 (m, 1H); 7.18 (m, 1H); 7.38 (m, 1H); 7.47 (m, 1H); 7.56 (m, 1H); 7.7 (m, 3H); 8.18 (d, J=8.4 Hz, 2H).
Example 14 - Ethyl 4"-diethylamino-3"-ethyl-4'-(2-hvdroxyethoxy)-M,1':3M"1- terphenyl-4-carboχylate
Figure imgf000036_0001
a) Ethyl 4''-diethylamino-3''-ethyl-4'-(2-hydroxyethoxy)-[1, 1';3', 1']' terphenyl-4-carboxylate 6.6 g of ethyl 2'-(2-acetoxyethoxy)-3-fe/t-butyl-4-diethylamino[1 ,1';4',1"]terphenyl-3"- carboxylate (obtained in Example 13b) are dissolved in 20O mL of a 2% solution of potassium carbonate in ethanol. The reaction medium is stirred for 2 hours at room temperature and then poured into saturated ammonium chloride solution and extracted with ethyl acetate. The residue obtained is purified by chromatography on silica gel (eluent: 7/3 heptane/ethyl acetate). 4 g of ethyl 4"-diethylamino-3"-ethyl-4'-(2-hydroxy- ethoxy)-[1 ,1';3',1"]terphenyl-4-carboxylate (yield = 66%) are obtained in the form of a white solid (m.p. = 970C).
1H NMR (DMSO. 400 MHz): 1.06 (t, J=7.0Hz, 6H); 1.28 (t, J=7.5Hz, 3H); 1.44 (t, J=7.1 Hz, 3H); 1.91 (bs, 1H); 2.80 (q, J=7.5Hz, 2H); 3.04 (q, J=7.0Hz, 4H); 3.90 (bs, 2H); 4.16 (m, 2H); 4.42 (q, J=7.1Hz, 2H); 7.10 (d, J=8.5Hz, 1H); 7.18 (d, J=8.5Hz, 1H); 7.37 (dd, J=2.1hz, 8.2Hz, 1H); 7.47 (d, J=2.0Hz, 1H); 7.57 (dd, J=2.4Hz, 8.5Hz, 1H); 7.66 (m, 1H); 7.69 (d, J=8.4Hz, 2H); 8.12 (d, J=8.4Hz, 2H).
Example 15 - Ethyl 3"-terf-butyl-4"-diethylamιno-4'-(2-hvdroxyethoxy)-n,r:3',1"1- terphenyl-4-carboxylate
Figure imgf000037_0001
a) Ethyl 3"-tert-butyl-4"-diethylamino-4'-(2-hydroxyethoxy)-[1, 1';3', 1"]terphenyl-4- carboxylate In a manner similar to that of Example 14a, by reacting 490 mg of ethyl 4'-(2- acetoxyethoxy)-3"-terf-butyl-4"-diethylamino[1 ,1';3',1"]terphenyl-4-carboxylate (0.9 mmol) obtained in Example 6a with 10 mL of a 2% solution of potassium carbonate in ethanol, 400 mg of ethyl 3"-fe/f-butyl-4"-diethylamino-4'-(2-hydroxyethoxy)-[1,1';3',1"]terphenyl-4- carboxylate are obtained (yield = 82%) in the form of a white solid (m.p. = 1270C).
1H NMR (DMSO, 400 MHz): 1.10 (t, J=7.0Hz, 6H); 1.41 (t, J=7.1Hz, 3H); 1.49 (s, 9H); 1.81 (bs, 1H); 2.90 (bs, 2H); 3.0 (bs, 2H); 3.87 (m, 2H); 4.13 (m, 2H); 4.40 (q, J=7.1Hz, 2H); 7.08 (d, J=8.5Hz, 1H); 7.30 (d, J=8.5Hz, 1H); 7.35 (dd, J=2.1hz, 8.2Hz, 1H); 7.56 (dd, J=2.0Hz, 8.1Hz, 1H); 7.62 (dd, J=2.4Hz, 8.5Hz, 1 H); 7.65 (m, 1H); 7.66 (d, J=8.4Hz, 2H); 8.09 (d, J=8.4Hz, 2H).
Example 16 - Ethyl 4"-diethv>amino-4'-(3-hvdroxypropoxy)-3"-methvin,1':3',1"1- terphenyl-4-carboxylate
Figure imgf000037_0002
a) (4-Bromo-2-methylphenyl)diethylamine In a manner similar to that of Example 1b, by reacting 4.7 g (0.12 mol) of sodium hydride with 1O g (54 mmol) of 4-bromo-2-methylaniline, 8 g of (4-bromo-2- methy!phenyl)diethylamine are obtained (yield = 62 %) in the form of a yellow oil.
b) 4-Diethylamino-3-methylphenylboronic acid
In a manner similar to that of Example 1c, by reacting 8 g of (4-bromo-2- methylphenyl)diethylamine (33 mmol) with 16 mL of a 2.5 M solution of n-butyllithium and 11.5 ml_ (50 mmol) of triisopropyl borate, 7.6 g of 4-diethylamino-3-methylphenylboronic acid (yield = 100 %) are obtained in the form of a thick oil.
c) Ethyl 4'-[3-(tert-butyldimethylsilanyloxy)propoxy]-4"-diethylamino-3"-methyl[1, 1 ';3', 1 "]- terphenyl-4-carboxylate
In a manner similar to that of Example 1d, by reacting 1 g (2 mmol) of ethyl 3'-bromo-4'-
[3-(terf-butyldimethylsilanyloxy)propoxy]biphenyl-4-carboxylate (obtained in Example 6b) with 630 mg of 4-diethylamino-3-methylphenylboronic acid (3 mmol) in the presence of tetrakis(triphenylphosphine)palladium, 1.1 g of ethyl 4'-[3-(terf-butyldimethylsilanyloxy)- propoxy]-4"-diethylamino-3"-methyl[1 ,1';3',TI]terphenyl-4-carboxylate (yield = 95 %) are obtained in the form of a pale yellow oil.
d) Ethyl 4"-diethylamino-4'-(3-hydroxypropoxy)-3"-methyl[1, 1';3',1"]terphenyl-4- carboxylate
In a manner similar to that of Example 2b, by reacting 1.1 g of ethyl 4'-[3-(te/f- butyldimethylsilanyloxy)propoxy]-4"-diethylamino-3"-methyl[1,1';3',1"]terphenyl-4- carboxylate (1.9 mmol) in 25 mL of tetrahydrofuran with 2.3 mL of 1M tetrabutylammonium fluoride, 130 mg of ethyl 4"-diethylamino-4'-(3-hydroxypropoxy)-3"- methyl[1,1';3',f ']terphenyl-4-carboxylate are obtained (yield = 15%).
1H NMR (CDCIg, 400 MHz): 1.06 (t, J=7.4Hz, 6H); 1.44 (t, J=7.6H, 3H); 2.05 (m, 2H); 2.37 (s, 3H); 3.05 (q, J=7.4Hz, 4H); 3.78 (q, J=5.6Hz, 2H); 4.19 (t, J=5.7Hz, 2H); 4.42 (q, J=7.6Hz, 2H); 7.09 (d, J=8.5Hz, 1H); 7.13 (d, J=8.1Hz, 1H); 7.35-7.39 (m, 2H); 7.57 (dd, J1=2.4Hz, J2=8.5Hz, 1H); 7.63 (d, J=2.4Hz, 1H); 7.68 (d, J=6.7Hz, 2H); 8.11 (d, J=6.7Hz, 2H). Example 17 - 4"-Diethylamino-4'-(3-hvdroxypropoxy)-3"-methvin.1':3M"1terphenyl- 4-carboxylic acid
Figure imgf000039_0001
In a manner similar to that of Example 12a, by reacting 130 mg (0.3 mmol) of ethyl 4"- diethylamino-4'-(3-hydroxypropoxy)-3"-methyl[1 , 1 ';3', 1 "]terphenyl-4-carboxylate (Example 15d) with 3 mL of 1N sodium hydroxide solution. 60 mg of 4"-diethylamino-4'-(3- hydroxypropoxy)-3"-methyl[1,1';3',1"]terphenyl-4-carboxylic acid are obtained in the form of a white solid (yield = 46%, m.p. = 2080C).
HPLC Thermo Aquasil C18, 3 microns, 2 x 150 mm, mobile phase: A (CH3CN / 0.1 v/v HCO2H); B (H2O / 0.1 v/v HCO2H), Flow rate: 0.5 mL/minutes. Gradient: 0 min: 90% B, 0- 20 min: 90-5% B, 20-30 min: 5% B; retention time: 8.95 min, purity: 92%, MS (ESI) m/z 434.3 (M+H)+.
Example 18 - Ethyl 3"-te/t-butyl-4'-(4-hvdroxybutoxy)-4"-Pyrrolidin-1-vin.1':3M"1- terphenyl-4-carboxylate
Figure imgf000039_0002
a) 1-(4-Bromo-2-tert-butylphenyl)pyrrolidine
5.7 g (0.14 mol) of sodium hydride are suspended in 20O mL of tetrahydrofuran. 10 g
(44 mmol) of 4-bromo-2-tert-butylaniline are added, along with 200 mL of dimethyl sulfoxide, added slowly. The mixture turns blue and, after 30 minutes, 13 mL (0.14 mol) of 1 ,4-dibromobutane are added and the reaction medium is stirred at room temperature for 13 hours. The reaction medium is then poured into saturated ammonium chloride solution and extracted with ethyl acetate, and the organic phase is then washed twice with water, dried and then concentrated to dryness. The residue is purified by chromatography on silica gel (eluent: 90/10 heptane/ethyl acetate). 6.4 g of 1-(4-bromo-2- te/f-butylphenyl)pyrrolidine are obtained (yield = 52%) in the form of a thick yellow oil.
b) 3-tert-Butyl-4-pyrrolidinophenylboronic acid In a manner similar to that of Example 1c, by reacting 4.7 g (17 mmol) of 1-(4-bromo-2- te/f-butylphenyl)pyrrolidine with 8 mL of a 2.5M solution of n-butyllithium and 6 mL (26 mmol) of triisopropyl borate, 2.8 g of 3-terf-butyl-4-pyrrolidinophenylboronic acid are obtained (yield = 66%).
c) Ethyl 3"-tert-butyl-4'-hydroxy-4"-pyrrolidin-1-yl[1, 1 ';3', 1 "]terphenyl-4-carboxylate
In a manner similar to that of Example 1d, by reacting 1 g of ethyl 3'-bromo-4'-hydroxy- biphenyl-4-carboxylate (3 mmol) with 1.2 g of 3-terf-butyl-4-pyrrolidinophenylboronic acid (4.5 mmol) in the presence of 5 mL of 2M potassium carbonate (10 mmol) and 360 mg of tetrakis(triphenylphosphine)palladium (Pd(PPh3)4), 900 mg of ethyl 3"-terf-butyl-4'- hydroxy-4"-pyrrolidin-1-yl[1,1';3',1"]terphenyl-4-carboxylate are obtained (yield = 63 %) in the form of a yellow solid.
d) Ethyl 3"-tert-butyl-4ψ-(tert-butyldimethylsilanyloxy)butoxy]-4"φyrrolidin-1-yl[1, 1 ';3', 1 "J- teφhenyl-4-carboxylate In a manner similar to that of Example 2a, by reacting 123 mg of ethyl 3"-te/f-butyl-4'- hydroxy-4"-pyrrolidin-1-yl[1,1';3',1"]terphenyl-4-carboxylate (0.27 mmol) with 110 mg (0.34 mmol) of caesium carbonate and 80 μL of 1-bromo-4-(terf-butyldimethylsilanyloxy)- butane (0.30 mmol), 170 mg of ethyl 3"-terf~butyl-4'-[4-(ferf-butyldimethylsilanyloxy)- butoxy]-4"-pyrrolidin-1-yl[1 ,1';3',1"]terphenyl-4-carboxylate are obtained (yield = 97%) in the form of an oil.
e) Ethyl 3"-tert-butyl-4'-(4-hydroxybutoxy)-4"-pyrrolidin-1-yl[1, 1 ';3', 1 "]terphenyl-4- carboxylate
In a manner similar to that of Example 2b, by reacting 170 mg (0.26 mmol) of ethyl 3"- terf-butyl-4'-[4-(teAf-butyldimethylsilanyloxy)butoxy]-4"-pyrrolidin-1 -yl[1 , 1 ';3', 1 "]terphenyl- 4-carboxylate with 200 μl_ of a 1M solution of tetrabutylammonium fluoride, 100 mg of ethyl 3"-ferf-butyl-4'-(4-hydroxybutoxy)-4"-pyrrolidin-1 -yl[1 , 1 ';3', 1 "]terphenyl-4-carboxylate are obtained (yield = 71%) in the form of a white solid.
1H NMR (CDCU - 400 MHz): 1.43 (t, J=7.5Hz, 3H); 1.47 (s, 9H); 1.64-1.71 (m, 2H); 1.85- 1.96 (m, 2H); 2.10-2.25 (m, 4H); 3.03 (m, 4H); 3.64 (m, 2H); 4.09 (t, J=6ΛHz, 2H); 4.41 (t, J=7.5Hz, 2H); 7.07 (d, J=8.0Hz, 1H); 7.30 (s, 2H); 7.56-7.65 (m, 3H); 7.67 (d, J=8.2Hz, 2H); 8.10 (d, J=8.2Hz, 2H).
Example 19 - 3"-tert-Butyl-4'-f4-hvdroxybutoxy)-4"-pyrrolidin-1-vin.1':3'.r'1- terphenyl-4-carboxylic acid
Figure imgf000041_0001
In a manner similar to that of Example 3, by reacting 100 mg of ethyl 3"-terf-butyl-4'-(4- hydroxybutoxy)-4"-pyrrolidin-1-yl[1 ,1';3',1"]terphenyl-4-carboxylate (0.18 mmol) with 0.3 mL of 1 N sodium hydroxide solution. 50 mg of 3"-terf-butyl-4'-(4-hydroxybutoxy)-4"- pyrrolidin-1-yl[1 l1';3',1"]terphenyl-4-carboxylic acid are obtained (yield = 56%) in the form of a white solid (m.p. = 2060C).
1H NMR (DMSO. 400 MHz): 1.42 (s, 9H); 1.51 (m, 2H); 1.72 (m, 2H); 1.9 (s, 4H); 3.4 (m, 2H); 4 (m, 2H); 7.2 (d, 1H, J=8.6Hz); 7.4 (d, 1H1 J=9.9Hz); 7.45 (d, J=8.2Hz); 7.55 (s); 7.63 (s, 1H); 7.67 (d, 1H, J=7.34Hz); 7.8 (d, 2H, J=8.45Hz); 7.97 (d, 2H1 J=8.4Hz).
Example 20 - Ethyl 4'-(4-hvdroxybutoxy)-4"-pyrrolidin-1-yl-3"-trifluoromethyl- f 1 , 1 ' :3'.1 "iterphenyl-4-carboxylate
Figure imgf000042_0001
a) 1-(4-Bromo-2-trifluoromethylphenyl)pyrrolidine
In a manner similar to that of Example 18a, by reacting 40 g of 4-bromo-2- trifluoromethylphenylamine (0.167 mol) with 16.6 g of sodium hydride (0.42 mol) and 49.7 mL of 1 ,4-dibromobutane (0.42 mol), 8.5 g of 1-(4-bromo-2-trifluoromethylphenyl)- pyrrolidine (yield = 17%) are obtained in the form of a yellow oil.
b) 4-Pyrrolidino-3-trifluoromethylphenylboronic acid In a manner similar to that of Example 1c, by reacting 2.3 g (7.9 mmol) of 1-(4-bromo-2- trifluoromethylphenyOpyrrolidine with 3.8 mL of a 2.5M solution of n-butyllithium and 2.7 mL of triisopropyl borate (12 mmol), 2 g of 4-pyrro!idino-3-trifluoromethylphenyl- boronic acid are obtained (yield = 100%) in the form of a beige-coloured solid.
c) Ethyl 3'-bromo-4'-[4-(tert-bυtyldimethylsilanyloxy)butoxy]biphenyl-4-carboxylate
In a manner similar to that of Example 2a, by reacting 2 g of ethyl 3'-bromo-4'-hydroxy- biphenyl-4-carboxylate (6 mmol) with 2.4 g (7.5 mmol) of caesium carbonate and 1.78 mL of 1-bromo-4-(terf-butyldimethylsilanyloxy)butane (6.7 mmol), 2.8 g of ethyl 3'-bromo-4'- [4-(ferf-butyldimethylsilanyloxy)butoxy]biphenyl-4-carboxylate are obtained (yield = 97%) in the form of an oil.
d) Ethyl 4'-[4-(tert-butyldimethylsilanyloxy)butoxy]-4"-pyrrolidin-1-yl-3"-trifluoromethyl-
[1,1 ";3', 1 "]terphenyl-4-carboxylate
In a manner similar to that of Example 1d, by reacting 500 mg of ethyl 3'-bromo-4'-[4-(terf- butyldimethylsilanyloxy)butoxy]biphenyl-4-carboxylate (1.2 mmol) with 450 mg of 4- pyrrolidino-3-trifluoromethylphenylboronic acid (1.7 mmol) in the presence of 1.5 mL of 2M potassium carbonate (3 mmol) and 40 mg of tetrakis(triphenylphosphine)palladium (Pd(PPh3)4), 400 mg of ethyl 4l-[4-(fθ/t-butyldimethylsilanyloxy)butoxy]-4"-pyrrolidin-1-yl- 3"-trifluoromethyl[1 ,1';3',1"]terphenyl-4-carboxylate are obtained (yield = 56%) in the form of a colourless oil. e) Ethyl ^-(^hydroxybutoxyyr-pyrrolidin-i-yl-r-trifluoromethylli, 1 ';3', 1 "]terphenyl-4- carboxylate
In a manner similar to that of Example 2b, by reacting 400 mg of ethyl 4'-[4-(tert- butyldimethylsilanyloxy)butoxy]-4"-pyrrolidin-1-yl-3"-trifluoromethyl[1 ,1';3',1"]terphenyl-4- carboxylate (0.6 mmol) with 0.75 ml. of a 1 N solution of tetrabutylammonium fluoride, 318 mg of ethyl 4'-(4-hydroxybutoxy)-4"-pyrrolidin-1-yl-3"-trifluoromethyl[1,r;3>,1"]- terphenyl-4-carboxylate are obtained (yield = 97%) in the form of a colourless oil.
1H NMR (CDCI3 - 400 MHz): 1.43 (t, J=7.5Hz, 3H); 1.55 (m, 2H); 1.68-1.73 (m, 2H); 1.93 (m, 8H); 3.42 (m, 2H); 4.08 (t, J=6.2Hz, 2H); 4.41 (t, J=7.5Hz, 2H); 4.43 (bs, 1H); 7.13 (d, J=8.7Hz, 1H); 7.21 (d, J=8.7Hz, 1H); 7.67-7.73 (m, 3H); 7.85 (d, J=8.2Hz, 2H); 7.87 (s, 1 H); 7.99 (d, J=8.2Hz, 2H).
Example 21 - 4'-(4-Hvdroxybutoxy)-4"-Pyrrolidin-1-yl-3"-trifluoromethyl^1,1':3M"^■ terphenyl-4-carboxylic acid
Figure imgf000043_0001
In a manner similar to that of Example 3, by reacting 318 mg of ethyl 4'-(4- hydroxybutoxy)-4"-pyrrolidin-1-yl-3"-trifluoromethyl[1 ,1';3'l1"]terphenyl-4-carboxylate with 6 mL of 1N sodium hydroxide solution, 75 mg of 4'-(4-hydroxybutoxy)-4"-pyrrolidin-1-yl- 3"-trifluoromethyl[1,1';3',1"]terphenyl-4-carboxylic acid are obtained (yield = 25%) in the form of a white solid (m.p. = 2370C).
1H NMR (DMSO, 400 MHz): 1.55 (m, 2H); 1.73 (m, 2H); 1.93 (m, 8H); 3.42 (m, 2H); 4.08 (t, J=6.2Hz, 2H); 4.43 (bs, 1H); 7.13 (d, J=8.7Hz, 1H); 7.21 (d, J=8.7Hz, 1H); 7.67-7.73 (m, 3H); 7.85 (d, J=8.2Hz, 2H); 7.87 (s, 1H); 7.99 (d, J=8.2Hz, 2H); 12.9 (bs, 1H). Example 22 - Ethyl 3"-fert-butvi-4'-(3-hvdroxypropoxy)-4"-Dyrrolidin-1-ylM.1':3'.1"y terphenyl-4-carboxylate
Figure imgf000044_0001
a) Ethyl 3"-tert-butyl-4'-[3-(tert-butyldimethylsilanyloxy)propoxy]-4"-pyrrolidin-1-yl- [1, 1 ';3', 1 "]terphenyl-4-carboxylate
In a manner similar to that of Example 1d, by reacting 500 mg of ethyl 3'-bromo-4'-[3-(feAt- butyldimethylsilanyloxy)propoxy]biphenyl-4-carboxylate obtained in Example 9b (1.2 mmol) with 380 mg of 3-tert-butyl-4-pyrrolidinophenylboronic acid (1.5 mmol) obtained in Example 17b in the presence of 1.3 ml. of 2M potassium carbonate (2.6 mmol) and 35 mg of tetrakis(triphenylphosphine)palladium (Pd(PPh3J4), 550 mg of ethyl 3"-/eAf-butyl-4'-[3-(te/t-butyldimethylsilanyloxy)propoxy]-4"-pyrrolidin-1 -yl[1 , 1 ';3', 1 "]- terphenyl-4-carboxylate are obtained (yield = 89%) in the form of a yellow oil.
b) Ethyl 3"-tert-butyl~4'-(3-hydroxypropoxy)-4"-pyrrolidin-1-yl[1, 1 ';3\ 1 "]terphenyl-4- carboxylate
In a manner similar to that of Example 2b, by reacting 550 mg of ethyl 3"-tert-butyl-4'-[3- (terf-butyldimethylsilanyloxy)propoxy]-4"-pyrrolidin-1-yl[1,1';3',1"]terphenyl-4-carboxylate (0.9 mmol) with 1.1 mL of a 1N solution of tetrabutylammonium fluoride, 260 mg of ethyl 3"-fe/f-butyl-4'-(3-hydroxypropoxy)-4"-pyrrolidin-1 -yl[1 , 1 ';3\ 1 "]terphenyl-4-carboxylate are obtained (yield = 58%) in the form of a yellow oil.
1H NMR (CDCI3 - 400 MHz): 1.43 (t, J=7.5Hz, 3H); 1.47 (s, 9H); 2.05 (m, 2H); 2.10-2.25 (m, 4H); 3.03 (m, 4H); 3.81 (m, 2H); 4.17 (t, J=5.7Hz, 2H); 4.41 (t, J=7.5Hz, 2H); 7.07 (d, J=8.0Hz, 1H); 7.30 (s, 2H); 7.56-7.65 (m, 3H); 7.67 (d, J=8.2Hz, 2H); 8.10 (d, J=8.2Hz, 2H).
Example 23 - 3"-feιt-Butyl-4'-(3-hvdroxypropoxy)-4"-pyrrolidin-1-viπ,1':3M"1- terphertyl-4-carboxylic acid
Figure imgf000045_0001
In a manner similar to that of Example 3, by reacting 260 mg of ethyl 3"-terf-butyl-4'-(3- hydroxypropoxy)-4"-pyrrolidin-1-yl[1 ,1';3',1"]terphenyl-4-carboxylate (0.5 mmol) with 5 ml_ of 1N sodium hydroxide solution, 120 mg of 3"-terf-butyl-4'-(3-hydroxypropoxy)-4"- pyrrolidin-1-yl[1,1';3',1"]terphenyl-4-carboxylic acid are obtained (yield = 48%) in the form of a white solid (m.p. = 23O0C).
HPLC Waters Atlantis C18, 5 microns, 2 x 150 mm, mobile phase: A (CH3CN / 0.1 v/v HCO2H); B (H2O / 0.1 v/v HCO2H), Flow rate: 0.5 mL/minutes. Gradient: 0 min: 90% B, 0- 20 min: 90-5% B, 20-30 min: 5% B; retention time: 13.2 min, purity: 97.8%, MS (ESI) m/z 474.3 (M+H)+.
Example 24 - Ethyl 3"-te/t-butyl-4'-f2-hvdroxyethoxy)-4"-pyrro>idin-1-viπ,1':3M"I- terphenyl-4-carboxylate
Figure imgf000045_0002
a) Ethyl 4'-(2-acetoxyethoxy)~3"-tert-butyl-4"-pyrrolidin-1-yl[1, 1 !;3', 1 "]terphenyl-4- carboxylate
In a manner similar to that of Example 1d, by reacting 800 mg of ethyl 3'-bromo-4'-(2- acetoxyethoxy)biphenyl-4-carboxylate obtained in Example 13a (2 mmol) with 730 mg of
S-terf-butyM-pyrrolidinophenylboronic acid (2.9 mmol) obtained in Example 18b in the presence of 2.6 mL of 2M potassium carbonate (5.2 mmol) and 70 mg of tetrakis(triphenylphosphine)palladium (Pd(PPh3)4), 500 mg of ethyl 4'-(2-acetoxyethoxy)- 3"-tert-butyl-4"-pyrrolidin-1-yl[1,r;3',1"]terpheny!-4-carboxylate are obtained (yield = 47%) in the form of a yellow oil.
JbJ Ethyl r-tert-butyl-^Σ-hydroxyethoxyj-r-pyrrolidin-i-ylti.r^iηterphenyl-^ carboxylate
In a manner similar to that of Example 14a, by reacting 110 mg of ethyl 4'-(2- acetoxyethoxy)-3"-terf-butyl-4"-pyrrolidin-1 -yl[1 , 1 ';3', 1 "]terphenyl-4-carboxylate (0.2 mmol) with 2 ml. of a 1% solution of potassium carbonate in ethanol, 40 mg of ethyl 3"-te/f-buty!-4'-(2-hydroxyethoxy)-4"-pyrrolidin-1 -yl[1 , 1 ';3', 1 "]terphenyl-4-carboxylate are obtained (yield = 39%) in the form of a white solid (m.p. = 1930C).
1H NMR (DMSO, 400 MHz): 1.40 (t, 3H); 1.46 (m, 4H); 1.54 (s, 9H); 1.9 (bs, 4H); 3.0 (bs, 3H); 3.9 (bs, 2H); 4.15 (m, 2H); 4.40 (m, 2H); 7.1 (d, J=8.6Hz, 1H); 7.4 (d, J=9.9Hz, 1H); 7.45 (d, J=8.2Hz, 1H); 7.55 (s, 1H); 7.63 (s, 1H); 7.67 (d, J=7.34Hz, 1H); 7.80 (d, J=8.45Hz, 2H); 7.97 (d, J=8.4Hz, 2H).
Example 25 - 3"-ter.-Butyl-4'-(2-hvdroxyethoxy)-4"-pyrrolidin-1-ylM,1':3',1"1- terphenyl-4-carboxylic acid
Figure imgf000046_0001
In a manner similar to that of Example 6b, by reacting 500 mg (0.9 mmol) of ethyl 4'-(2- acetoxyethoxy)-3"-terf-butyl-4"-pyrrolidin-1 -yl[1 , 1 ';3', 1 "]terphenyl-4-carboxylate with
300 mg (8 mmol) of sodium hydroxide, 242 mg of 3"-tert-butyl-4'-(2-hydroxyethoxy)-4"- pyrrolidin-1-yl[1l1';3',1"]terphenyl-4-carboxylic acid are obtained (yield = 55 %) in the form of a white solid (m.p. = 2230C).
1H NMR (DMSO. 400 MHz): 1.43 (s, 9H); 1.90 (m, 4H); 3.0 (m, 4H); 3.73 (d, J=4.7Hz, 2H); 4.1 (m, 2H); 4.7 (s, 1H); 7.2 (d, 1H, J=8.6Hz); 7.48 (m, 2H); 7.59 (d, J=1.6Hz, 1H); 7.64 (d, J=UHz, 1H); 7.68 (dd, J=2Hz, 7.8Hz, 1H); 7.82 (d, J=8.3Hz, 2H); 7.99 (d, J=8.4Hz, 2H).
Example 26 - 4'-(3-Hvdroχypropoxy)-4"-Pyrroliclin-1-viri,1';3',1"Uerphenyl-4- carboxylic acid
Figure imgf000047_0001
a) 4-Pyrrolidinophenylboronic acid
In a manner similar to that of Example 1c, by reacting 8.6 g (38 mmol) of 4-bromophenyl- 1-pyrrolidine with 18 mL of a 2.5M solution of n-butyllithium and 13 mL of triisopropyl borate (57 mmol), 5 g of 4-pyrrolidinophenylboronic acid are obtained (yield = 69%) in the form of a beige-coloured solid.
b) Ethyl 4'~[3-(tert-butyldimethylsilanyloxy)propoxy]-4"-pyrrolidin-1-yl[1, 1';3', 1"]terphenyl-
4-carboxylate
In a manner similar to that of Example 1d, by reacting 520 mg of ethyl 3'-bromo-4'-[3-(te/f- butyldimethylsilanyloxy)propoxy]biphenyl-4-carboxylate obtained in Example 8b (1 mmol) with 290 mg of 4-pyrrolidinophenylboronic acid (1.5 mmol) in the presence of 1.3 mL of 2M potassium carbonate (2.6 mmol) and 35 mg of tetrakis(triphenylphosphine)palladium (Pd(PPh3)4), 170 mg of ethyl 4'-[3-(terf-butyldimethylsilanyloxy)propoxy]-4"-pyrrolidin-1- yl[1 ,1';3',1"]terphenyl-4-carboxylate are obtained (yield = 30%) in the form of a yellow oil.
c) Ethyl 4'-(3-hydroxypropoxy)-4"-pyrrolidin-1-yl[1, 1 ';3!, 1 "]terphenyl-4-carboxylate
In a manner similar to that of Example 2b, by reacting 170 mg of ethyl 4'-[3-(terf- butyldimethylsilanyloxy)propoxy]-4"-pyrrolidin-1 -yl[1 , 1 ';3', 1 "]terphenyl-4-carboxylate (0.3 mmol) with 0.4 mL of a 1 N solution of tetrabutylammonium fluoride, 70 mg of ethyl 41- (3-hydroxypropoxy)-4"-pyrrolidin-1-yl[1,1';3',1"]terphenyl-4-carboxylate are obtained (yield = 52%) in the form of a yellow oil. d) 4'-(3-Hydroxypropoxy)-4"-pyrrolidin-1-yl[1, 1';3',1"]terphenyl-4-carboxylic acid In a manner similar to that of Example 3, by reacting 70 mg of ethyl 4'-(3- hydroxypropoxy)-4"-pyrrolidin-1 -yl[1 , 1 ';3', 1 "]terphenyl-4-carboxylate (0.16 mmol) with 1.6 mL of 1N sodium hydroxide solution, 10 mg of 4'-(3-hydroxypropoxy)-4"-pyrrolidin-1- yl[1 ,1 ';3',r]terphenyl-4-carboxylic acid are obtained (yield = 15%) in the form of a white solid (m.p. = 1950C).
HPLC Thermo Aquasil C18, 3 microns, 2 x 150 mm, mobile phase: A (CH3CN / 0.1 v/v HCO2H); B (H2O / 0.1v/v HCO2H), Flow rate: 0.5 mL/minutes. Gradient: 0 min: 90% B, 0- 20 min: 90-5% B, 20-30 min: 5% B; retention time: 14.77 min, purity: 93%, MS (ESI) m/z 418.2 (M+H)+.
Example 27 - 3"-te/t-Butyl-4"-diethylamino-4'-hvdroxyπ.1>:3M"1terphenyl-4- carboxylic acid
In a manner similar to that of Example 3, by reacting 300 mg of ethyl 3"-terf-butyl-4"- diethylamino-4'-hydroxy[1,1';3',1"]terphenyl-4-carboxylate obtained in Example 1d (0.67 mmol) with 7 mL of 1N sodium hydroxide solution, 236 mg of 3"-terf-butyl-4"- diethylamino-4'-hydroxy[1,1';3',1"]terphenyl-4-carboxylic acid are obtained (yield = 84%) in the form of a white solid (m.p. = 1900C).
1H NMR (DMSO, 400 MHz): 1.06 (t, J=7.4Hz, 6H); 1.46 (s, 9H); 2.84 (bs, 2H); 2.94 (bs, 2H); 7.05 (d, J=8.5Hz, 1H); 7.31-7.47 (m, 2H); 7.54-7.62 (m, 3H); 7.78 (d, J=6.7Hz, 2H); 7.97 (d, J=6.7Hz, 2H); 9.82 (s, 1H); 12.90 (bs, 1H).
Example 28 - Ethyl 4"-diethylamino-4'-hvdroxy-3"-trifluoromethvin.1':3M"1- terphenyl-4-carboxylate
Figure imgf000049_0001
a) (4-Bromo-2-trifluoromethylphenyl)diethylamine
In a manner similar to that of Example 1b, by reacting 10 g of 4-bromo-2- trifluoromethylphenylamine (41 mmol) with 5 g (125 mmol) of 60% sodium hydride and 1O mL (125 mmol) of ethyl iodide, 7 g of (4-bromo-2-trifluoromethylphenyl)diethylamine are obtained (yield = 60%) in the form of a yellow oil.
b) 4-Diethylamino-3-trifluoromethylphenylboronic acid In a manner similar to that of Example 1c, by reacting 5 g of (4-bromo-2- trifluoromethylphenyl)diethylamine with 8.1 ml_ of a 2.5 M solution of n-butyllithium and 5.8 mL of triisopropyl borate, 4.3 g of 4-diethylamino-3-trifluoromethylphenylboronic acid are obtained (yield = 100%) in the form of a thick orange oil.
c) Ethyl 4 "-diethylamino-4 '-hydroxy-3"-trifluoromethyl[1 , 1 ';3', 1 "]terphenyl-4-carboxylate In a manner similar to that of Example 1d, by reacting 3.5 g of ethyl 3'-bromo-4'-hydroxy- biphenyl-4-carboxylate (10.9 mmol) with 4.3 g of 4-diethylamino-3-trifluoromethyl- phenylboronic acid (16.4 mmol) in the presence of 14.3 mL of 2M potassium carbonate solution (28.5 mmol) and 380 mg of tetrakis(triphenylphosphine)palladium (0.3 mmol), 1.4 g of ethyl 4"-diethylamino-4'-hydroxy-3"-trifluoromethyl[1,1';3',1"]terphenyl-4- carboxylate are obtained (yield = 28%) in the form of a white solid (m.p. = 17O0C).
1H NMR (DMSO. 400 MHzV. 0.97 (t, J=7.1 Hz, 6H); 1.44 (t, J=7.6H, 3H); 2.98 (q, J=7.1Hz, 4H); 5.49 (s, 1H); 7.09 (d, J=8.4 Hz, 1 H); 7.60 (m, 2H); 7.69 (d, J=2.3Hz, 1H); 7.81 (d, J=8.4Hz, 2H); 7.93 (m, 2H); 7.97 d, J=8.4Hz, 2H).
Example 29 - 4"-Diethylamino-4'-hvdroxy-3"-trifluoromethvin,1':3M"1terphenyl-4- carboxylic acid
Figure imgf000050_0001
In a manner similar to that of Example 3, by reacting 200 mg of ethyl 4"-diethylamino-4'- hydroxy-3"-trifluoromethyl[1 ,1';3',1"]terphenyl-4-carboxylate (0.44 mmol) with 4 ml. of 1 N sodium hydroxide solution, 100 mg of 4"-diethylamino-4'-hydroxy-3"-trifluoromethyl- [1 ,1';3',1"]terphenyl-4-carboxylic acid are obtained (yield = 50%) in the form of a white solid (m.p. = 1950C).
1H NMR (DMSO, 400 MHz): 0.97 (t, J=7.1 Hz, 6H); 2.98 (q, J=JAHz, 4H); 7.09 (d, J=8.4 Hz, 1H); 7.60 (m, 2H); 7.69 (d, J=2.3Hz, 1H); 7.81 (d, J=8.4Hz, 2H); 7.93 (m, 2H); 7.97 d, J=8.4Hz, 2H); 10.05 (s, 1H); 12.90 (bs, 1H).
Example 30 - 3"-terf-Butyl-4"-diethylamino-4'-(4-isopropylaminobutoxy)-n,1':3M"1- terphenyl-4-carboxylic acid
Figure imgf000050_0002
a) Ethyl 3"-tert-butyl-4"-diethylamino-4'-(4-oxobutoxy)-[1, 1';3', 1"]terphenyl-4-carboxylate 20 mL of dichloromethane placed in a three-necked flask are cooled to -780C and 0.3 mL of oxalyl chloride are added, followed by addition of 0.54 mL of dimethyl sulfoxide diluted in 4 mL of dichloromethane. The reaction medium is stirred at -78°C for 30 minutes. 900 mg of ethyl 3"-tørt-butyl-4"-diethylamino-4l-(4-hydroxybutoxyH1 -1';3',1"]terphenyl-4- carboxylate obtained in Example 2b (1.7 mmol), dissolved in 55 mL of dichloromethane in the presence of 1 equivalent of triethylamine are added. The reaction medium is stirred at -780C for 1 hour and then at room temperature for 12 hours. The reaction is stopped by adding 100 ml_ of saturated ammonium chloride solution and then extracted with dichloromethane. The organic phase is washed twice with water, dried over magnesium sulfate, filtered and concentrated. The residue obtained is chromatographed on silica gel (70/30 heptane/ethyl acetate). 720 mg of ethyl 3"-te/t- butyl-4"-diethylamino-4'-(4-oxobutoxy)-[1 ,1';3',1"]terphenyl-4-carboxylate are obtained (yield = 78%) in the form of a yellow oil.
b) Ethyl 3"-tert-butyl-4"-diethylamino-4'-(4-isopropylaminobutoxy)-[1, 1 ';3!, 1 "]terphenyl-4- carboxylate 720 mg of aldehyde ethyl 3"-ferf-butyl-4"-diethylamino-4'-(4-oxobutoxyH1,1';3',1"]- terphenyl-4-carboxylate (1.3 mmol) are dissolved in 15 ml_ of methanol under a nitrogen atmosphere. 0.6 mL of isopropylamine are then added. The reaction medium is stirred at room temperature for 1 hour 15 minutes. 94 mg of sodium cyanoborohydride are then added to the reaction medium with stirring. The medium is stirred for 3 days. The reaction is stopped by adding 5 mL of water and then extracted with ethyl acetate. The organic phases are combined and dried over magnesium sulfate. The solvents are evaporated off and the residue is precipitated from 8 mL of heptane and filtered through a sinter funnel. 178 mg of ethyl 3"-feAf-butyl-4"-diethylamino-4'-(4-isopropylaminobutoxy)- [1 ,1';3',1"]terphenyl-4-carboxylate are obtained (yield = 24%) in the form of a white solid.
c) 3"-tert-Butyl-4"-diethylamino-4'-(4-isopropylaminobutoxy)-[1,1';3',1"]teφhenyl-4- carboxylic acid
In a manner similar to that of Example 3, by reacting 190 mg of ethyl 3"-te/if-butyl-4"- diethylamino-4'-(4-isopropylaminobutoxy)-[1 ,1';3',1"]terphenyl-4-carboxyiate (0.3 mmol) with 0.5 mL of 1N sodium hydroxide solution, 45 mg of 3"-fe/t-butyi-4"-diethylamino-4'-(4- isopropylaminobutoxy)-[1,1';3',1"]terphenyl-4-carboxylic acid are obtained (yield = 25%) in the form of a white solid.
1H NMR (CD?OD, 400 MHz): 1.11 (t, 6H); 1.26 (d, 6H); 1.52 (s, 9H); 1.84 (m, 2H);1.90 (m, 2H); 2.98 (s, 4H); 3.2 (m, 1H); 3.3 (m, 2H); 4.13 (t, 2H); 7.19 (d, J=8.54Hz, 1H); 7.36 (s, 1H); 7.42 (s, 1H); 7.61 (s, 1H); 7.65 (s, 2H); 7.72 (d, J=8.36Hz, 2H); 8.08 (d, J=8.35Hz, 2H). Example 31 - 3"-terf-Butyl-4'-(4-isopropylaminobutoxy)-4"-pyrrolid8n-1-vin.1>:3M"l- terphenvt-4-carboχylic acid
Figure imgf000052_0001
a) Ethyl 3"-tert-butyl-4'-(4-oxobutoxy)-4"-pyrrolidin-1-yl[1, 1';3',1"]terphenyl-4-carboxylate In a manner similar to that of Example 30a, by reacting 900 mg of ethyl 3"-fert-butyl-4'-(4- hydroxybutoxy)-4"-pyrrolidin-1-yl[1,1';3',1"]terphenyl-4-carboxylate obtained in Example 18e with 0.3 ml_ of oxalyl chloride, 0.54 ml_ of DMSO and 0.25 ml_ of triethylamine, 700 mg of ethyl 3"-tert-butyl-4'-(4-oxobutoxy)-4"-pyrrolidin-1-yl[1,1';3',1"]terphenyl-4- carboxylate are obtained (yield = 78%) in the form of a yellow oil.
b) Ethyl 3"-tert-butyl-4'-(4-isopropylaminobutoxy)-4"-pyrrolidin-1-yl[1, 1 !;3', 1 "]terphenyl-4- carboxylate In a manner similar to that of Example 30b, by reacting 700 g of ethyl 3"-terf-butyl-4'-(4- oxobutoxy)-4"-pyrrolidin-1-yl[1,1';3',1"]terphenyl-4-carboxylate with 0.6 ml- of isopropylamine and 94 mg of sodium cyanoborohydride, 228 mg of ethyl 3"-tert-butyl-4'- (4-isopropylaminobutoxy)-4"-pyrrolidin-1-yl[1,1';3',1"]terphenyl-4-carboxylate are obtained (yield = 24%) in the form of a white solid.
c) 3''-tert-Butyl-4'-(4-isopropylaminobutoxy)-4''φyrrolidin-1-yl[1J';3', 1"]terphenyl-4- carboxylic acid
In a manner similar to that of Example 3, by reacting 190 mg of ethyl 3"-terf-butyl-4'-(4- isopropylaminobutoxy)-4"-pyrrolidin-1-yl[1,1';3',1"]terphenyl-4-carboxylate (0.3 mmol) with 2 mL of 1N sodium hydroxide solution, 45 mg of 3"-terf-butyl-4"-diethylamino-4'-(4- isopropylaminobutoxyH1.1';3'.'l"]terphenyl-4-carboxylic acid are obtained (yield = 25%) in the form of a white solid.
HPLC Waters Atlantis C18, 5 microns, 2 x 150 mm, mobile phase: A (CH3CN / 0.05 v/v CF3CO2H); B (H2O / 0.05v/v CF3CO2H), Flow rate: 1 mL/minutes. Gradient: 0 min: 90% B, 0-20 min: 90-10% B, 20-30 min: 10% B; retention time: 17.5 min, purity: 98%, MS (ESI) m/z 541.3 (M+H)+.
Example 32 - Ethyl 3"-terf-butyl-4"-diethylamino-4'-(3-hvclroxyDropyn-ri,1':3'.1"1- terphenyl-4-carboxylate
Figure imgf000053_0001
a) Ethyl 3"-tert-butyl-4"-diethylamino-4'-trifluoromethanesulfonyloxy[1, 1 ';3', 1 "]terphenyl-4- carboxylate
1.1 g of ethyl 3"-fe/f-butyl-4"-diethyiamino-4'-hydroxy[1,1';3',1"]terphenyl-4-carboxylate obtained in Example 1d (2.5 mmol) are dissolved at room temperature in 22.4 mL of dichloromethane and the temperature of the reaction medium is then lowered to O0C; 112 mg of dimethylaminopyridine are added, followed by addition of 0.88 mL of triethylamine (6 mmol) and dropwise addition of 0.5 mL of trifiic anhydride (3 mmol). The temperature is raised to room temperature and the reaction medium is stirred for 20 minutes. The reaction is stopped by adding 30 mL of water and then extracted with 30 mL of dichloromethane. The organic phases are washed with 60 mL of water and then dried over sodium sulfate. The solvents are evaporated off and the residue is then purified by chromatography on silica gel (eluent: heptane). 1.2 g of ethyl 3"-terf-butyl-4"- diethylamino-4'-trifluoromethanesulfonyloxy[1 , 1 ';3', 1 "]terphenyl-4-carboxylate are obtained (yield = 79%).
b) Ethyl 3"-tert-butyl-4"-diethylamino-4'-vinyl[1, 1 ';3', 1 "]terphenyl-4-carboxylate
1.2 g of ethyl 3"-ferf-butyl-4"-diethylamino-4l-trifluoromethanesulfonyloxy[1,1';3',1"]- terphenyl-4-carboxylate (2 mmol) are dissolved at room temperature in 23 mL of dimethylformamide, and 250 mg of LiCI (6 mmol) and 0.74 mL of allyltributyltin (2.4 mmol) are then added. The reaction medium is heated and, at 400C, 70 mg of dichlorobis(triphenylphosphine)palladium (0.1 mmol) are added and the reaction medium brought to 12O0C and stirred for 20 minutes. The reaction is stopped by adding 30 mL of water and then extracted with 30 m L of ethyl acetate. The organic phases are washed with 80 ml_ of water and then dried over magnesium sulfate. The solvents are evaporated off and the residue is then purified by chromatography on silica gel (eluent: heptane). 940 mg of ethyl 3"-te/t-butyl-4"-diethylamino-4'-vinyl[1 ,1';3',1"]terphenyl-4-carboxylate are obtained (yield = 100%).
c) Ethyl 3"-tert-butyl-4"-diethylamino-4'-(3-hydroxypropyl)-[1, 1 ';3', 1 "]terphenyl-4- carboxylate
8 g of ethyl 3"-te/t-butyl-4"-diethylamino-4'-vinyl[1,1';3',1"]terphenyl-4-carboxylate (17 mmol) are dissolved in 400 ml_ of THF with stirring and, under cold conditions (ice bath), 6.2 g of 9 borabicyclo[3.3.1]nonane (51 mmol) are added and the ice bath is removed to raise the temperature of the reaction medium to room temperature, at which point the reaction medium is stirred for 1 hour 30 minutes. The temperature of the reaction medium is again reduced to 00C, 52.8 mL of NaOH (53 mmol) are added portionwise, and the medium is stirred for 10 minutes at O0C; 37.3 mL of H2O2 (426 mmol) are then added dropwise and the reaction medium is warmed to room temperature and then stirred for 2 hours 30 minutes. The reaction is stopped by adding 500 mL of ice- water and then extracted with 500 mL of ethyl acetate. The organic phases are washed with 1 L of water and then dried over magnesium sulfate. The solvents are evaporated off and the residue is then purified by chromatography on silica gel (eluent: 7/3 heptane/ethyl acetate). 6.4 g of ethyl 3"-tert-butyl-4"-diethylamino-4'-(3-hydroxypropyl)- [1 I1';3',1"3terphenyl-4-carboxylate are obtained (yield = 75%).
1H NMR (CDCk 400 MHz): 1.13 (t, 6H); 1.44 (t, J=7.5Hz, 3H); 1.50 (s, 9H); 1.75-1.78 (m, 2H), 2.76 (t, 2H); 2.88 (bs, 2H); 2.97 (bs, 2H); 3.51-3.56 (m, 2H); 4.41 (q, J=7.5Hz, 2H); 7.19 (m, 1H); 7.32 (d, J=8Hz, 1H); 7.38-7.42 ( m, 2H); 7.55-7.61 (m, 2H); 7.72 (d, J=8.4Hz, 2H); 8.11 (d, J=8.4Hz, 2H). 1.09 (t, 6H); 1.5 (s, 9H); 1.7 (m, 2H), 2.75 (t, 2H); 2.90-2.99 (m, 4H); 3.5 (t, 2H); 7.19 (d, 1H, J=7.0Hz); 7.31 (d, 1H, J=8Hz); 7.42 ( d, 2H, J=8Hz); 7.56 (s, 2H); 7.76 (d, 2H, J=8.4Hz); 8.17 (d, 2H, J=8.4Hz).
Example 33 - 3"-ter.-Butyl-4"-diethylamino-4'-(3-hvdroχvpropyn-n.r:3',1"1- terphenyl-4-carboxylic acid
Figure imgf000055_0001
In a manner similar to that of Example 3, by reacting 70 mg of ethyl 3"-tert-butyl-4"- diethylamino-4'-(3-hydroxypropyl)-[1,1';3',1"]terphenyl-4-carboxylate (0.14 mmol) with 0.2 mL of 1 N sodium hydroxide solution, 64 mg of 3"-terf-butyl-4"-diethylamino-4'-(3- hydroxypropyl)-[1,1';3',1"]terphenyl-4-carboxylic acid are obtained (yield = 94%) in the form of a white solid (m.p. = 95°C).
1H NMR (CDCI3, 400 MHz): 1.09 (t, 6H); 1.5 (s, 9H); 1.7 (m, 2H)1 2.75 (t, 2H); 2.90-2.99 (m, 4H); 3.5 (t, 2H); 7.19 (d, 1H, J=7.0Hz); 7.31 (d, 1H, J=8Hz); 7.42 ( d, 2H, J=8Hz); 7.56 (S, 2H); 7.76 (d, 2H, J=8.4Hz); 8.17 (d, 2H, J=8.4Hz).
Example 34 - Ethyl 3"-teft-butyl-4"-diethylamino-4'-(2,3-dihvdroxypropyl)- π,1>;3',1"1terphenyl-4-carboxylate
Figure imgf000055_0002
150 mg of ethyl 3"-feAf-butyl-4"-diethylamino-4l-vinyl[1,1';3',1"]teφhenyl-4-carboxylate obtained in Example 32b are dissolved in 10 mL of dichloromethane under a nitrogen atmosphere. 45 mg of N-methylmorpholine are added to the reaction medium, and
0.5 mL of a commercial 2.5% solution of osmium tetroxide in water is then added dropwise and the reaction medium is stirred at room temperature for 3 hours. The reaction is then stopped by adding 10 mL of water and extracted with dichloromethane. The organic phase is washed with water, dried over magnesium sulfate and filtered through a sinter funnel. The solvent is evaporated off and the residue obtained is purified by chromatography on silica (eluent: 7/3 heptane/ethyl acetate). 20 mg of ethyl 3"-tert- butyl-4"-diethylamino-4'-(2,3-dihydroxypropyl)-[1 ,1';3',1"]terphenyl-4-carboxylate are obtained in the form of a white solid.
1H NMR (CDCL 400 MHz): 1.12 (t, 6H); 1.43 (t, J=7.5Hz, 3H); 1.57 (s, 9H); 2.87 (t, 2H); 2.9 (bs, 2H); 2.97 (bs, 2H); 3.33-3.52 (m, 2H); 3.77 (m, 1H); 4.42 (q, J=7.5Hz, 2H); 7.18 (d, 1H, J=8.0Hz); 7.31 (d, J=8.0Hz, 1H); 7.39 (d, J=2Hz, 1H); 7.47 (d, J=7.8Hz); 7.57-7.60 (m, 2H); 7.71 (d, J=8.4Hz, 2H); 8.12 (d, J=8.4Hz, 2H).
Example 35 - 3"-feft-Butyl-4"-diethylamino-4'-(2.3-dihvdroxypropyl)-n,1':3\1"1- terphenyl-4-carboxylic acid
Figure imgf000056_0001
In a manner similar to that of Example 3, by reacting 70 mg of ethyl 3"-te/f-butyl-4"- diethylamino-4'-(2,3-dihydroxypropyl)-[1,1';3',1"]terphenyl-4-carboxylate (0.14 mmol) with 0.2 mL of 1 N sodium hydroxide solution, 58 mg of 3"-fe/f-butyl-4"-diethylamino-4'-(3- hydroxypropyl)-[1,1';3',1"]terphenyl-4-carboxylic acid are obtained (yield = 86%) in the form of a white solid (m.p. = 13O0C).
1H NMR (CDCk 400 MHz): 1.09 (t, 6H); 1.49 (s, 9H); 2.83 (t, 2H); 2.92 (m, 4H); 3.33-3.52 (m, 2H); 3.77 (m, 1H); 7.18 (d, J=7.9Hz, 1H); 7.31 (d, J=8Hz, 1H); 7.42 (d, J=8Hz, 2H); 7.56 (s, 2H); 7.76 (d, J=8.4Hz, 2H); 8.17 (d, J=8.4Hz, 2H).
Example 36 - Ethyl 4"-facetylethylamino)-3"-teιt-butvt-4'-f3-hvdroxypropyl)- n .1 ':3M"1terphenyl-4-carboxylate
Figure imgf000057_0001
a) Ethyl 4"-(acetylethylamino)-3"-tert-butyl-4'-trifluoromethanesulfonyloxy[1, 1 ';3', 1 "]- terphenyl-4-carboxylate In a manner similar to that of Example 32a, by reacting 7 g (58.5 mmol) of ethyl 4"- (acetylethylamino)-3"-fert-butyl-4'-hydroxy[1 ,1';3',1"]terphenyl-4-carboxylate obtained in Example 4d with 3.85 g (38 mmol, 5.3 mL) of triethylamine and 0.70 g (5.7 mmol) of 4-dimethylaminopyridine and 5.16 g (18 mmol, 3.1 mL) of triflic anhydride, 2.56 g of ethyl 4"-(acetylethylamino)-3"-te/f-butyl-4'-trifluoromethanesulfonyloxy[1 , 1 ';3\ 1 "]terphenyl-4- carboxylate are obtained (yield = 28%) in the form of a yellow oil.
b) Ethyl 4"-(acetylethylamino)-4'-allyl-3"-tert-butyl[1, 1';3',1"]terphenyl-4-carboxylate.
In a manner similar to that of Example 32b, by reacting 2.5 g (4.3 mmol) of ethyl 4"- (acetylethylamino)-3"-feAt-butyl-4'-trifluoromethanesulfonyloxy[1 , 1 ';3', 1 "]terphenyl-4- carboxylate with 540 mg (12.7 mmol) of lithium chloride and 1.66 g (5.0 mmol) of allyltributyltin and 148 mg (0.2 mmol) of dichlorobis(triphenylphosphine)palladium, 1.67 g of ethyl 4"-(acetylethylamino)-4'-allyl-3"-tert-butyl[1,1';3',1"]terphenyl-4-carboxylate are obtained (yield = 80%) in the form of a yellow oil.
c) Ethyl 4"-(acetylethylamino)-3"-tert-butyl-4'-(3-hydroxypropyl)-[1, 1 ';3', 1 "]terphenyl-4- carboxylate
In a manner similar to that of Example 32c, by reacting 0.2 g (0.41 mmol) of ethyl 4"- (acetylethylamino)-4'-allyl-3"-tert-butyl/'1,1';3',1"]terphenyl-4-carboxylate with 150 mg (1.24 mmol) of 9-borabicyclo[3.3.1]nonane, followed by addition of 1.25 mL (1.28 mmol) of 1N sodium hydroxide solution and 1 g (10.3 mmol) of hydrogen peroxide, 205 mg of ethyl 4"-(acetylethylamino)-3"-te/t-butyl-4'-(3-hydroxypropyl)-[1 ,1';3',1"]terphenyl-4- carboxylate are obtained (yield = 100%) in the form of a colourless oil.
1H NMR (CDCI3. 400 MHz): 1.28 (t, J=7.2 Hz, 3H); 1.43 (s, 9H); 1.46 (t, 3H); 1.78 (m, 2H); 1.88 (s, 3H); 2.76 (t, J=7.2 Hz, 2H); 2.94 (m, 1H); 3.57 (t, J=6.4 Hz, 2H); 4.43 (t,
J=7.2Hz, 2H); 4.45 (m, 1H); 7.07 (d, J=8.0Hz, 1H); 7.23 (dd, J1=2Hz, J2=8.0 Hz, 1H); 7.45 (d, J=8.0 Hz1 1H); 7.52 (d, J=2.0 Hz, 1H); 7.56 (d, J=2.0 Hz, 1H); 7.62 (dd, J1=2.0 Hz, J2=8.0 Hz, 1H); 7.73 (d, J=8.4 Hz, 2H); 8.12 (d, J=8.4 Hz, 2H).
Example 37 - 4"-(Acetylethylamino)-3"-teft-butvi-4'-(3-hvdroxypropyl)-ri,1';3M"'|- terphenyl-4-carboxylic acid
Figure imgf000058_0001
In a manner similar to that of Example 3, by reacting 200 mg of ethyl 4"- (acetylethylamino)-3"-terf-butyl-4'-(3-hydroxypropyl)-[1 , 1 ';3\ 1 "]terphenyl-4-carboxylate (0.4 mmol) with 1 mL of 1N sodium hydroxide solution, 45 mg of 4"-(acetylethylamino)-3"- teAf-butyl-4'-(3-hydroxypropyl)-[1,1';3',1"]terphenyl-4-carboxylic acid are obtained (yield = 23%) in the form of a white solid (m.p. = 2090C).
1H NMR (CDCk 400 MHz): 1.21 (t, J=7.2 Hz, 3H); 1.41 (s, 9H); 1.78 (m, 2H); 1.88 (s, 3H); 2.75 (t, J=7.2 Hz, 2H); 2.94 (m, 1H); 3.56 (t, J=6.4 Hz, 2H); 4.45 (m, 1H); 7.07 (d, J=8.0Hz, 1H); 7.23 (dd, J1=2Hz, J2=8.0 Hz, 1H); 7.45 (d, J=8.0 Hz, 1H); 7.52 (d, J=2.0 Hz, 1H); 7.56 (d, J=2.0 Hz, 1H); 7.62 (dd, ^=2.0 Hz, J2=8.0 Hz, 1H); 7.73 (d, J=8.4 Hz, 2H); 8.18 (d, J=8.4 Hz, 2H).
Example 38 - Ethyl 3"-feιt-butyl-4'-(3-cvclopropylanninopropyπ-4"-diethylamino- π,<r;3M"1terphenyl-4-carboxylate
Figure imgf000059_0001
a) Ethyl 4'-(3-bromopropyl)-3''-tert-butyl-4"-diethylamino[1, 1';3', 1']' terphenyl-4-carboxylate 6.4 g of ethyl 3"-tert-butyl-4"-diethylamino-4'-(3-hyclroxypropyl)-[1 ,1';3',1"]terphenyl-4- carboxylate obtained in Example 32c (13 mmol) are dissolved in 128 ml. of diethyl ether. The dissolution is performed under cold conditions (00C), and 11.4 mL of trioctylphosphine are then added (26 mmol) followed by addition of a solution of 8.5 g of carbon tetrabromide (26 mmol) dissolved in 10 volumes of Et2O added dropwise. The reaction medium is stirred at 0°C for 30 minutes and then for 1 hour 30 minutes at room temperature. The reaction is stopped by adding 100 mL of water and then extracted with 100 mL of ethyl acetate. The organic phases are washed with 400 mL of water and then dried over magnesium sulfate. The solvents are evaporated off and the residue is then purified by chromatography on silica gel (eluent: 9/1 heptane/ethyl acetate). 6 g of ethyl 4'-(3-bromopropyl)-3"-terf-butyl-4"-diethylamino[1 , 1 ';3', 1 "]terphenyl-4-carboxylate are obtained (yield = 83%) in the form of a thick brown oil.
b) Ethyl 3"-tert-butyl-4'-(3-cyclopropylaminopropyl)-4"-diethylamino[1, 1 ';3', 1 "]terphenyl-4- carboxylate
600 mg of ethyl 4'-(3-bromopropyl)-3"-ferf-butyl-4"-diethylamino[1,1';3'I1"]terphenyl-4- carboxylate (1.1 mmol) are dissolved in 12 mL of ethanol at room temperature, and
0.76 mL of cyclopropylamine (11 mmol) are then added. The medium is brought to reflux, and stirred for 24 hours. After concentrating the reaction mixture, the residue is purified by chromatography on silica gel.
(eluent: 95/5 dichloromethane/methanol). 300 mg of ethyl 3"-ferf-butyl-4'-(3- cyclopropylaminopropyl)-4"-diethylamino[1 ,1';3',1"]terphenyl-4-carboxylate are obtained
(yield = 53%).
1H NMR (CDCk 400 MHz): 0.66 (d, J=6.7Hz, 2H); 0.95 (d, J=7.3Hz, 2H); 1.12 (t,
J=7.2Hz, 6H); 1.43 (t, J=7.5Hz, 3H); 1.49 (s, 9H); 2.01-2.08 (m, 2H); 2.30-2.34 (m, 1H); 2.76 (t, J=7.7Hz, 2H); 2.83 (t, J=7.7Hz, 2H); 2.90 (bs, 2H); 2.98 (bs, 2H); 4.42 (q, J=7.5Hz, 2H); 7.16 (m, 1H); 7.28-7.34 (m, 2H); 7.43 (d, J=8.0Hz, 1H); 7.52-7.56 (m, 2H); 7.68 (dd, J1=I^Hz, J2=6.8Hz, 2H); 8.10 (d, Ji=1.9Hz, J2=6.8Hz, 2H).
Example 39 - 3"-fert-Butyl-4'-(3-cvclopropylaminopropyl)-4"-diethylamino- n ,1 ':3',1 "Iterphenyl-4-carboxylic acid
Figure imgf000060_0001
In a manner similar to that of Example 3, by reacting 300 mg of ethyl 3"-terf-butyl-4'-(3- cyclopropylaminopropyl)-4"-diethylamino[1 ,1 ';3',1"]terphenyl-4-carboxylate (0.57 mmol) with 2 ml_ of 1N sodium hydroxide solution, 50 mg of 3"-tert-butyl-4'-(3- cyclopropylaminopropyl)-4"-diethylamino[1,1';3',1"]terphenyl-4-carboxylic acid are obtained (yield = 18%) in the form of a white solid (m.p. = 189°C).
1H NMR (CDaOD. 400 MHz): 0.62 (m, 2H); 0.72 (m, 2H); 1.14 (t, J=IM Hz, 6H); 1.52 (s, 9H); 1.83 (m, 2H); 2.42 (m, 1H); 2.81 (m, 4H); 2.92 (m, 2H); 3.05 (m, 2H); 7.22 (dd, J1=2.01Hz, J2=8.04Hz, 1H); 7.24 - 7.44 (m, 3H); 7.49 (s, 1H); 7.61-7.67 (m, 3H); 8.03 (d, J=8.39 Hz, 2H).
Example 40 - Ethyl 3"-tert-butyl-4'-(3-cvclopentylaminopropyi)-4"-diethylamino- H,1':3',1"1terphenyl-4-carboxvlate
Figure imgf000061_0001
In a manner similar to that of Example 38b, by reacting 600 mg of ethyl 4'-(3- bromopropyl)-3"-terf-butyl-4"-diethylamino[1 ,1 ';3',1"]terphenyl-4-carboxylate (1.1 mmol) with 1.1 ml_ of cyclopentylamine (11 mmol), 560 mg of ethyl 3"-terf-butyl-4'-(3- cyclopentylaminopropyl)-4"-diethylamino[1,1';3',1"]terphenyl-4-carboxylate are obtained (yield = 93%) in the form of an orange-coloured oil.
1H NMR (CDCU. 400 MHz): 1.14 (t, J=8.2Hz, 6H); 1.46 (t, J=7.5Hz, 3H); 1.49 (s, 9H); 1.52-1.54 m, 2H); 1.75 -1.81 (m, 2H); 1.91-1.98 (m, 2H); 2.07-2.13 (m, 2H); 2.73 (t, J=8.2Hz, 4H); 2.94 (bs, 2H); 3.0 (bs, 2H); 3.20 (m, 1H); 4.41 (q, J=7.5Hz, 2H); 5.2 (bs, 1H); 7.15 (m, 1H); 7.29-7.32 (m, 2H); 7.44 (d, J=8.0Hz, 1H); 7.51-7.55 (m, 2H); 7.67 (dd, J1=LSHz, J2=6.7Hz, 2H); 8.09 (d, J1=ISHz, J2=6.7Hz, 2H).
Example 41 - 3"-fe/t-Butyl-4'-(3-cvclopentylaminopropyl)-4"-diethylamino- π .1':3M"1terphenyl-4-carboxyHc acid
Figure imgf000061_0002
In a manner similar to that of Example 3, by reacting 300 mg of ethyl 3"-terf-butyl-4'-(3- cyclopentylaminopropyl)-4"-diethylamino[1l1';3',1"]terphenyl-4-carboxylate (0.57 mmol) with 2 mL of 1 N sodium hydroxide solution, 300 mg of 3"-terf-butyl-4'-(3- cyclopentylaminopropyl)-4"-diethylamino[1 ,1';3',1"]terphenyl-4-carboxylic acid are obtained (yield = 56%) in the form of a white solid (m.p. = 255°C).
1H NMR (CD.OD, 400 MHzV. 1.14 (t, J=7.18Hz, 6H); 1.52 (s, 9H); 1.45 -1.95 (m, 8H); 2.03 (m, 2H); 2.82 (t, J=8.06Hz, 4H); 2.94 (m, 2H); 3.05 (m, 2H); 7.24 (d, J=2.08Hz, 2H); 7.40 (m, 2H); 7.49 (d, J=1.94Hz, 1H);7.62 (m, 3 H); 8.0 (d, J=8.4Hz, 2H).
Example 42 - Ethyl 3"-tert-butyl-4'-(3-cvclohexylaminopropyl)-4"-diethylamino- Ii .1 ':3M "Uerphenyl-4-carboxylate
Figure imgf000062_0001
In a manner similar to that of Example 38b, by reacting 600 mg of ethyl 4'-(3- bromopropyl)-3"-tert-butyl-4"-diethylamino[1,1';3',1"]terphenyl-4-carboxylate (1.1 mmol) with 1.25 mL of cyclohexylamine (11 mmol), 620 mg of ethyl 3"-terf-butyl-4'-(3- cyclohexylaminopropyl)-4"-diethylamino[1 ,1 ';3',1"]terphenyl-4-carboxylate are obtained (yield = 100%) in the form of an orange-coloured oil.
1H NMR (CDCU. 400 MHzV. 1.12 (t, J=7.8Hz, 6H); 1.46 (t, J=7.5Hz, 3H); 1.49 (s, 9H);
1.52-1.54 m, 2H); 1.71 -1.81 (m, 4H); 1.91-1.98 (m, 2H); 2.00-2.05 (m, 2H); 2.71 (m, 4H);
2.90 (bs, 2H); 2.90 m, 1H); 2.97 (bs, 2H); 3.20 (m, 1H); 4.2 (bs, 1H); 4.41 (q, J=7.5Hz,
2H); 7.15 (m, 1H); 7.28-7.33 (m, 2H); 7.45 (d, J=7.8Hz, 1H); 7.52-7.56 (m, 2H); 7.67 (dd,
J-,=1.8Hz, J2=6.7Hz, 2H); 8.10 (dd, J1=IeHz, J2=6.7Hz, 2H).
Example 43 - 3"-tert-Butyl-4'-(3-cvclohexylaminopropyl)-4"-diethylaminon,1':3M'1- terphenyl-4-carboxylic acid
Figure imgf000063_0001
In a manner similar to that of Example 3, by reacting 600 mg of ethyl 3"-terf-butyl-4'-(3- cyclohexylaminopropyl)-4"-diethylamino[1,1';3',1"]terphenyl-4-carboxylate (1.2 mmol) with 3 mL of 1N sodium hydroxide solution, 400 mg of 3"-terf-butyl-4'-(3-cyclohexylamino- propyl)-4"-diethylamino[1,1I;3',1"]terphenyl-4-carboxylic acid are obtained (yield = 56%) in the form of a white solid (m.p. = 253°C).
1H NMR (CD3QD, 400 MHzV 1.13 (t, J=7.13Hz, 6H); 1.52 (s, 9H); 1.58 - 1.93 (m, 12H); 2.45 (m, 1H); 2.52 (t, J=7.66Hz, 2H); 2.73 (t, J=7.67Hz, 2H); 2.52 (m, 2H); 3.05 (m, 2H); 7.22 (dd, J-,=2.02Hz, J2=7.98Hz, 1H); 7.39 (m, 3H); 7.47 (d, J=1.90Hz, 1H); 7.61 (m, 3H); 8.02 (d, J=8.28Hz, 2H).
Example 44 - Ethyl 3"-fe/t-butvi-4'-(3-fe/t-butylaminopropyl)-4"-diethylamino- π .1 ';3',1 "1terphenyl-4-carboxylate
Figure imgf000063_0002
In a manner similar to that of Example 38b, by reacting 600 mg of ethyl 4'-(3- bromopropyl)-3"-terf-butyl-4"-diethylamino[1 ,1 ';3',1"]terphenyl-4-carboxylate (1.1 mmol) with 1.06 mL of tert-butylamine (11 mmol), 500 mg of ethyl 3"-tert-butyl-4'-(3-fert- butylaminopropyl)-4"-diethylamino[1,1';3',1"]terphenyl-4-carboxylate are obtained (yield = 92%) in the form of an orange-coloured oil. 1H NMR (CDCk 400 MHzV 1.12 (t, J=7.2Hz, 6H); 1.43 (t, J=7.5Hz, 3H); 1.44 (s, 9H); 1.48 (s, 9H); 2.37-2.41 (m, 2H); 2.68-2.74 (m, 4H); 2.85 (bs, 2H); 2.95 (bs, 2H); 4.40 (q, J=7.5Hz, 2H); 7.12 (m, 1H); 7.28-7.31 (m, 2H); 7.44 (d, J=8.0Hz, 1H); 7.50-7.53 (m, 2H); 7.63 (d, J=6.8Hz, 2H); 8.07 (d, J=6.8Hz, 2H); 8.88 (bs, 1H).
Example 45- 3"-feft-Butyl-4'-(3-fert-butylaminopropyl)-4"-diethylaminof1,1>:3'.1"1- terphenyl-4-carboxylic acid
Figure imgf000064_0001
In a manner similar to that of Example 3, by reacting 480 mg of ethyl 3"-fe/f-butyl-4'-(3- fert-butylaminopropyl)-4"-diethylamino[1 ,1';3',1"]terphenyl-4-carboxylate (0.8 mmol) with 3 mL of 1N sodium hydroxide solution, 250 mg of 3"-teAf-butyl-4'-(3-te/f- butylaminopropyl)-4"-diethylamino[1,1';3',1"]terphenyl-4-carboxylic acid are obtained (yield = 55%) in the form of a white solid (m.p. = 273°C).
1H NMR (CDCI3, 400 MHz): 1.10 (t, J=7.2Hz, 6H); 1.41 (s, 9H); 1.46 (s.9H); 2.31 (m, 2H); 2.64 (m, 2H); 2.72 (m, 2H); 2.89 (m, 2H); 2.97 (m, 2H); 7.11 (m, 2H); 7.21 (d, J=8.0Hz, 1H); 7.28 (m, 2H); 7.42-7.47 (m, 3H); 7.94 (d, J=8.0Hz, 2H); 9.28 (bs.1H).
Example 46 - Ethyl 4"-(acetylethylamino)-3"-ferf-butyl-4'-(3-cvclopropylamino- propyπ-ri,1':3M"1terphenyl-4-carboxylate
Figure imgf000065_0001
a) Ethyl 4"-(acetylethylamino)-4'-(3-bromopropyl)-3"-tert-butyl[1, 1 ';3', 1 "]terphenyl-4- carboxylate In a manner similar to that of Example 38a, by reacting 450 mg of ethyl 4"- (acetylethylamino)-3"-fθ/t-butyl-4'-(3-hydroxypropyl)-[1 , 1 ';3\ 1 "]terphenyl-4-carboxylate (0.9 mmol) with 665 mg (1.8 mmol, 0.80 ml.) of trioctylphosphine and 600 mg (1.80 mmol) of carbon tetrabromide, 500 mg of ethyl 4"-(acetylethylamino)-4'-(3- bromopropyl)-3"-ferf-butyl/i,1';3\r]terphenyl-4-carboxylate are obtained (yield = 98%) in the form of an orange oil.
b) Ethyl 4"-(acetylethylamino)-3"-tert-butyl-4'-(3-cyclopropylaminopropyl)-[1, 1 ';3', 1 "]- terphenyl-4-carboxylate
In a manner similar to that of Example 38b, by reacting 490 mg of ethyl 4"- (acetylethylamino)-4'-(3-bromopropyl)-3"-fert-butyl[1,1';3',1"]terphenyl-4-carboxylate
(0.87 mmol) with 0.6 mL of cyclopropylamine (9 mmol). 270 mg of ethyl 4"- (acetylethylamino)-3"-ferf-butyl-4'-(3-cyclopropylaminopropylH1 ,1';3',1 "]terphenyl-4- carboxylate are obtained (yield = 57%) in the form of an orange-coloured oil.
1H NMR (CDCL 400 MHz): 0.73 (m, 4H); 1.27 (t, J=6.8Hz, 3H); 1.42 (s, 9H); 1.44 (t, 3H); 1.87 (s, 3H); 1.89 (m, 2H); 2.48 (m, 1H); 2.73 (t, J=8.0Hz, 2H); 2.86 (t, J=8.0Hz, 2H); 2.97 (m, 1H); 3.89 (m, 2H); 4.42 (q, J=7.4Hz, 2H); 7.12 (d, J=8.0Hz, 1H); 7.25 (m, 1H); 7.50- 7.53 (m, 3H); 7.58-7.62 (m, 1 H); 7.68 (d, J=8.0Hz, 2H); 8.11 (d, J=8.0Hz, 2H).
Example 47 - 4"-(Acetylethylamino)-3"-ferf-butyl-4'-(3-cvclopropylaminopropyl)- ri.1':3M"1terphenyl-4-carboxylic acid
Figure imgf000066_0001
In a manner similar to that of Example 3, by reacting 260 mg of ethyl 4"- (acetylethylamino)-3"-fert-butyl-4'-(3-cyclopropylaminopropyl)-[1,1';3',1"]terphenyl-4- carboxylate (0.48 mmol) with 2 mL of 1N sodium hydroxide solution, 100 mg of 4"- (acetylethylamino)-3"-tert-butyl-4'-(3-cyclopropylaminopropyl)-[1,1';3',1"]terphenyi-4- carboxylic acid are obtained (yield = 41%) in the form of a white solid (m.p. = 1900C).
1H NMR (CDCL 400 MHz): 0.73 (m, 4H); 1.26 (t, J=6.8Hz, 3H); 1.42 (s, 9H); 1.87 (s, 3H); 1.89 (m, 2H); 2.48 (m, 1H); 2.73 (t, J=8.0Hz, 2H); 2.86 (t, J=8.0Hz, 2H); 2.97 (m, 1H); 4.34 (m, 1H); 7.12 (d, J=8.0Hz, 1H); 2.58 (dd, J1=2.0Hz, J2=8.0Hz, 1H); 7.35 (d, J=8.0Hz, 1H); 7.49 (d, J=2.0Hz, 1H); 7.51 (dd, ^2.0Hz, J2=8.0Hz, 1H); 7.58-7.62 (m, 3H); 8.00 (d, J=8.0Hz, 2H).
Example 48 - Ethyl 3"-fert-butyl-4"-diethylamino-4'-(3-isopropylaminopropyl)- M .1 ':3M "1terphenyl-4-carboxylate
Figure imgf000066_0002
In a manner similar to that of Example 38b, by reacting 600 mg of ethyl 4'-(3- bromopropyl)-3"-tert-butyl-4"-diethylamino[1 ,1';3',1"]terphenyl-4-carboxylate (1.1 mmol) with 0.93 mL of isopropylamine (11 mmol), 353 mg of ethyl 3"-terf-butyl-4'-(3- isopropylaminopropyl)-4"-diethylamino[1 ,1';3',1"]terphenyl-4-carboxylate are obtained (yield = 57%) in the form of a white solid. 1H NMR (CDCk 400 MHz): 1.16 (t, J=7.2Hz, 6H); 1.37 (d, J=6.8Hz, 6H); 1.42 (t, 3H); 1.48 (st 9H); 2.20-2.25 (m, 2H); 2.75-2.79 (m, 4H); 2.93 (bs, 2H); 3.00 (bs, 2H); 3.28 m, 1H); 4.41 (q, J=7.5Hz, 2H); 7.15 (d, J=2.0Hz, 1H); 7.30 (dd, J1=2.iHz, J2=8.3Hz, 2H); 7.44-7.55 (m, 3H); 7.65 (d, J=8.0Hz, 2H); 8.09 (d, J=8.0Hz, 2H); 8.98 (bs, 1H).
Example 49 - 3"-fert-Butv[-4'-(3-isopropylaminopropyl)-4"-diethylaminof1,1';3M"1- terphenyl-4-carboxylic acid
Figure imgf000067_0001
In a manner similar to that of Example 3, by reacting 350 mg of ethyl 3"-terf-butyl-4'-(3- isopropylaminopropyl)-4"-diethylamino[1,1';3',1"]terphenyl-4-carboxylate (0.67 mmol) with 2 mL of 1N sodium hydroxide solution, 200 mg of 3"-tert-butyl-4'-(3-isopropylamino- propyl)-4"-diethyiamino[1,1';3',1"]terphenyl-4-carboxylic acid are obtained (yield = 59%) in the form of a white solid (m.p. = 2530C).
1H NMR (CDsOD, 400 MHz): 1.23 (t, J=7.2Hz, 6H); 1.37 (d, J=6.8Hz, 6H); 1.62 (s, 9H); 1.97 (m, 2H); 2.74 (m, 1H); 2.89-2.96 (m, 4H); 3.02 (m, 2H); 3.14 (m, 2H); 7.35 (dd, J1=2.0Hz, 1H); 7.49-7.51 (m, 2H); 7.55 (d, J=8.0Hz, 1H); 7.62 (d, J=2.0Hz, 1H); 7.75 (dd, J1=2.0Hz, J2=8.0Hz, 1H); 7.78 (d, J=8.0Hz, 2H); 8.13 (d, J=8.0Hz, 2H).
Example 50 - Ethyl 3"-terf-butyl-4'-(3-aminopropyl)-4"-diethylaminon,1':3M"1- terphenyl-4-carboxvlate
Figure imgf000068_0001
a) Ethyl 3''-tert-butyl-4''-diethylamino-4'-[3-(1,3-dioxo-1,3-dihydroisoindol-2-yl)propyl]- [1, 1 ';3', 1 "]terphenyl-4-carboxylate In a 50 mL three-necked flask under a nitrogen atmosphere, equipped with a magnetic stirrer, 1.0 g (1.82 mmol) of ethyl 4'-(3-bromopropyl)-3"-fert-butyl-4"-diethylamino- [1 ,1';3',1"]terphenyl-4-carboxylate, 294 mg (2 mmol) of isoindole-1 ,3-dione and 276 mg of potassium carbonate (2 mmol) are placed in 20 mL of dimethylformamide. The reaction medium is heated at 1000C for 3 hours and is then poured into water beforehand and acidified slightly with a 1 mol/L solution of hydrochloric acid, and extracted twice with ethyl acetate. The organic phases obtained are combined and washed with water, dried over anhydrous magnesium sulfate, filtered and evaporated to give a brownish oil. This oil is purified by chromatography on silica (eluent: 80/20 heptane/ethyl acetate) to give 950 mg of ethyl 3"-terf-butyl-4"-diethylamino-4'-[3-(1 ,3-dioxo-1 ,3-dihydroisoindol-2-yl)propyl]- [1 , 1 ';3', 1 "]terphenyl-4-carboxylate (yield = 86%) in the form of a colourless oil.
b) Ethyl 3"-tert-butyl-4'-(3-aminopropyl)-4"-diethylamino[1, 1 ';3', 1 "]terphenyl-4-carboxylate In a 50 mL three-necked flask under a nitrogen atmosphere, equipped with a magnetic stirrer, 900 mg (1.46 mmol) of ethyl 3"-tert-butyl-4"-diethylamino-4l-[3-(1 ,3-dioxo-1,3- dihydroisoindol-2-yl)propylH1,1';3',1"]terphenyl-4-carboxylate and 292 mg (5.8 mmol) of hydrazine hydrate are placed in 20 mL of ethanol. The reaction medium is heated to the reflux point of the ethanol for 20 hours and then filtered; the filtrate obtained is evaporated and then purified directly on a column of silica (eluent: 94/6 dichloromethane/methanol) to give, after evaporation of the purest fractions, 545 mg of ethyl 3"-terf-butyl-4'-(3- aminopropyl)-4"-diethylamino[1,1';3',1"]terphenyl-4-carboxylate (yield = 77%) in the form of a colourless oil.
1H NMR (CDCI3, 400 MHz): 1.12 (t, J=7.2Hz, 6H); 1.43 (t, </=7.5Hz, 3H); 1.50 (s, 9H); 1.63-1.69 (m, 2H); 2.61 (t, J=6.9Hz, 2H); 2.70 (t, J=6.9 Hz, 2H); 2.90 (bs, 2H); 2.95 (bs, 2H); 4.42 (q, J=7.5Hz, 2H); 7.18 (m, 1H); 7.28-7.32 (m, 1H); 7.38 (d, J=2.0Hz, 1H); 7.40 (d, J=8.3 Hz, 1H); 7.55-7.59 (m, 2H); 7.71 (d, J=6.8Hz, 2H); 8.11 (d, J=6.8Hz, 2H). Example 51 - 3"-terf-Butyl-4'-f3-aminopropyl)-4"-diethylaminori,1':3',1"1terphenyl-4- carboxylic acid
Figure imgf000069_0001
In a manner similar to that of Example 3, by reacting 545 mg of ethyl 3"-terf-butyl-4'-(3- aminopropyl)-4"-diethylamino[1 ,1';3',1"]terphenyl-4-carboxylate (1.1 mmol) with 4 mL of 1N sodium hydroxide solution, 282 mg of 3"-ferf-butyl-4'-(3-aminopropyl)-4"-diethylamino [1 ,1';3',1"]terphenyl-4-carboxylic acid are obtained (yield = 55%) in the form of a white solid (m.p. = 2720C).
1H NMR (CDCIa + εCD.COOD, 400 MHz): 1.11 (t, J=7.2Hz, 6H); 1.47 (s, 9H); 1.91 (m, 2H); 2.72 (t, J=7.2Hz, 2H); 2.84 (t, J=7.6Hz, 2H); 2.92 (m, 2H); 3.00 (m, 2H); 7.14 (dd, J.,=2.0Hz, J2=8.0Hz, 1H); 7.31 (m, 2H); 7.38 (d, J=7.6Hz, 1H); 7.52-7.56 (m, 2H); 7.70 (d, J=8.4Hz, 2H); 8.12 (d, J=8.4Hz, 2H).
Example 52 - r3"-feft-Butyl-4-carboxy-4'-(3-hvdroxypropyl)-n,1':3',1"1terphenyl-4"- ylidiethylamine hydrochloride
Cl"
Figure imgf000069_0002
0.7 g of 3"-te/t-butyl-4"-diethylamino-4'-(3-hydroxypropyl)-[1 ,1';3',1"]terphenyl-4- carboxylic acid (1.5 mmol, 1 eq) obtained in Example 33 are dissolved at room temperature in 7 ml_ of Et2O (10 vol) and 7 ml of ethanol, and 0.14 ml_ of HCI (1.6 mmol, 1.1 eq) is then added.
The reaction mixture is then stirred for 5 hours. Crystallization is performed in THF. 0.3 g of [3"-te/f-butyl-4-carboxy-4l-(3-hydroxypropyl)-[1 ,1';3',1"]terphenyl-4"-yl]diethyl- amine hydrochloride is obtained (yield = 41%), (m.p. =164-166°C).
1H NMR (Methanol. 400 MHz)
1.36 (m, 6H); 1.61 (s, 9H); 1.72 (m, 2H); 1.68 (m, 1H); 2.71 (m, 2H); 3.47 (t, 6.3 Hz, 2H); 3.74 (m, 1H); 3.90 (m, 2H); 3.99 (m, 2H); 7.50 (d, 8.04 Hz, 1H); 7.53 (d, 1.30 Hz, 1 H); 7.58 (d, 7.8 Hz, 1H); 7.70 (m, 5.52 Hz, 2H); 7.76 (d, 8.2 Hz, 2H); 7.81 (d, 1H); 8.10 (d, 8.2 Hz, 2H).
Example 53 - 3"-tert-Butyl-4'-(2-hvdroxyethoxy)-4"-f2-oxopyrrolidin-1-yl)- π.r:3'.1"1terphenyl-4-carboxylic acid
Figure imgf000070_0001
a) N-(2-tert-Butyl-4-bromophenyl)-4-chlorobutanamide: 20 g (0.0877 mol; 1 eq.) of 2-tert-butyl-4-bromoaniline (prepared according to Example 1 a)) are dissolved in 100 ml of dichloromethane at about O0C.
13 ml (0.0921 mol; 1.05 eq.) of triethylamine are added, followed, after 15 minutes, by addition of 10.5 ml (0.0921 mol; 1.05 eq.) of 4-chlorobutanoyl chloride.
At the end of the addition, the reaction medium is returned to room temperature and stirred for 1 hour 30 minutes. 70 ml of H2O are added and the reaction medium is then allowed to settle. The aqueous phase is re-extracted with dichloromethane, and the organic phases are collected and washed successively with aqueous 1M NaHCθ3 and then with H2O.
The resulting organic phase is dried over sodium sulfate, filtered and concentrated on a rotavapor. An orange crystalline powder (m = 31 g) is obtained, which, after recristallization from heptane/ethyl acetate medium, gives 24 g of N-(2-tert-butyl-4-bromophenyl)-4- chlorobutanamide (yield = 82%).
b) 1-(-2-tert-Butyl-4-bromophenyl)pyrrolidin-2-one;
24 g (0.0721 mol; 1 eq.) of N-(2-tert-butyl-4-bromophenyl)-4-chlorobutanamide (obtained from step a)) are suspended in 170 ml of absolute ethanol.
This suspension is cooled to about 00C, and 60 ml (0.155 mol; 2.2 eq.) of sodium ethoxide as a 21% w/w solution in ethanol are added slowly. The reaction medium is then brownish-coloured; it is stirred for 15 hours at room temperature. 200 ml of H2O are added and the mixture is extracted with heptane/ethyl acetate and washed with H2O until the aqueous phase is neutral. The organic phase is concentrated on a rotavapor: 20 g of an orange crystalline powder are isolated and recrystallized from 200 ml of diisopropyl ether. Finally, 16 g of 1-(-2-tert-butyl-4-bromophenyl)pyrrolidin-2-one are obtained (yield = 75%).
c) 1-[2-tert-Butyl-4-(4, 4, 5, 5-tetramethyl[1 , 3, 2]dioxaborolan-2-yl)phenyl]pyrrolidin-2-one: 6.5 g (0.022 mol; 1 eq.) of 1-(-2-tert-butyl-4-bromophenyl)pyrrolidin-2-one (obtained in step b)), 5.85 g (0.023 mol; 1.05 eq.) of bis(pinacolato)diborane and 6.46 g (0.066 mol; 3 eq.) of potassium acetate are suspended in 50 ml of dimethylformamide. After bubbling nitrogen into the reaction medium for 15 minutes, 540 mg (0.66 mmol; 0.03 eq.) of catalyst (PdCI2(dppf)) are added and the medium is then heated at 9O0C until the reaction is complete.
The reaction medium cooled to room temperature and filtered through a sinter funnel packed with Celite; the filter cake is rinsed thoroughly with ethyl acetate, and H2O is added to the filtrate, which is then allowed to settle. The organic phase obtained is then concentrated on a rotavapor to give a residue, which is purified by chromatography on silica.
5.7 g of 1-[2-tert-butyl-4-(4I4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)phenyl]pyrrolidin-2- one are isolated in the form of a white powder (yield = 75%).
d) Ethyl [3'-bromo-4'-(2-hydroxyethoxy)]biphenyl-4-benzoate:
70 g (0.218 mol; 1 eq.) of ethyl [3'-bromo-4'-hydroxy]biphenyl-4-benzoate are suspended with 45.2 g (0.327 mol; 1.5 eq.) of potassium carbonate, in 700 ml of methyl ethyl ketone. 39 ml (0.545 mol; 2.5 eq.) of 2-bromoethanol are added in a single portion, and this suspension is heated to reflux. The reaction medium is maintained under these conditions for 14 hours and then cooled to room temperature.
The reaction medium is filtered and the filtrate is concentrated. The residue is added to ethyl acetate, washed with H2O and once again concentrated. 90 g of a powder are obtained, which product is recrystailized from heptane/ethyl acetate to give after drying 65 g of ethyl [3'-bromo-4'-(2-hydroxyethoxy)]biphenyl-4-benzoate, in the form of a white crystalline powder (yield = 82%).
e) [3'-Bromo-4'-(2-hydroxyethoxy)]biphenyl-4-carboxylic acid:
63 g (0.173 mol; 1 eq.) of ethyl [3'-bromo-4'-(2-hydroxyethoxy)]biphenyl-4-benzoate
(obtained in step d)) are dissolved in 300 ml of tetrahydrofuran. 10.9 g (0.259 mol; 1.5 eq.) of lithium hydroxide monohydrate as a solution in 70 ml of H2O are added at room temperature.
The reaction medium is refluxed for about 1 hour 30 minutes.
The reaction medium is then cooled to room temperature and dilute hydrochloric acid solution is added (330 ml; ~1M). 100 ml of H2O are added and this suspension is cooled to about 00C; it is maintained at this temperature for about 15 minutes then filtered. After drying, 59 g of a white powder are obtained.
This product is slurried in 240 ml of acetone for two hours at room temperature and then filtered and oven-dried. 55 g of [3'-bromo-4'-(2-hydroxyethoxy)]biphenyl-4-carboxylic acid are thus isolated (yield = 95%).
f) 3''-tert-Butyl-4'-(2-hydroxyethoxy)-4''-(2-oxopyιrolidin-1-ylH1, 1\3\ iηterphenyl-4~ carboxylic acid: 1.3 g (3.78 mmol; 1 eq.) of 1-[2-tert-butyl-4-(4,4,5,5-tetramethyl[1 ,3,2]dioxaborolan-2- yl)phenyl]pyrrolidin-2-one (obtained in step c)) and 1.68 g (4.98 mmol; 1.3 eq.) of [3'- bromo-4'-(2-hydroxyethoxy)]biphenyl-4-carboxylic acid (obtained in step e)) are dissolved in 8 ml of dimethylformamide. 7.5 ml (0.015 mol; 3.97 eq.) of aqueous 2M potassium carbonate solution and 35 mg (0.10 mmol; 0.026 eq.) of 2-dicyclohexylphosphinobiphenyl are then added. A stream of nitrogen is bubbled through the medium for about 10 minutes, and 11 mg (0.08 mmol; 0.014 eq.) of palladium acetate are introduced. The mixture is then heated to about 9O0C and maintained under these conditions for 4-6 hours. The reaction medium is then cooled to room temperature, filtered through a sinter funnel packed with Celite and rinsed with a minimum amount of dimethylformamide, and dilute hydrochloric acid solution (~2M) is added to the filtrate.
After stirring for 4 hours, the precipitate formed is filtered off, rinsed to neutrality with H2O, filtered off by suction and oven-dried. 1.05 g of 3"-tert-butyl-4'-(2-hydroxyethoxy)-4"-(2- oxopyrrolidin-1-yl)-[1,1l,3l,1"]terphenyl-4-carboxylic acid are thus isolated (yield = 57%).
Example 54 - 3"-tert-Butyl-4"-ethylamino-4'-(3-hvdroxypropoxy)-ri.1':3M"1ter- phenyl-4- carboxylic acid
Figure imgf000073_0001
a) N-(2-tert-Butyl-4-bromophenyl)acetamide:
18 g (0.079 mol; 1 eq.) of 2-tert-butyl-4-bromoaniline (prepared according to Example 1 a)) are dissolved in 150 ml of dichloromethane at about 00C. 12.1 ml (0.087 mol; 1.1 eq.) of triethylamine are added, followed, after 15 minutes, by addition of 6.2 ml (0.087 mol; 1.1 eq.) of acetyl chloride. The mixture is warmed to room temperature at the end of addition and stirred for 2 hours. 70 ml of H2O are added and the resulting mixture is allowed to settle. The aqueous phase is re-extracted with dichloromethane, and the organic phases are combined, washed to neutrality with H2O, dried over sodium sulfate, filtered and concentrated on a rotavapor.
21 g of a beige-coloured crystalline powder are obtained, which product is slurried in heptane for 2 hours at room temperature, chilled and then filtered. After drying, 17.6 g of N-(2-tert-butyl-4-bromophenyl)acetamide are obtained (yield = 83%).
b) (2-tert-Butyl-4-bromophenyl)ethylamine:
17.5 g (0.065 mol; 1 eq.) of N-(2-tert-butyl-4-bromophenyl)acetamide (obtained in step a)) are suspended in 100 ml of tetrahydrofuran. 162 ml (0.162 mol; 2.5 eq.) of 1M borane-tetrahydrofuran complex are added and the mixture is heated to reflux. The conditions are maintained for about 12 hours. The reaction mixture is cooled to room temperature and 70 ml of methanol are added to destroy the excess borane. The mixture is stirred until the evolution of gas has ceased and is then concentrated on a rotavapor. The oil obtained is dissolved in ethyl acetate and washed with saturated aqueous ammonium chloride solution and then with H2O. The resulting solution is concentrated and purified by filtration on silica; 13 g of (2-tert- butyl-4-bromophenyl)ethylamine are thus obtained in the form of a relatively colourless oil (yield = 78%).
c) [2-tert-Butyl-4-(4, 4, 5, 5-tetramethyl[1 , 3, 2Jdioxaborolan-2-yl)phenyl]ethylamine:
13 g (0.0507 mol; 1 eq.) of (2-tert-butyl-4-bromophenyl)ethylamine (obtained in step b)), 15.5 g (0.061 mol; 1.2 eq.) of bis(pinacolato)diborane and 15 g (0.152 mol; 3 eq.) of potassium acetate are suspended in 75 ml of dimethylformamide. After bubbling a stream of nitrogen through the reaction medium for 15 minutes, 1.66 g (2.03 mmol; 0.04 eq.) of catalyst (PdCI2(dppf)) are added and the medium is heated at about 900C for about 10 hours. The reaction medium is cooled to room temperature and filtered through a sinter funnel packed with Celite; the filter cake is rinsed thoroughly with ethyl acetate, and H2O is added to the filtrate and the phases are allowed to separate by settling. The organic phase obtained is thus concentrated on a rotavapor to give a residue, which is chromatographed on a column of silica. 7 g of [2-tert-butyl-4-(4,4,5,5-tetramethyl[1,3,2]- dioxaborolan-2-yl)phenyl]ethylamine are isolated in the form of an orange crystalline powder (yield = 45%).
d) Ethyl [3'-bromo-4'-(3-hydroxypropoxy)]biphenyl-4-benzoate:
47 g (0.146 mol; 1 eq.) of ethyl [3'-bromo-4'-hydroxy]biphenyl-4-benzoate are suspended with 30.3 g (0.219 mol; 1.5 eq.) of potassium carbonate in 470 ml of methyl ethyl ketone.
13.5 ml (0.154 mol; 1.05 eq.) of 3-bromopropan-1-ol are added in a single portion and this suspension is brought to reflux. These conditions are maintained for 14 hours and the mixture is then cooled to room temperature. The medium is filtered and the filtrate is concentrated. The residue is taken up in ethyl acetate, washed with H2O and then concentrated again. 60 g of a powder are isolated, and are recrystallized from a heptane/ethyl acetate mixture to give, after drying, 40 g of ethyl [3'-bromo-4'-(3- hydroxypropoxy)]biphenyl-4-benzoate in the form of an off-white crystalline powder (yield = 72%).
e) Ethyl [3'-bromo-4'-(3-acetoxypropoxy)]biphenyl-4-henzoate:
2 g (5.27 mmol; 1 eq.) of ethyl [3'-bromo-4'-(3-hydroxypropoxy)]biphenyl-4-benzoate (obtained in step d)) are dissolved in 20 ml of dichloromethane. 64 mg (0.527 mmol; 0.1 eq.) of 4-dimethylaminopyridine and 430 μl (5.27 mmol; 1 eq.) of pyridine are added at room temperature. The mixture is stirred for 15 minutes at room temperature, and 750 μl (7.91 mmol; 1.5 eq.) of acetic anhydride are then added. The mixture is maintained at room temperature for 1 hour. H2O is added, the phases are allowed to separate by settling and the organic phase is neutralized with aqueous 1M NHCO3 solution. The resulting organic phase is washed with H2O until neutral and concentrated on a rotavapor. 2.2 g of a powder are obtained, and are recrystallized from a heptane/ethyl acetate mixture. This gives, after drying, 1.9 g of ethyl [3'-bromo-4'-(3-acetoxypropoxy)]- biphenyl-4-benzoate in the form of a white crystalline powder (yield = 85%).
f) Ethyl 4'-(3-acetoxypropoxy)-3"-tert-butyl-4"-ethylamino[1, 1',3', 1"]terphenyl-4-benzoate: 720 mg (2.3 mmol; 1 eq.) of [2-tert-butyl-4-(4,4,5,5-tetramethyl[1 ,3,2]dioxaborolan-2-yl)- phenyl]ethylamine (obtained in step c)) and 1 g (2.3 mmol; 1 eq.) of ethyl [3'-bromo-4'-(3- acetoxypropoxy)]biphenyl-4-benzoate (obtained in step e)) are dissolved in 10 ml of dimethylformamide. 2.5 ml (5 mmol; 2 eq.) of aqueous 2M tribasic potassium phosphate solution and 16.1 mg (0.046 mmol; 0.02 eq.) of 2-dicyclohexylphosphinobiphenyl are added at room temperature.
After bubbling a stream of nitrogen into the medium for about 10 minutes, 5.2 mg (0.023 mmol; 0.01 eq.) of palladium acetate are added and the mixture is heated at 80°C for about 5 hours. The reaction medium is filtered through a sinter funnel packed with Celite and rinsed thoroughly with ethyl acetate. Saturated aqueous ammonium chloride solution is then added to the filtrate, the phases are allowed to separate by settling and the organic phase is washed with H2O and then dried over sodium sulfate. The organic phase is concentrated; the oil obtained is chromatographed on a column of silica, and 900 mg of ethyl 4'-(3-acetoxypropoxy)-3"-tert-butyl-4"-ethylamino[1 , 1 ',3', 1 "]terphenyl-4-benzoate are isolated (yield = 73%). g) 3"-tert-Butyl-4"-ethylamino-4'-(3-hydroxypropoxy)-[i, 1 ',3', 1 ψerphenyl-4-carboxylic acid:
900 mg (1.74 mmol; 1 eq.) of ethyl 4'-(3-acetoxypropoxy)-3"-tert-butyl-4"-ethylamino-
[1 ,1 ',3',1"]terphenyl-4-benzoate are dissolved in 10 ml of absolute ethanol. 312 mg (7.8 mmol; 4.5 eq.) of sodium hydroxide and 4 ml of H2O are added at room temperature and the mixture is then heated to reflux. These conditions are maintained for about 1 hour 30 minutes. The reaction medium is concentrated to a small volume; H2O is added to the precipitate formed, and the mixture is then acidified with acetic acid to pH ~4-5. This suspension is fluidized by adding H2O and stirred at room temperature for 1 hour. The resulting mixture is filtered through a sinter funnel, rinsed with H2O until the filtrate is neutral, and oven-dried. 694 mg of 3"-tert-butyl-4"-ethylamino-4'-(3-hydroxypropoxy)- [1 ,1',3',1"]terphenyl-4-carboxylic acid are thus obtained in the form of a white powder (yield = 89%).
EXAMPLE 55: TRANSACTIVATION TEST
The activation of receptors with an agonist (activator) in HeLa cells leads to the expression of a reporter gene, luciferase, which, in the presence of a substrate, generates light. The activation of the receptors may thus be measured by quantifying the luminescence produced after incubating the cells in the presence of a reference agonist. The inhibitory products displace the agonist from its site, thus preventing activation of the receptor. The activity is measured by quantifying the reduction in light produced. This measurement makes it possible to determine the inhibitory activity of the compounds according to the invention.
In this study, a constant is determined which represents the affinity of the molecule for the receptor. Since this value can fluctuate depending on the basal activity and the expression of the receptor, it is referred to as the Kd apparent (KdApp).
To determine this constant, "crossed curves" of the test product against a reference agonist, 4-[2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)propenyl]benzoic acid, are performed in 96-well plates. The test product is used at 10 concentrations and the reference agonist at 7 concentrations. In each well, the cells are in contact with a concentration of the test product and a concentration of the reference agonist, 4-[2- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)propenyl]benzoic acid. Measurements are also taken for the total agonist (4-[2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2- naphthyl)propenyl]benzoic acid) and inverse agonist, 4-{(E)-3-[4-(4-ferf-butylphenyl)- 5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl]-3-oxopropenyl}benzoic acid, controls.
These crossed curves make it possible to determine the AC50 values (concentration at which 50% activation is observed) for the reference ligand at various concentrations of test product. These AC50 values are used to calculate the Schild regression by plotting a straight line corresponding to the Schild equation ("quantitation in receptor pharmacology" Terry P. Kenakin, Receptors and Channels, 2001, 7, 371-385).
The HeLa cell lines used are stable transfectants containing the plasmids ERE-βGlob- Luc-SV-Neo (reporter gene) and RAR (α, β, γ) ER-DBD-puro. These cells are inoculated into 96-well plates at a rate of 10 000 cells per well in 100 μl of DMEM medium without phenol red, and supplemented with 10% defatted calf serum. The plates are then incubated at 37°C and 7% CO2 for 4 hours.
The various dilutions of the test products, of the reference ligand (4-[2-(5, 5,8,8- tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)propenyl]benzoic acid), of the 100% control (100 nM 4-[2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)propenyl]benzoic acid) and of the 0% control (500 nM 4-{(E)-3-[4-(4-tert-butylphenyl)-5,5,8,8-tetramethyl-5,6,7,8- tetrahydro-2-naphthyl]-3-oxopropenyl}benzoic acid) are added at a rate of 5 μl per well. The plates are then incubated for 18 hours at 37°C and 7% CO2.
The culture medium is removed by turning over and 100 μl of a 1 :1 PBS/luciferine mixture is added to each well. After 5 minutes, the plates are read using the luminescence reader.
Figure imgf000077_0001
Figure imgf000078_0001
The results obtained with the compounds according to the invention clearly show Kdapp values of less than or equal to 1000 nM.
EXAMPLE 56: FORMULATION EXAMPLES
This example illustrates various concrete formulations based on the compounds according to the invention.
A - ORAL ROUTE
(a) 0.2 g tablet Compound of Example 5 0.001 g Starch 0.114 g
Dicalcium phosphate 0.020 g Silica 0.020 g Lactose 0.030 g Talc 0.01O g Magnesium stearate 0.005 g
(b) Drinkable suspension in 5 ml ampoules Compound of Example 3 0.001 g
Glycerol 0.500 g
70% sorbitol 0.500 g
Sodium saccharinate 0.01O g
Methyl para-hydroxybenzoate 0.040 g
Flavouring qs
Purified water qs δ ml
(c) 0.8 g tablet
Compound of Example 4 0.500 g
Pregelatinized starch 0.100 g
Microcrystalline cellulose 0.115 g
Lactose 0.075 g
Magnesium stearate 0.01O g
(d) Drinkable suspension in 10 ml ampoules
Compound of Example 2 0.200 g
Glycerol 1.00O g
70% sorbitol 1.00O g
Sodium saccharinate 0.01O g
Methyl para-hydroxybenzoate 0.080 g
Flavouring qs
Purified water qs 10 ml
B - PARENTERAL ROUTE
(a) Composition
Compound of Example 3 0.002 g
Ethyl oleate qs 10 g
(b) Composition
Compound of Example 1 0.05%
Polyethylene glycol 20%
0.9% NaCI solution qs 100 (c) Composition
Compound of Example 3 2.5%
Polyethylene glycol 400 20%
0.9% NaCI solution qs 100
(d) Injectable cyclodextrin composition
Compound of Example 3 0.1 mg β-Cyclodextrin 0.1O g
Water for injection qs 10.0O g
C - TOPICAL ROUTE
(a) Ointment
Compound of Example 2 0.020 g lsopropyl myristate 81.70O g
Liquid petroleum jelly oil 9.10O g
Silica ("Aerosil 200" sold by Degussa) 9.18O g
(b) Ointment
Compound of Example 5 0.300 g
White petroleum jelly codex qs 100 g
(c) Nonionic water-in-oil cream
Compound of Example 4 0.100 g
Mixture of emulsifying lanolin alcohols, waxes and oils
("Anhydrous Eucerin" sold by BDF) 39.900 g
Methyl para-hydroxybenzoate 0.075 g
Propyl para-hydroxybenzoate 0.075 g
Sterile demineralized water qs 100 g
(d) Lotion
Compound of Example 2 0.100 g
Polyethylene glycol (PEG 400) 69.900 g
95% ethanol 30.000 g (e) Hydrophobic ointment
Compound of Example 4 0.300 g lsopropyl myristate 36.400 g Silicone oil ("Rhodorsil 47 V 300" sold by Rhone-Poulenc) 36.400 g
Beeswax 13.600 g
Silicone oil ("Abil 300 000 cSt" sold by Goldschmidt) qs 100 g
(f) Nonionic oil-in-water cream
Compound of Example 5 1.000 g
Cetyl alcohol 4.000 g
Glyceryl monostearate 2.500 g
PEG 50 stearate 2.500 g
Shea butter 9.200 g
Propylene glycol 2.000 g
Methyl para-hydroxybenzoate 0.075 g
Propyl para-hydroxybenzoate 0.075 g
Sterile demineralized water qs 100 g

Claims

1. Compounds characterized in that they correspond to formula (I) below:
Figure imgf000082_0001
in which:
R1 is a hydrogen atom, an alky! radical of 1 to 4 carbon atoms or a -CF3 radical;
R2 is a hydrogen atom, an alkyl or alkoxy radical of 1 to 4 carbon atoms or a chlorine atom;
R3 is a hydrogen atom or a linear or branched alkyl or alkoxy radical of 1 to 10 carbon atoms optionally substituted with a methoxy group;
- R4 is a hydrogen atom or an alkyl radical of 1 to 3 carbon atoms;
- R5 is a hydrogen atom or an alkyl radical of 1 to 3 carbon atoms;
- or alternatively R4 and R5 form, together with the bond -N-C(=Y)-, a ring of pyrrolidine, pyrrolidinone, piperidine or piperidinone type;
- Y represents two hydrogen atoms or a hetero atom, for instance oxygen or sulfur;
- Ar represents a 1 ,4-phenyl, 2,5-pyridyl, 5,2-pyridyl or 2,5-thiophenyl ring;
- X represents an oxygen atom optionally substituted with an alkyl or alkylamine chain or a C-C single bond; - A represents a hydrogen atom or the following formula:
Figure imgf000083_0001
in which, o Q is an oxygen atom or an -NH- bond;
o R6 represents a hydrogen atom, an alkyl radical of 1 to 6 carbon atoms, a cycloalkyl radical of 3 to 6 carbon atoms or a -C(O)CH3 or -C(O)CH2CH3 radical;
o R7 and R7' represent, independently of each other, a hydrogen atom or a hydroxyl group, on condition that R7 and R7' are not simultaneously a hydroxyl group;
o n is 0, 1, 2, 3, 4 or 5;
and the salts of the compounds of formula (I) when R3 represents a hydrogen atom, OH and also the geometrical isomers of the said compounds of formula (I).
2. Compounds according to Claim 1 , characterized in that they are in the form of alkali metal or alkaline-earth metal salts, zinc salts or salts of an organic amine or of an acidic partner when the compound is itself basic.
3. Compound according to Claim 1 , characterized in that the alkyl radical of 1 to 3 carbon atoms is chosen from methyl, ethyl, i-propyl and n-propyl radicals.
4. Compound according to Claim 1 , characterized in that the alkyl radical of 1 to 4 carbon atoms is chosen from methyl, ethyl, i-propyl, i-butyl and t-butyl radicals.
5. Compound according to Claim 1 , characterized in that the alkyl radical of 1 to 10 carbon atoms is chosen from methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl, hexyl, heptyl, octyl, nonyl and dodecyl radicals. 6. Compound according to Claim 1 , characterized in that the alkoxy radical containing from 1 to 10 carbon atoms is chosen from methoxy, ethoxy, isopropyloxy, tert-butaxy and hexyloxy radicals.
7. Compound according to Claim 1 , characterized in that the alkoxy radical containing from 1 to 4 carbon atoms is chosen from methoxy, ethoxy, isopropyloxy and ferf-butoxy radicals.
8. Compound according to Claim 1 , characterized in that the cycloalkyl radical of 3 to 6 carbon atoms is chosen from cyclopropyl, cyclopentyl and cyclohexy! radicals.
9. Compounds of formula (I) according to any one of the preceding claims, chosen from:
1. ethyl 3"-tert-butyl-4"-diethylamino-4'-hydroxy[1 ,1 ';3',1"]terphenyl-4-carboxylate
2. ethyl 3"-terf-butyl-4"-diethylamino-4'-(4-hydroxybutoxy)-[1 , 1 ';3', 1 "]terphenyl-4- carboxylate
3. 3"-tert-butyl-4"-diethylamino-4'-(4-hydroxybutoxy)-[1 , 1 ';3', 1 "]terphenyl-4-carboxylic acid
4. ethyl 4"-(acetytethylamino)-3"-tert-buty{-4'-(4-hydroxybutoxy)-[1 , 1 ';3', 1 "Jterphenyl-4- carboxylate 5. 4"-(acetylethylamino)-3"-tert-butyl-4'-(4-hydroxybutoxy)-[1 ,1>;3l,1Il]terphenyl-4- carboxylic acid
6. 3"-tøn?-butyl-4"-diethylamino-4'-(2-hydroxyethoxy)-[1 , 1 ';3', 1 "]terphenyl-4-carboxylic acid
7. ethyl 3"-ferf-butyl-4"-diethylamino-4'-(3-hydroxypropoxy)-[1 ,1';3',1"]terphenyl-4- carboxylate
8. 3"-fe/t-butyl-4"-diethylamino-4'-(3-hydroxypropoxy)-[1 , 1 ';3', 1 "]terphenyl-4-carboxylic acid
9. ethyl 4"-diethylamino-4'-(3-hydroxypropoxy)-[1I1';3',1"]terphenyl-4-carboxylate
10. 4"-diethylamino-4'-(3-hydroxypropoxy)-[1 , 1 ';3', 1 "]terphenyl-4-carboxylic acid
11. ethyl 4"-diethylamino-3"-ethyl-4'-(3-hydroxypropoxy)-[1,1';3',1"]terphenyl-4- carboxylate
12. 4"-diethylamino-3"-ethyl-4'-(3-hydroxypropoxy)-[1 , 1 ';3', 1 "]terphenyl-4-carboxylic acid
13. 4"-diethylamino-3"-ethyl-4'-(2-hydroxyethoxy)-[1 , 1 ';3', 1 "]terphenyl-4-carboxylic acid
14. ethyl 4"-diethylamino-3"-ethyl-4'-(2-hydroxyethoxy)-[1 , 1 ';3', 1 "]terphenyl-4-carboxylate
15. ethyl 3"-te/f-butyl-4"-diethylamino-4'-(2-hydroxyethoxy)-[1 , 1 ';3\ 1 "]terphenyl-4- carboxylate
16. ethyl 4"-diethylamino-4'-(3-hydroxypropoxy)-3"-methyl[1 , 1 ';3', 1 "]terphenyl-4- carboxylate
17. 4"-diethylamino-41-(3-hydroxypropoxy)-3"-methyl[1 , 1 ';3', 1 "]terphenyl-4-carboxylic acid
18. ethyl 3"-te/t-butyl-4'-(4-hydroxybutoxy)-4"-pyrrolidin-1 -yl[1 , 1 ';3\ 1 "]terphenyl-4- carboxylate
19. 3"-tert-butyl-4'-(4-hydroxybutoxy)-4"-pyrrolidin-1-yl[1 ,1l;3',1"]terphenyl-4-carboxylic acid
20. ethyl 4'-(4-hydroxybutoxy)-4"-pyrrolidin-1 -yl-3"-trifluoromethyl[1 , 1 ';3', 1 "]terphenyl-4- carboxylate
21. 4'-(4-hydroxybutoxy)-4"-pyrrolidin-1-yl-3"-trifluoromethyI[1,1';3',1"]terphenyl-4- carboxylic acid
22. ethyl 3"-tert-butyl-4'-(3-hydroxypropoxy)-4"-pyrrolidin-1-yl[1,1';3',1"]terphenyl-4- carboxylate
23. 3"-fe/if-butyl-4'-(3-hydroxypropoxy)-4"-pyrrolidin-1-yl[1,1';3',1"]terphenyl-4-carboxylic acid
24. ethyl 3"-ferf-butyl-4'-(2-hydroxyethoxy)-4"-pyrrolidin-1-yl[1 ,1 ';3',1 "]terphenyl-4- carboxylate
25. 3"-te/f-butyl-4'-(2-hydroxyethoxy)-4"-pyrrolidin-1-yl[1 ,1';3',1"]terphenyl-4-carboxylic acid
26. 4'-(3-hydroxypropoxy)-4"-pyrrolidin-1 -yl[1 , 1 ';3', 1 "]terphenyl-4-carboxylic acid
27. 3"-fert-butyl-4"-diethylamino-4'-hydroxy[1 ,1 ';3',1"]terphenyl-4-carboxylic acid
28. ethyl 4"-diethylamino-4l-hydroxy-3"-trifluoromethyl[1 ,1';3',1"]terphenyl-4- carboxylate
29. 4"-diethylamino-4'-hydroxy-3"-trifluoromethyl[1 , 1 ';3', 1 "]terphenyl-4-carboxylic acid
30. 3"-fe/f-butyl-4"-diethylamino-4'-(4-isopropylaminobutoxy)-[1 , 1 ';3', 1 "]terphenyl-4- carboxylic acid
31. 3"-te/f-butyl-4'-(4-isopropylaminobutoxy)-4"-pyrrolidin-1 -yl[1 , 1 ';3', 1 "]terphenyl-4- carboxylic acid
32. ethyl 3"-terf-butyl-4"-diethylamino-4'-(3-hydroxypropyl)-[1 , 1 ';3', 1 "]terphenyl-4- carboxylate
33. 3"-fe/t-butyl-4"-diethylamino-4'-(3-hydroxypropyl)-[1 , 1 ';3', 1 "]terphenyl-4-carboxylic acid
34. ethyl 3^terf-butyl-4"-diethylamino-442>dihydroxypropylH1 ,r;3',1"]terphenyl-4- carboxylate
35. 3"-te/if-butyl-4"-diethylamino-4l-(2,3-dihydroxypropylH1 , 1 ';3', 1 "]terphenyl-4-carboxylic acid
36. ethyl 4"-(acetylethylamino)-3"-te/f-butyl-4l-(3-hydroxypropyl)-[1 ,1';3M"]terphenyl-4- carboxylate
37. 4"-(acetylethyIamino)-3"-te/t-butyl-4'-(3-hydroxypropyl)-[1 , 1 ';3\ 1 "jterphenyl-4- carboxylic acid
38. ethyl 3"-terf-butyl-4'-(3-cyclopropylaminopropyl)-4"-diethylamino[1 ,1';3',1"]terphenyl- 4-carboxylate
39. SMerf-butyl-^S-cyclopropylaminopropylM' -diethylaminofi , 1 ';3', 1 "]terphenyl-4- carboxylic acid
40. ethyl 3"-tert-butyl-4'-(3-cyclopentylaminopropyl)-4"-diethylamino[1 , 1 ';3' , 1 "]terphenyl- 4-carboxylate
41. 3"-te/t-butyl-4'-(3-cyclopentylaminopropyl)-4"-diethylamino[1 , 1 ';3', 1 "]terphenyl-4- carboxylic acid
42. ethyl 3"-teAt-butyl-4'-(3-cyclohexylaminopropyl)-4"-diethylannino[1 , 1 ';3', 1 "]terphenyl-4- carboxylate
43. 3"-te/f-butyl-4'-(3-cycIohexylaminopropyl)-4"-diethylamino[1,1';3',1"]terphenyl-4- carboxylic acid
44. ethyl 3M-feAf-butyl-4'-(3-ferf-butylaminopropyl)-4"-diethylamino[1 ,1 ';3',1"]terphenyl-4- carboxylate
45. 3"-ferf-butyl-4'-(3-tert-butylaminopropyl)-4"-diethylaminoI1 , 1 ';3', 1 "]terphenyl-4- carboxylic acid
46. ethyl 4"-(acetylethylamino)-3"-terf-butyl-4'-(3-cyclopropylaminopropyl)-[1 ,1';3',1"]ter- phenyl-4-carboxylate
47. 4n-(acetylethylamino)-3"-te/t-butyl-4'-(3-cyclopropylaminopropyl)-[1 ,1';3',1"]terphenyl- 4-carboxylic acid
48. ethyl 3"-terf-butyl-4"-diethylamino-4'-(3-isopropylaminopropyl)-[1 ,1 ';3',1"]terphenyl-4- carboxylate
49. 3"-tert-butyl-4"-diethylamino-4'-(3-isopropylaminopropyl)-[1 , 1 ';3', 1 "]terphenyl-4- carboxylic acid
50. ethyl 4'-(3-aminopropyl)-3"-terf-butyl-4"-diethylamino[1 ,1';3',1"]terphenyl-4- carboxylate
51. 4'-(3-aminopropyl)-3"-tert-butyl-4"-diethylamino[1 ,1';3',1"]terphenyl-4-carboxylic acid
52. [3"-feAf-butyl-4-carboxy-4'-(3-hydroxypropyl)-[1,r;3',1"]terphenyl-4"-yl]diethylamine hydrochloride
53. 3"-tert-butyl-4l-(2-hydroxyethoxy)-4"-(2-oxopyrrolidin-1-yl)-[1,1';3l,1"]terphenyl-4- carboxylic acid
54. 3"-tert-butyl-4"-ethylamino-4'-(3-hydroxypropoxy)-[1.1'^'J^terphenyM-carboxylic acid
55. 4'-(3-acetoxypropoxy)-3"-fe/ϊ-butyl-4"-diethylamino[1 , 1 ';3', 1 "]terphenyl-4-carboxylic acid
56. 3"-terf-butyl-4"-diethylamino-4'-(3-propionyloxypropoxy)-[1 ,1';3',1"]terphenyl-4- carboxylic acid
57. methyl 3"-feAf-butyl-4"-diethylamino-4'-(3-hydroxypropoxy)-[1 , 1 ';3', 1 "]terpheny!-4- carboxylate
58. isopropyl 3"-fe/t-butyl-4"-d!ethylamino-4'-(3-hydroxypropoxy)-[1 ,1';3',1"]terphenyl-4- carboxylate
59. isobutyl 3"-fe/t-butyl-4"-diethylamino-4'-(3-hydroxypropoxy)-[1 , 1 ';3\ 1 "]terphenyl-4- carboxylate
60. 3"-tø/f-butyl-4"-diethylamino-4'-(3-hydroxypropoxy)-5"-methyl[1 , 1 ';3', 1 "]terphenyl-4- carboxylic acid
61. 4"-diethylamino-4l-(3-hydroxypropoxy)-3"-isopropyl-5"-methyl[1,1';3',1"]terphenyl-4- carboxylic acid
62. 3"-tert-butyl-5"-chloro-4"-diethylamino-4l-(3-hydroxypropoxy)-[1 ,1 ';3',1 "]terphenyl-4- carboxylic acid
63. 4"-diethylamino-4'-(3-hydroxypropoxy)-3",5"-diisopropyl[1,1';3',1"]terphenyl-4- carboxylic acid
64. 3",5"-di-ferf-butyl-4"-diethylamino-4l-(3-hydroxypropoxy)-[1 l1';3',1"]terphenyl-4- carboxylic acid
65. 4"-diethylamino-4'-(3-hydroxypropoxy)-3"-trifiuoromethyl[1 ,1 ';3',1"]terphenyl-4- carboxylic acid
66. 3"-te/t-butyl-4"-(ethylmethylamino)-4I-(2-hydroxyethoxy)-[1 ,1';3',1"]terphenyl-4- carboxylic acid
67. 3"-tert-butyl-4"-dimethylamino-4'-(2-hydroxyethoxy)-[1 ,1 ';3',1"]terphenyl-4-carboxylic acid
68. 3"-tert-butyl-4"-(ethylisopropylamino)-4'-(2-hydroxyethoxy)-[1 , 1 ';3', 1 "]terphenyl-4- carboxylic acid
69. 3"-fert-butyl-4"-(ethylpropy!amino)-4'-(2-hydroxyethoxy)-[1 ,1';3',1 "]terphenyl-4- carboxylic acid
70. 3"-tert-butyl-4"-dipropylamino-4'-(2-hydroxyethoxy)-[1,1';3',1"]terphenyl-4-carboxylic acid
71. 3"-fert-butyl-4"-(ethylpropionylamino)-4l-(2-hydroxyethoxy)-[1,1';3',1"]terphenyl-4- carboxylic acid
72. 6-[3'-te/f-butyl-4'-diethyIamino-6-(2-hydroxyethoxy)biphenyI-3-yl]nicotinic acid
73. 5-[3'-tert-butyl-4'-diethylamino-6-(2-hydroxyethoxy)biphenyl-3-yl]pyridine-2-carboxylic acid
74. 5-[3'-te/f-butyl-4'-diethy!amino-6-(2-hydroxyethoxy)biphenyl-3-yl]thiophene-2- carboxylic acid
75. 3"-tert-butyl-4'-(2-hydroxyethoxy)-5"-methyl-4"-pyrrolidin-1-yl[1 ,1';3',1"]terphenyl-4- carboxylic acid
76. 3"-tør/-butyl-5"-ch!oro-4I-(2-hydroxyethoxy)-4"-pyrrolidin-1 -yl[1 , 1 ';3', 1 "]terphenyl-4- carboxylic acid
77. 4'-(2-hydroxyethoxy)-3"-isopropyl-4"-pyrrolidin-1-yl[1 ,1';3',1"]terphenyl-4-carboxylic acid
78. 3"-ethyl-4'-(2-hydroxyethoxy)-4"-pyrrolidin-1-yl[1,1';3',1"]terphenyl-4-carboxylic acid
79. 4l-(2-hydroxyethoxy)-3",5"-diisopropyl-4"-pyrrolidin-1-yl[1 ,1';3',1"]terphenyl-4- carboxylic acid
80. 3",5"-diethyl-4I-(2-hydroxyethoxy)-4"-pyrrolidin-1-yl[1 ,1l;3l,ri]terphenyl-4-carboxylic acid
81. 3",5"-dimethyl-4'-(2-hydroxyethoxy)-4"-pyrrolidin-1-yl[1 ,1 ';3',1"]terphenyl-4-carboxylic acid
82. 4'-(2-acetoxyethoxy)-3"-feff-butyl-4"-pyrrolidin-1-yl[1 ,1';3l,T']terphenyl-4-carboxylic acid
83. 4'-(2-propionyloxyethoxy)-3"-terf-butyl-4"-pyrrolidin-1-yl[1 ,1 ';3',1"]terphenyl-4- carboxylic acid
84. methyl 3"-tenf-butyl-4'-(2-hydroxyethoxy)-4"-pyrrolidin-1 -yl[1 , 1 ';3', 1 "]terphenyl-4- carboxylate
85. isopropyl 3"-terf-butyl-4'-(2-hydroxyethoxy)-4"-pyrroHdin-1 -yl[1 , 1 ';3', 1 "]terphenyl-4- carboxylate
86. isobutyl 3II-terf-butyl-4I-(2-hydroxyethoxy)-4"-pyrrolidin-1-yl[1,1';3',1ll3terphenyl-4- carboxylate
87. ethyl 3"-tert-butyl-4'-(3-hydroxypropoxy)-4"-pyrrolidin-1-yl[1 ,1';3',1"]terphenyl-4- carboxylate
88. ethyl 3"-tert-butyl-5"-chloro-4l-(2-hydroxyethoxy)-4"-pyrrolidin-1-yl[1 , 1 ';3', 1 "]ter- phenyl-4-carboxylate
89. 6-[3'-te/t-butyl-6-(2-hydroxyethoxy)-4l-pyrrolidin-1-ylbiphenyl-3-yl]nicotinic acid
90. δ-lS'-tert-butyl-e-Ca-hydroxyethoxyH'-pyrrolidin-i-ylbiphenyl-S-yπpyridine-a- carboxylic acid
91. ethyl 6-[3'-terf-butyl-6-(2-hydroxyethoxy)-4'-pyrrolidin-1 -ylbiphenyl-3-yl]nicotinate
92. ethyl 3"-ferf-butyl-4'-(3-hydroxypropyl)-4"-pyrrolidin-1-yl[1 ,1';3',1"]terphenyl-4- carboxylate
93. 3"-te/f-butyl~4'-(3-hydroxypropyl)-4"-pyrrolidin-1 -yl[1 , 1 ';3', 1 "]terphenyl-4-carboxylic acid
94. 3"-terf-butyl-4'-(2-hydroxyethoxy)-4"-(2-oxopyrrolidin-1 -yl)-[1 , 1 ';3\ 1 "]terphenyl-4- carboxylic acid
95. 3"-te/f-butyl-4'-(2-hydroxyethoxy)-4"-(2-oxopiperid-1 -yl)-[1 , 1 ';3', 1 "Jterphenyl-4- carboxylic acid
96. 3"-tert-butyl-4'-(2-hydroxyethoxy)-4"-piperid-1-yl[1,1';3',1"]terphenyl-4-carboxyIic acid
97. 5-[3'-fert-butyl-6-(2-hydroxyethoxy)-4'-pyrro((din-1-ylbiphenyl-3-ylJthiophene-2- carboxylic acid.
10. Compounds according to Claim 1, characterized in that they have at least one of the following characteristics:
- R1 is a hydrogen atom or a t-butyl or i-propyl radical;
- R2 is a hydrogen atom or a t-butyl or i-propyl radical; - R3 is a hydrogen atom or an ethyl radical;
- R4 and R5 are, independently of each other, a methyl or ethyl radical or together form a pyrrolidine ring;
- A is as defined above in which R6 represents a hydrogen atom, an i-propyl or t-butyl radical, a cycloalkyl radical of 3 to 6 carbon atoms or a -C(O)CH3 or -C(O)CH2CH3 radical.
11. Compounds according to Claim 10, characterized in that they have all of the following characteristics:
- R1 is a hydrogen atom or a t-butyl or i-propyl radical; - R2 is a hydrogen atom or a t-butyl or i-propyl radical; - R3 is a hydrogen atom or an ethyl radical;
- R4 and R5 are, independently of each other, a methyl or ethyl radical or together form a pyrrolidine ring;
- A is as defined above in which R6 represents a hydrogen atom, an i-propyl or t-butyl radical, a cycloalkyl radical of 3 to 6 carbon atoms or a -C(O)CH3 or -C(O)CH2CH3 radical.
12. Compounds according to any one of Claims 1 to 11, as medicaments.
13. Use of a compound according to any one of Claims 1 to 11 in the manufacture of a composition for treating:
- dermatological complaints associated with a keratinization disorder relating to cell differentiation and proliferation;
- ichthyosis, ichthyosiform conditions, Darier's disease, palmoplanar keratoderma, leukoplakia and leukoplakiform conditions, and cutaneous or mucous (buccal) lichen;
- dermatological complaints with an inflammatory immunoallergic component, with or without a cell proliferation disorder;
- skin disorders caused by exposure to UV radiation, photoinduced or chronological ageing of the skin, or actinic pigmentations and keratoses; - pathologies associated with chronological or actinic ageing of the skin;
- benign or malignant dermal or epidermal proliferations, of viral or non-viral origin;
- proliferations that may be induced by ultraviolet radiation;
- precancerous skin lesions;
- immune dermatoses; - immune bullous diseases;
- collagen diseases;
- dermatological complaints with an immunological component;
- ophthalmologic^ disorders;
- stigmata of epidermal and/or dermal atrophy induced by local or systemic corticosteroids, or any other form of cutaneous atrophy;
- skin complaints of viral origin;
- skin disorders caused by exposure to UV radiation, photoinduced or chronological ageing of the skin, or actinic pigmentations and keratoses;
- pathologies associated with chronological or actinic ageing of the skin; - disorders of sebaceous function; - cicatrization disorders or stretch marks; or
- pigmentation disorders.
14. Use according to Claim 13, characterized in that the dermatological complaints associated with a keratinization disorder relating to cell differentiation and proliferation are chosen from common acne, comedones, polymorphonuclear leukocytes, acne rosacea, nodulocystic acne, acne conglobata, senile acne, and secondary acnes such as solar acne, medication-related acne or occupational acne.
15. Use according to Claim 13, characterized in that the dermatological complaints with an inflammatory immunoallergic component, with or without a cell proliferation disorder, are chosen from all forms of psoriasis, whether cutaneous, mucous or ungual psoriasis, and even psoriatic rheumatism, cutaneous atopy, such as eczema, or respiratory atopy, or even gingival hypertrophy.
16. Pharmaceutical composition, characterized in that it comprises, in a physiologically acceptable support, at least one of the compounds as defined in any one of Claims 1 to 11.
17. Composition according to Claim 16, characterized in that the concentration of compound(s) according to any one of Claims 1 to 11 is between 0.001% and 10% by weight relative to the total weight of the composition.
18. Composition according to Claim 17, characterized in that the concentration of compound(s) according to one of Claims 1 to 11 is between 0.01% and 1% by weight relative to the total weight of the composition.
19. Cosmetic composition, characterized in that it comprises, in a physiologically acceptable medium, at least one of the compounds as defined in any one of Claims 1 to 11.
20. Composition according to Claim 19, characterized in that the concentration of compound(s) according to one of Claims 1 to 11 is between 0.001% and 3% by weight relative to the total weight of the composition. 21. Non-therapeutic use of a cosmetic composition as defined in one of Claims 1 to 11, for preventing and/or treating the signs of ageing and/or dry skin.
22. Non-therapeutic use of a cosmetic composition as defined in one of Claims 1 to 11 , for body or hair hygiene.
23. Cosmetic process for enhancing the appearance of the skin, characterized in that a composition as defined in any one of Claims 1 to 11 is applied to the skin.
PCT/EP2005/014217 2004-12-23 2005-12-21 Novel ligands that modulate rar receptors, and use thereof in human medicine and in cosmetics WO2006066978A1 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
CA2590246A CA2590246C (en) 2004-12-23 2005-12-21 Novel ligands that modulate rar receptors, and use thereof in human medicine and in cosmetics
BRPI0517500A BRPI0517500B8 (en) 2004-12-23 2005-12-21 compound, use of a composition, pharmaceutical composition, cosmetic composition, non-therapeutic uses of a cosmetic composition, and cosmetic process to improve the appearance of the skin
ES05824484T ES2380777T3 (en) 2004-12-23 2005-12-21 New ligands that modulate RAR receptors and their use in human medicine and cosmetics
JP2007547399A JP5258299B2 (en) 2004-12-23 2005-12-21 Novel ligands that modulate RAR receptors and their use in human pharmaceuticals and cosmetics
KR1020077014372A KR101316992B1 (en) 2004-12-23 2005-12-21 Novel ligands that modulate rar receptors, and use thereof in human medicine and in cosmetics
AT05824484T ATE542791T1 (en) 2004-12-23 2005-12-21 NEW LIGANDS AS RAR RECEPTOR MODULATORS AND THEIR USE IN HUMAN MEDICINE AND COSMETICS
AU2005318292A AU2005318292B2 (en) 2004-12-23 2005-12-21 Novel ligands that modulate RAR receptors, and use thereof in human medicine and in cosmetics
CN2005800447781A CN101087752B (en) 2004-12-23 2005-12-21 Novel ligands that modulate RAR receptors, and use thereof in human medicine and in cosmetics
EP05824484A EP1831149B1 (en) 2004-12-23 2005-12-21 Novel ligands that modulate rar receptors and use thereof in human medicine and in cosmetics
DK05824484.9T DK1831149T3 (en) 2004-12-23 2005-12-21 Novel ligands that modulate scar receptors and their use in human medicine and cosmetics
SI200531509T SI1831149T1 (en) 2004-12-23 2005-12-21 Novel ligands that modulate rar receptors and use thereof in human medicine and in cosmetics
PL05824484T PL1831149T3 (en) 2004-12-23 2005-12-21 Novel ligands that modulate rar receptors and use thereof in human medicine and in cosmetics
MX2007007696A MX2007007696A (en) 2004-12-23 2005-12-21 Novel ligands that modulate rar receptors, and use thereof in human medicine and in cosmetics.
US11/819,068 US7807708B2 (en) 2004-12-23 2007-06-25 Ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof
US12/842,347 US8227507B2 (en) 2004-12-23 2010-07-23 Ligands that modulate RAR receptors
US13/527,299 US8470871B2 (en) 2004-12-23 2012-06-19 Ligands that modulate RAR receptors
NL301042C NL301042I2 (en) 2004-12-23 2020-06-10 Trifarotene, optionally in the form of a pharmaceutically acceptable salt
LTPA2022002C LTC1831149I2 (en) 2004-12-23 2022-03-10

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR0413848A FR2880020B1 (en) 2004-12-23 2004-12-23 NEW MODULATORY LIGANDS OF RAR RECEPTORS, USE IN HUMAN MEDICINE AND COSMETICS
FR04/13848 2004-12-23
US64738305P 2005-01-28 2005-01-28
US60/647,383 2005-01-28

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/819,068 Continuation US7807708B2 (en) 2004-12-23 2007-06-25 Ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof

Publications (1)

Publication Number Publication Date
WO2006066978A1 true WO2006066978A1 (en) 2006-06-29

Family

ID=35981712

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/014217 WO2006066978A1 (en) 2004-12-23 2005-12-21 Novel ligands that modulate rar receptors, and use thereof in human medicine and in cosmetics

Country Status (11)

Country Link
EP (1) EP1831149B1 (en)
JP (1) JP5258299B2 (en)
KR (1) KR101316992B1 (en)
AU (1) AU2005318292B2 (en)
BR (1) BRPI0517500B8 (en)
CA (1) CA2590246C (en)
CY (1) CY1112721T1 (en)
MX (1) MX2007007696A (en)
NL (1) NL301042I2 (en)
PL (1) PL1831149T3 (en)
WO (1) WO2006066978A1 (en)

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009067600A2 (en) * 2007-11-21 2009-05-28 Decode Genetics Ehf Biaryl pde4 inhibitors for treating inflammation
WO2009156675A2 (en) 2008-05-30 2009-12-30 Galderma Research & Development Novel depigmenting compositions in the form of a petroleum jelly-free and elastomer-free anhydrous composition comprising a solubilized phenolic derivative and a retinoid
US20100143445A1 (en) * 2007-05-04 2010-06-10 Galderma Research & Development Dermatological/cosmetic skin depigmenting compositions
WO2010119992A1 (en) 2009-04-16 2010-10-21 Takeda Pharmaceutical Company Limited Derivatives of n-acyl-n'-phenylpiperazine useful (inter alia) for the prophylaxis or treatment of diabetes
WO2011012897A1 (en) 2009-07-31 2011-02-03 Astrazeneca Ab New combinations for the treatment of asthma
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
WO2012085583A1 (en) 2010-12-23 2012-06-28 Astrazeneca Ab New compound
WO2012085582A1 (en) 2010-12-23 2012-06-28 Astrazeneca Ab Compound
WO2013178749A1 (en) 2012-06-01 2013-12-05 Galderma Research & Development Lipid nanocapsules comprising a retinoid, nanodispersion and composition containing same, method of producing same and use thereof in dermatology
WO2013178759A1 (en) * 2012-06-01 2013-12-05 Galderma Research & Development Topical compositions in the form of a gel containing a particular solubilised retinoid
WO2013178745A1 (en) * 2012-06-01 2013-12-05 Galderma Research & Development Aqueous-gel-type topical compositions in the form of a homogenous suspension of an active principle of the class of retinoids containing at least one hydrophobic silica
WO2013178756A1 (en) 2012-06-01 2013-12-05 Galderma Research & Development Dermatological composition including oleosomes and retinoids, method for preparing same and use thereof
WO2013178758A1 (en) 2012-06-01 2013-12-05 Galderma Research & Development O/w-emulsion-type topical pharmaceutical compositions containing a retinoid
WO2013178752A1 (en) 2012-06-01 2013-12-05 Galderma Research & Development Method for preparing a dermatological composition including oleosomes
WO2013178760A1 (en) * 2012-06-01 2013-12-05 Galderma Research & Development Oil/water-emulsion-type topical compositions containing a retinoid
WO2013178743A1 (en) 2012-06-01 2013-12-05 Galderma Research & Development Microcapsules containing retinoids, method for preparing same, and pharmaceutical compositions containing same
US8791267B2 (en) 2007-11-21 2014-07-29 Decode Genetics Ehf Biaryl PDE4 inhibitors for treating inflammatory, cardiovascular and CNS disorders
WO2015082659A1 (en) * 2013-12-04 2015-06-11 Galderma Research & Development Lipid microcapsules preferably comprising a retinoid, and composition containing same, method for the production thereof, and use thereof in dermatology
FR3028763A1 (en) * 2014-11-20 2016-05-27 Galderma Sa COMPOSITIONS COMPRISING A COMPOUND OF THE AVERMECTIN FAMILY AND AN ANTAGONIST COMPOUND OF AT LEAST ONE OF THE RAR RECEPTORS FOR THE TREATMENT OF ACNE
US20180185329A1 (en) * 2015-06-23 2018-07-05 Galderma Research & Development Compositions comprising water dispersible nanoparticles of a retinoid compound
US20180325859A1 (en) * 2014-11-20 2018-11-15 Galderma Sa Compositions comprising a compound from the family of avermectins and an agonist compound for at least one of the retinoic acid receptors for treating acne
RU2677885C2 (en) * 2013-05-10 2019-01-22 Басф Се Products with high content of uv stabilizers
WO2021064072A1 (en) 2019-10-02 2021-04-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of retinoic acid receptor (rar) agonists for reversing, preventing, or delaying calcification of aortic valve
WO2021119351A1 (en) 2019-12-11 2021-06-17 Taro Pharmaceutical Industries Ltd. Preparation of trifarotene and intermediates and polymorphs thereof
US11197831B2 (en) 2015-05-29 2021-12-14 Galderma Research And Development Compositions comprising at least one dispersed active principle and lipid microcapsules
CN113999117A (en) * 2021-09-10 2022-02-01 南京迈诺威医药科技有限公司 Preparation method of biphenyl compound

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007087442A2 (en) 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Substituted biaryl compounds for inflammation and immune-related uses
US9084778B2 (en) 2012-06-01 2015-07-21 Galderma Research & Development Topical compositions containing a retinoid of the oil-in-water emulsion type

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999010308A1 (en) * 1997-08-21 1999-03-04 Galderma Research & Development Biphenyl derivatives substituted by an aromatic or heteroaromatic radical and pharmaceutical and cosmetic compositions containing same
US6150413A (en) * 1997-05-23 2000-11-21 Centre International De Recherches Dermatologiques Triaromatic compounds and pharmaceutical/cosmetic compositions comprised thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9604926D0 (en) * 1996-03-08 1996-05-08 Sandoz Ltd Organic compounds
FR2759292B1 (en) * 1997-02-10 2000-08-11 Cird Galderma USE OF RETINOIDS AS PIGMENTATION INDUCING AGENTS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150413A (en) * 1997-05-23 2000-11-21 Centre International De Recherches Dermatologiques Triaromatic compounds and pharmaceutical/cosmetic compositions comprised thereof
WO1999010308A1 (en) * 1997-08-21 1999-03-04 Galderma Research & Development Biphenyl derivatives substituted by an aromatic or heteroaromatic radical and pharmaceutical and cosmetic compositions containing same

Cited By (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100143445A1 (en) * 2007-05-04 2010-06-10 Galderma Research & Development Dermatological/cosmetic skin depigmenting compositions
US8791267B2 (en) 2007-11-21 2014-07-29 Decode Genetics Ehf Biaryl PDE4 inhibitors for treating inflammatory, cardiovascular and CNS disorders
WO2009067600A3 (en) * 2007-11-21 2009-07-30 Decode Genetics Ehf Biaryl pde4 inhibitors for treating inflammation
WO2009067600A2 (en) * 2007-11-21 2009-05-28 Decode Genetics Ehf Biaryl pde4 inhibitors for treating inflammation
WO2009156675A2 (en) 2008-05-30 2009-12-30 Galderma Research & Development Novel depigmenting compositions in the form of a petroleum jelly-free and elastomer-free anhydrous composition comprising a solubilized phenolic derivative and a retinoid
WO2010119992A1 (en) 2009-04-16 2010-10-21 Takeda Pharmaceutical Company Limited Derivatives of n-acyl-n'-phenylpiperazine useful (inter alia) for the prophylaxis or treatment of diabetes
WO2011012897A1 (en) 2009-07-31 2011-02-03 Astrazeneca Ab New combinations for the treatment of asthma
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
WO2012085583A1 (en) 2010-12-23 2012-06-28 Astrazeneca Ab New compound
WO2012085582A1 (en) 2010-12-23 2012-06-28 Astrazeneca Ab Compound
US9498465B2 (en) 2012-06-01 2016-11-22 Galderma Research & Development Topical compositions in the form of a gel containing a particular solubilized retinoid
US9855244B2 (en) 2012-06-01 2018-01-02 Galderma Research & Development O/W-emulsion-type topical pharmaceutical compositions containing a retinoid
WO2013178756A1 (en) 2012-06-01 2013-12-05 Galderma Research & Development Dermatological composition including oleosomes and retinoids, method for preparing same and use thereof
WO2013178758A1 (en) 2012-06-01 2013-12-05 Galderma Research & Development O/w-emulsion-type topical pharmaceutical compositions containing a retinoid
WO2013178752A1 (en) 2012-06-01 2013-12-05 Galderma Research & Development Method for preparing a dermatological composition including oleosomes
WO2013178760A1 (en) * 2012-06-01 2013-12-05 Galderma Research & Development Oil/water-emulsion-type topical compositions containing a retinoid
WO2013178743A1 (en) 2012-06-01 2013-12-05 Galderma Research & Development Microcapsules containing retinoids, method for preparing same, and pharmaceutical compositions containing same
FR2991175A1 (en) * 2012-06-01 2013-12-06 Galderma Res & Dev TOPICAL PHARMACEUTICAL COMPOSITIONS OF O / W EMULSION TYPE CONTAINING RETINOID
FR2991172A1 (en) * 2012-06-01 2013-12-06 Galderma Res & Dev TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING MICROCAPSULES
FR2991177A1 (en) * 2012-06-01 2013-12-06 Galderma Res & Dev TOPICAL COMPOSITIONS, CONTAINING RETINOID, EMULSION TYPE EMULSION IN WATER WITHOUT EMULSIFIER
FR2991176A1 (en) * 2012-06-01 2013-12-06 Galderma Res & Dev TOPICAL COMPOSITIONS CONTAINING SOLUBILIZED RETINOID OF HYDROGLYCOLIC GEL TYPE
FR2991174A1 (en) * 2012-06-01 2013-12-06 Galderma Res & Dev DERMATOLOGICAL COMPOSITION COMPRISING OLEOSOMES AND RETINOIDS, PROCESS FOR PREPARING SAME AND USE THEREOF
FR2991178A1 (en) * 2012-06-01 2013-12-06 Galderma Res & Dev AQUEOUS GEL-LIKE TOPICAL COMPOSITIONS IN THE FORM OF A HOMOGENEOUS SUSPENSION OF AN ACTIVE PRINCIPLE OF THE RETINOID CLASS CONTAINING AT LEAST ONE HYDROPHOBIC SILICA.
WO2013178759A1 (en) * 2012-06-01 2013-12-05 Galderma Research & Development Topical compositions in the form of a gel containing a particular solubilised retinoid
CN104507469A (en) * 2012-06-01 2015-04-08 盖尔德马研究及发展公司 Oil/water-emulsion-type topical compositions containing a retinoid
US20150125520A1 (en) * 2012-06-01 2015-05-07 Galderma Research & Development Lipid nanocapsules comprising a retinoid, nanodispersion and composition containing the same, process for preparing the same and use thereof in dermatology
EP4169512A1 (en) * 2012-06-01 2023-04-26 Galderma Research & Development Dermatological composition comprising oleosomes and retinoids, method for preparing same and use thereof
EP2854803B2 (en) † 2012-06-01 2022-08-24 Galderma Research & Development Topical gel composition comprising a solubilized specific retinoid
US9375477B2 (en) 2012-06-01 2016-06-28 Galderma Research & Development Topical compositions of aqueous gel type in the form of a homogeneous suspension of an active principle of the retinoid class containing at least one hydrophobic silica
WO2013178749A1 (en) 2012-06-01 2013-12-05 Galderma Research & Development Lipid nanocapsules comprising a retinoid, nanodispersion and composition containing same, method of producing same and use thereof in dermatology
AU2013269582B2 (en) * 2012-06-01 2017-08-10 Galderma Research & Development Topical compositions in the form of a gel containing a particular solubilised retinoid
AU2013269583B2 (en) * 2012-06-01 2017-08-24 Galderma Research & Development Oil/water-emulsion-type topical compositions containing a retinoid
RU2637408C2 (en) * 2012-06-01 2017-12-04 Галдерма Ресерч Энд Девелопмент Retinoid-containing compounds for local application of "oil in water" emulsion type
WO2013178745A1 (en) * 2012-06-01 2013-12-05 Galderma Research & Development Aqueous-gel-type topical compositions in the form of a homogenous suspension of an active principle of the class of retinoids containing at least one hydrophobic silica
CN104507469B (en) * 2012-06-01 2018-01-02 盖尔德马研究及发展公司 Oil-in-water emulsion type topical composition containing biostearin
AU2013269581B2 (en) * 2012-06-01 2018-03-01 Galderma Research & Development O/W-emulsion-type topical pharmaceutical compositions containing a retinoid
RU2655305C2 (en) * 2012-06-01 2018-05-24 Галдерма Ресерч Энд Девелопмент Oil-in-water emulsion-type topical pharmaceutical compositions containing retinoid
EP2854803B1 (en) 2012-06-01 2018-06-27 Galderma Research & Development Topical gel composition comprising a solubilized specific retinoid
US10702604B2 (en) 2012-06-01 2020-07-07 Galderma Research & Development Lipid nanocapsules comprising a retinoid, nanodispersion and composition containing the same, process for preparing the same and use thereof in dermatology
RU2677885C2 (en) * 2013-05-10 2019-01-22 Басф Се Products with high content of uv stabilizers
US10772807B2 (en) 2013-12-04 2020-09-15 Galderma Research & Development Lipid microcapsules preferably comprising a retinoid, and composition containing same, method for the production thereof, and use of same in dermatology
US10857080B2 (en) 2013-12-04 2020-12-08 Galderma Research & Development Lipid microcapsules preferably comprising a lipophilic active substance and composition containing same, method for the production thereof, and use of same in dermatology and in cosmetics
CN113559083A (en) * 2013-12-04 2021-10-29 盖尔德马研究及发展公司 Lipid microcapsules comprising a retinoid
WO2015082659A1 (en) * 2013-12-04 2015-06-11 Galderma Research & Development Lipid microcapsules preferably comprising a retinoid, and composition containing same, method for the production thereof, and use thereof in dermatology
FR3028763A1 (en) * 2014-11-20 2016-05-27 Galderma Sa COMPOSITIONS COMPRISING A COMPOUND OF THE AVERMECTIN FAMILY AND AN ANTAGONIST COMPOUND OF AT LEAST ONE OF THE RAR RECEPTORS FOR THE TREATMENT OF ACNE
US10653659B2 (en) 2014-11-20 2020-05-19 Galderma S.A. Compositions comprising a compound from the family of avermectins and an agonist compound for at least one of the retinoic acid receptors for treating acne
US20180325859A1 (en) * 2014-11-20 2018-11-15 Galderma Sa Compositions comprising a compound from the family of avermectins and an agonist compound for at least one of the retinoic acid receptors for treating acne
US11197831B2 (en) 2015-05-29 2021-12-14 Galderma Research And Development Compositions comprising at least one dispersed active principle and lipid microcapsules
US20180185329A1 (en) * 2015-06-23 2018-07-05 Galderma Research & Development Compositions comprising water dispersible nanoparticles of a retinoid compound
US10925855B2 (en) * 2015-06-23 2021-02-23 Galderma Research & Development Compositions comprising water dispersible nanoparticles of a retinoid compound
WO2021064072A1 (en) 2019-10-02 2021-04-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of retinoic acid receptor (rar) agonists for reversing, preventing, or delaying calcification of aortic valve
WO2021119351A1 (en) 2019-12-11 2021-06-17 Taro Pharmaceutical Industries Ltd. Preparation of trifarotene and intermediates and polymorphs thereof
CN114787129A (en) * 2019-12-11 2022-07-22 塔罗制药工业有限公司 Preparation of trefarosin and intermediates and polymorphs thereof
AU2020402049B2 (en) * 2019-12-11 2023-06-01 Taro Pharmaceutical Industries Ltd. Preparation of Trifarotene and intermediates and polymorphs thereof
US11691946B2 (en) 2019-12-11 2023-07-04 Taro Pharmaceutical Industries Ltd. Preparation of Trifarotene and intermediates and polymorphs thereof
CN113999117A (en) * 2021-09-10 2022-02-01 南京迈诺威医药科技有限公司 Preparation method of biphenyl compound
CN113999117B (en) * 2021-09-10 2023-12-08 南京迈诺威医药科技有限公司 Preparation method of biphenyl compound

Also Published As

Publication number Publication date
JP2008525364A (en) 2008-07-17
BRPI0517500A (en) 2008-10-07
CA2590246C (en) 2015-07-14
KR101316992B1 (en) 2013-10-11
CA2590246A1 (en) 2006-06-29
AU2005318292A1 (en) 2006-06-29
EP1831149A1 (en) 2007-09-12
NL301042I1 (en) 2020-06-17
CY1112721T1 (en) 2016-02-10
JP5258299B2 (en) 2013-08-07
BRPI0517500B1 (en) 2018-10-09
EP1831149B1 (en) 2012-01-25
AU2005318292B2 (en) 2011-09-22
MX2007007696A (en) 2007-08-17
KR20070087626A (en) 2007-08-28
RU2007127867A (en) 2009-01-27
NL301042I2 (en) 2020-08-10
RU2440973C2 (en) 2012-01-27
BRPI0517500B8 (en) 2021-05-25
PL1831149T3 (en) 2012-06-29

Similar Documents

Publication Publication Date Title
EP1831149B1 (en) Novel ligands that modulate rar receptors and use thereof in human medicine and in cosmetics
US8470871B2 (en) Ligands that modulate RAR receptors
US7872026B2 (en) Ligand activators of the RAR receptors and pharmaceutical/cosmetic applications thereof
US7348449B2 (en) Ligand antagonists of RAR receptors and pharmaceutical/cosmetic applications thereof
US7439396B2 (en) Pharmaceutical/cosmetic compositions comprising novel ligands that activate RAR receptors
ES2357193T3 (en) NEW LEGAND AGONISTS OF RAR RECEPTORS, USED IN HUMAN MEDICINE AND ALSO IN COSMETICS.
MXPA04011972A (en) Novel ligands that are inhibitors of the rar receptors, process for preparing them and use thereof in human medicine and in cosmetics.
EP1694627A2 (en) Novel ligands that are activators of the rar receptors, use in human medicine and in cosmetics
US7326803B2 (en) Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005824484

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2005318292

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2590246

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007547399

Country of ref document: JP

Ref document number: MX/a/2007/007696

Country of ref document: MX

Ref document number: 1020077014372

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 200580044778.1

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2005318292

Country of ref document: AU

Date of ref document: 20051221

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 5201/DELNP/2007

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 2005318292

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007/05930

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2007127867

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2005824484

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0517500

Country of ref document: BR